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Summary 
Methylglyoxal is a physiological dicarbonyl metabolite and potent arginine-
directed glycating agent.  It often modifies proteins at functional sites producing loss 
of positive charge, structural distortion and inactivation.  Plasma methylglyoxal is 
increased in hyperglycaemia associated with diabetes and is linked to the 
development of vascular complications of diabetes – particularly nephropathy, 
retinopathy and neuropathy.  The effects of dicarbonyl glycation on beta cells and 
involvement in early stage dysfunction and development of type 2 diabetes mellitus 
are not known.  The aim of this project was to investigate the effect of dicarbonyl 
protein glycation on beta cell function and related involvement in the development of 
diabetes.  Studies were performed in an in vitro model of beta cell dysfunction - 
MIN6 insulinoma cells incubated under low and high glucose concentrations, and in 
a pre-clinical in vivo model of decline of glucose tolerance preceding development of 
type 2 diabetes - high fat diet-induced insulin resistant mice.  Dicarbonyl metabolism 
and protein damage by glycation and oxidation were studied by stable isotopic 
dilution analysis liquid chromatography-tandem mass spectrometry.  Localisation of 
methylglyoxal glycation adducts within the pancreas were visualised by 
immunostaining.  Interactions between the extracellular matrix protein, collagen IV, 
and MIN6 cells in vitro were investigated and impairments in adhesion were 
assessed following glycation with methylglyoxal.  Impairments in adhesion of MIN6 
cells to methylglyoxal-glycated collagen IV were assessed using atomic force 
microscopy force spectroscopy.  
The results show that MIN6 cells were resistant to accumulation of 
methylglyoxal when incubated in high glucose concentration although the flux of 
methylglyoxal was increased 41%.  Glycation of collagen IV by methylglyoxal 
impairs binding to MIN6 cells in vitro resulting in a 91% decrease in the energy 
necessary to detach cells from the extracellular matrix protein.  In high fat diet fed 
mice the concentration of methylglyoxal in the pancreas was increased.  
Visualisation of MG-H1 adduct residues in the pancreas showed they were 
predominantly on the extracellular matrix.   
In conclusion, protein glycation by methylglyoxal occurs in MIN6 cells in 
vitro and in the mouse pancreas in vivo.  Although the methylglyoxal concentration 
in the pancreas of high fat diet fed, insulin resistant mice was increased, the lack of a 
concurrent increase in methylglyoxal protein glycation adducts suggests there may 
be increased turnover of methylglyoxal-modified proteins.  Impairment of beta cell 
attachment to the extracellular matrix protein, collagen IV, by methylglyoxal and 
increased protein turnover stimulated by an increased rate of methylglyoxal 
glycation may impair beta cell function in pre-diabetes in vivo.  Glycation by 
methylglyoxal may contribute to beta cell glucotoxicity and dysfunction with 
progression to type 2 diabetes mellitus.  
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3DG-H1; 2-amino-5-(2-amino-5-hydro-5-(2,3,4-trihydroxybutyl) -
4-imidazolon-1-yl)pentanoic acid, 3DG-H2; 2-amino-5-(2-amino-
4-hydro-4-(2,3,4-trihydroxybutyl)--5-imidazolon-1-yl)pentanoic 
acid, 3DG-H3. 
3-NT 3-nitrotyrosine 
AAA α-aminoadipic acid 
AASA α-aminoadipic semialdehyde 
ADA American Diabetes Association 
ADP adenosine diphosphate 
AFM-FS atomic force microscopy force spectroscopy 
AGEs advanced glycation end products 
AKR aldoketo reductase 
Atg7 autophagy-related protein 7 
ATP adenosine triphosphate 
BCAA branched-chain amino acid 
BMI body mass index 
BrBzGSHCp2 S-p-bromobenzylglutathione cyclopentyl diester 
BSA bovine serum albumin 
cAMP cyclic adenosine monophosphate 
CBQCA 3-(4-carboxybenzoyl)quinoline-2- carboxaldehyde 
CDK cyclin dependent kinase 
cDNA complementary deoxyribonucleic acid 
CEL (1-carboxyethyl)lysine 
CMA Nω-carboxymethyl-arginine 
CML Nε-carboxymethyl-lysine 
CO2 carbon dioxide 
CV coefficient of variation 
CVD cardiovascular disease 
Cx36 connexin36 
Cx43 connexin43 
DAPI 4’,6-diamidino-2-phenylindole 
DETAPAC diethylenetriaminepentaacetic acid 
dG deoxyguanosine 
DHA docosahexaenoic acid 
DHAP dihydroxyacetonephosphate 
DMEM Dulbecco’s Modified Eagles Medium 
DMSO dimethyl sulphoxide 
dNTP deoxyribonucleotide triphosphate 
19 
 
DTNB 5,5’-dithiobis-(2-nitrobenzoic acid), Ellman’s reagent 
EASD European Association for the Study of Diabetes 
E-cadherin epithelial-cadherin 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EHS Engelbreth-Holm-Swarm 
EPA eicosapentaenoic acid 
ER endoplasmic reticulum 
EURODIAB European Epidemiology and prevention of diabetes collaborative 
research group established in 1988 
eV electronvolt 
FBS fetal bovine serum 
FL Nε-Fructosyl-lysine 
FTO fat-mass and obesity-related gene 
G guanine 
G6P glucose-6-phosphate 
GA3P glyceraldehyde-3-phosphate 
GDM gestational diabetes mellitus 
GEEK ε-(γ-Glutamyl)lysine 
G-H1 hydroimidazolone of glyoxal, N-(5-hydro-4-imidazolon-2-yl)-
ornithine 
Glo1 glyoxalase 1 
Glo2 glyoxalase 2 
GLUT2 glucose transporter type 2 
GSA glutamic semialdehyde 
GSH reduced glutathione 
GSIS glucose stimulated insulin secretion 
GSSG oxidised glutathione 
HC hyperplastic islet-derived cells 
HCl hydrochloric acid 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HFD high fat diet 
HIT hamster pancreatic beta cell line 
HNF hepatocyte nuclear factor 
HOMA homeostatic model assessment 
HPLC high performance liquid chromatography 
HSA human serum albumin 
ICAM-1 intercellular adhesion molecule -1 
IDF International Diabetes Federation 
IGT impaired glucose tolerance 
IgG immunoglobulin 
IL-1β interleukin-1β 
IL-6 interleukin-6 
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Ins1 rodent insulin gene 1 
Ins2 rodent insulin gene 2 
IRS-1 insulin-receptor substrate 1 
Itgb1 integrin beta 1 
K
+
ATP ATP sensitive potassium channels 
KCl potassium chloride 
KCNJ15 potassium inwardly rectifying channel, subfamily J, member 15 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
LC-PUFA long-chain polyunsaturated fatty acids 
LDL low-density lipoprotein 
LoD limit of detection 
MafA V-maf musculoaponeurotic fibrosarcoma oncogene homologue A 
MAPK mitogen-activated protein kinase 
MC4R melanocortin-4 receptor 
MeCN acetonitrile 
MetSO methionine sulphoxide 
MG methylglyoxal 
MgCl2 magnesium chloride 
MG-H1 hydroimidazolone of methylglyoxal, N-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine 
MGdG Methylglyoxal derived imidazopurinone 3-(2’-deoxyribosyl)-6,7-
dihydro-6,7-dihydroxy-6-methylimidazo[2,3-b]purin-9(8)one 
MIN6 mouse insulinoma derived cell line-6 
MODY maturity onset diabetes of the young 
MOLD methylglyoxal derived lysine dimer 
MRM multiple reaction monitoring 
mRNA messenger ribonucleic acid 
MTT thiazolyl blue tetrazolium bromide 
NA numerical aperture 
NaCl sodium chloride 
NAD+ nicotinamide adenine dinucleotide 
NADH nicotinamide adenine dinucleotide (reduced form) 
NEFA non-esterified fatty acids 
NeuroD1 neurogenic differentiation 1 
NFK N-formylkynurenine 
NOD Non-obese diabetic 
Nrf2 nuclear erythroid factor E2 related factor-2 
ODS octadecyl silane 
PBS phosphate buffered saline 
PCA perchloric acid 
qPCR quantitative polymerase chain reaction 
Pdx-1 pancreatic duodenum homeobox-1 
PFA paraformaldehyde 
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RGD L-arginylglycyl-L-aspartic acid 
RIN rat insulinoma cell line 
ROS reactive oxygen species 
SAX strong anion exchange 
SPE solid phase extraction 
STZ streptozotocin 
SV40 Simian vacuolating virus 40 
T1DM type 1 diabetes mellitus 
T2DM type 2 diabetes mellitus 
TBS tris buffered saline 
TCA trichloroacetic acid 
TES N-[Tris(hydroxymethyl)methyl]-2-aminoethanesulphonic acid 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
TNB 2-nitro-5-thiobenzoate anion 
TNF-α tumour necrosis factor-α 
TQS triple quadrupole mass spectrometry 
UKPDS United Kingdom Prospective Diabetes Study 
VGCC voltage-gated calcium channels 
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1. Introduction: Diabetes Mellitus 
1.1. Classification and types of diabetes mellitus 
1.1.1. Prevalence of diabetes 
Diabetes is a group of metabolic diseases characterised by hyperglycaemia 
which arises from defects in insulin secretion, insulin action, or both (American 
Diabetes Association, 2012).  It poses a major health threat worldwide with 
increasing impact.  The International Diabetes Federation (IDF) estimates that more 
than 371 million people worldwide have diabetes, of which half are undiagnosed  
(International Diabetes Federation, 2012).  In 2008 it was estimated that the number 
of adults worldwide with diabetes was 248 million and that this would reach 380 
million by 2025 (The Lancet, 2008).  Although a number of causative factors are 
implicated in the development of the disease, impairment in the ability to produce, 
release, or respond to insulin, and hence an inability to maintain normal glucose 
levels underlies these causes.  Maintaining normal beta cell function is of paramount 
importance to metabolic health.  Even in healthy individuals insulin secretion 
declines at the rate of 0.7% per year, increasing to 1.2% per year in people with 
impaired glucose tolerance (Szoke, et al., 2008).    
 
1.1.2. Diagnosis of diabetes mellitus  
Diabetes is diagnosed on the basis of plasma glucose criteria: - either a 
fasting plasma glucose concentration greater than 7.0 mM or a plasma glucose 
concentration greater than 11.1 mM after 2 h during an oral glucose tolerance test 
(American Diabetes Association, 2013).  However, in 2009 an International Expert 
Committee composed of representatives of the American Diabetes Association 
(ADA), IDF and the European Association for the Study of Diabetes (EASD) 
recommended the use of the glycated haemoglobin HbA1C  or “A1C” test for 
diagnosis, with a threshold of greater than or equal to 6.5% and this criterion was 
adopted by the ADA in 2010 (American Diabetes Association, 2012; International 
Expert Committee, 2009).  This has the advantage of giving a better indication of 
long-term glycaemic control (glycaemic control in 6 - 8 weeks preceding blood 
sampling) with a mean red blood cell age of 38 – 60 days and so not markedly 
influenced by short-term fluctuations in plasma glucose levels (Cohen, et al., 2008).  
23 
 
An A1C value of between 5.7% and 6.4% has been accepted by the ADA for the 
diagnosis of pre-diabetes – impaired fasting glucose and impaired glucose tolerance 
(IGT), with individuals with A1C measurements above 6% considered at high risk of 
both diabetes and cardiovascular disease (CVD) (American Diabetes Association, 
2013).  This is still controversial and as discussed by Bergman et al. (2013) the 
World Health Organisation has not accepted A1C measurement for diagnosis of 
glucose intolerance, although it has been accepted for diagnosis of diabetes.  The 
A1C measurement has limitations, such as in rapidly developing type 1 diabetes 
mellitus (T1DM) cases it will not be elevated as early as plasma glucose 
(International Expert Committee, 2009).  Haemoglobinopathies such as sickle cell 
anaemia and conditions that affect red blood cell turnover such as malaria, 
haemolytic anaemia, and blood transfusions may lead to unreliable A1C results 
(International Expert Committee, 2009; Kilpatrick, et al., 2009).  It is therefore 
advised that diagnosis of diabetes should be on the basis of repeated analysis or on a 
combination of both A1C and plasma glucose criteria. 
In 1985 a model was published to quantify insulin resistance and beta cell 
function – homeostatic model assessment, HOMA (Matthews, et al., 1985).  This 
model, based on measurements of fasting plasma glucose and insulin, has been 
widely utilised; the impact of this model was discussed by Nolan and Færch (2012).  
HOMA is used as a method to measure insulin resistance, but it has not been used 
extensively to assess beta cell function. 
 
1.1.3. Gestational diabetes 
Gestational diabetes mellitus (GDM) has been defined as ‘any degree of 
glucose intolerance with onset or first recognition during pregnancy’ (The Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997).  
However, recently it has been recommended that women diagnosed with diabetes at 
their initial prenatal visit are diagnosed with overt, and not gestational diabetes, since 
these women, most likely, had undiagnosed type 2 diabetes mellitus (T2DM) before 
pregnancy (American Diabetes Association, 2012).  In GDM not enough insulin is 
secreted during pregnancy to meet the increased demands, and therefore there is an 
increase in blood glucose levels (hyperglycaemia) in both the mother and foetus.  
Most cases of GDM resolve post-delivery, but the hyperglycaemic environment in 
utero may have long term effects on the foetus.  In addition, women diagnosed with 
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GDM are at heightened risk of developing T2DM and some remain diabetic after the 
pregnancy. 
 
1.1.4. Type 1 diabetes mellitus 
T1DM is typically diagnosis in childhood or adolescence, but it can occur at 
any age.  It is characterised by a deficiency in insulin production, with little or no 
insulin being secreted, and is therefore treated by exogenous administration of 
insulin.  The first known use of insulin as a successful treatment for T1DM was in 
January 1922 when Banting and Best used a pancreatic extract isolated by Collip to 
treat a 14 year old, Leonard Thompson.  By the end of 1923, insulin was being used 
commercially and safely as a treatment of T1DM in Western countries (Bliss, 1993). 
Autoimmune destruction of beta cells leads to this absolute insulin deficiency 
(Atkinson and Maclaren, 1994).  There is currently no established prevention of 
T1DM although clinical studies are being conducted to test methods of prevention in 
individuals with evidence of autoimmunity (Orban, et al., 2011; Pescovitz, et al., 
2009).  Incidence of T1DM in children under the age of 15 in Europe is predicted to 
increase from 94,000 in 2005 to 160,000 in 2020 and evidence from the Europe and 
Diabetes Study (EURODIAB) register predicts that new cases in children under the 
age of five will double between 2005 and 2020 (Ma and Chan, 2009; Patterson, et 
al., 2009). 
   
1.1.5. Type 2 diabetes mellitus 
T2DM is the most common form of diabetes mellitus, accounting for over 
90% of cases globally (American Diabetes Association, 2012; Zimmet, et al., 2001).  
It is characterised by a state in which tissues in the body become less responsive or 
resistant to insulin - insulin resistance - and/or insufficient insulin is secreted, either 
of which may predominate.  Gerald Reaven was the first to define insulin resistance 
in the pathogenesis of T2DM (Nolan and Færch, 2012; Reaven, 1988).  Although 
insulin levels may initially appear normal, or even elevated (hyperinsulinaemia), 
given the higher blood glucose levels observed in such patients with diabetes, there 
is a relative deficiency of insulin activity in comparison to that expected with normal 
beta cell function (American Diabetes Association, 2011).  Hyperglycaemia 
develops gradually and T2DM is often asymptomatic; therefore it often goes 
undiagnosed for a number of years. 
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 T2DM is a multi-factorial disease with both modifiable lifestyle factors - 
obesity and inactivity - and non-modifiable risk factors - age and genetic 
susceptibility - increasing the risk.  Studies of diabetes in monozygotic twins has 
indicated that genetic susceptibility is implicated to a greater extent with age – with 
more discordance observed in twins diagnosed at a younger age.  In addition, the 
concordance rate was higher in identical than non-identical twins regardless of age of 
onset indicating the genetic involvement (Barnett, et al., 1981).  Most genetic risk 
loci currently discovered act through changes in insulin secretion and beta cell 
function and not through insulin action.  Abnormalities in beta cell mass and 
function are critical in the development of type 2 diabetes (Florez, 2008; McCarthy, 
2010; Rosengren, et al., 2012).  Some of the known genetic variants associated with 
T2DM are listed in Table 1.  Whilst a number of risk variants have been identified, 
their impact is limited as indicated by the association of the fat-mass and obesity-
related (FTO) gene; it is one of the strongest known associations of genetic loci with 
obesity and body mass index (BMI) and accounts for less than 0.5% of overall 
variance in BMI.  This equates to approximately a 2 - 3 kg difference between adults 
homozygous for the risk allele and those homozygous for the alternative allele 
(McCarthy, 2010). 
 Lifestyle intervention studies in the United States, China and Finland 
targeting diet and exercise have shown efficiency of these interventions in 
decreasing the risk of developing diabetes from IGT.  Other studies, such as the 
United Kingdom Prospective Diabetes Study (UKPDS), indicate that these 
interventions would not be sufficient to prevent all cases of T2DM (UKPDS, 1995; 
UKPDS, 1998; Zimmet, et al., 2001). 
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Table 1: Genetic Susceptibility factors implicated in T2DM 
Data source: American Diabetes Association (2004), Mathews and Mathews (2012), 
McCarthy (2010), McCarthy et al. (2013), Rosengren et al. (2012), and Voight et al. 
(2010).  
 
Genetic factor Implication in diabetes 
Hepatocyte nuclear 
factor (HNF)-1α 
Abnormalities cause the most common form of maturity 
onset diabetes of the young (MODY).  It is also a known 
risk variant for type 2 diabetes.  HNF-1α is expressed in 
the liver, but affects the expression of insulin. 
TCF7L2 A transcription factor which modulates pancreatic islet 
function – implicated in beta cell dysfunction.  Associated 
with decreased glucose stimulated insulin secretion (GSIS) 
and decreased depolarisation evoked insulin exocytosis.  
Genetic variants in TCF7L2 have a 30% increase in risk 
per risk allele - the largest known effect on T2DM 
susceptibility. 
Melanocortin-4 
receptor (MC4R) 
Low frequency coding variants implicated in 2 - 3% of 
severe obesity. 
CDKAL1, CDKN2A 
and CDKN2B 
Regulators of cyclin dependent kinases (CDKs).  Each 
copy of a susceptibility allele of these loci is associated 
with 15 - 20% increased risk of diabetes; implicated in 
decreased beta cell mass and decreased insulin secretion. 
Insulin-receptor 
substrate 1 (IRS1) 
Risk variant for T2DM implicated in insulin resistance. 
FTO One of strongest associations of genetic loci with obesity 
risk and BMI. 
KCNQ1 
 
Encodes a voltage-gated potassium channel.  Variants 
affect insulin granule docking and show decreased 
depolarisation-evoked insulin secretion – hence impaired 
exocytosis and declining beta cell function. 
Potassium inwardly 
rectifying channel, 
subfamily J, member 
15 (KCNJ15) 
Associated with beta cell dysfunction.  The risk allele is 
present at elevated levels due to increased mRNA stability.  
Overexpression of KCNJ15 in the beta cell line INS-1 
resulted in decreased GSIS. 
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1.1.6. Other types of diabetes mellitus  
There are other types of diabetes mellitus of low prevalence, including 
diabetes linked to rare genetic mutations, pre-existing pancreatic disease and 
endocrine disorders with diabetes as an associated complication.  Approximately 1 -
2% of the total diabetes mellitus cases are monogenic (Muoio and Newgard, 2008).  
These cases are usually diagnosed at a young age and involve defects in GSIS.  
Genetic conditions, known as MODY, include mutations in HNF-1α, Neurogenic 
differentiation 1 (NeuroD1) and glucokinase and are inherited in an autosomal 
dominant pattern (American Diabetes Association, 2012).  The most common form 
of MODY involves a mutation in the transcription factor HNF-1α and results in 
impaired insulin secretion.  Similarly, mutation of the transcription factor NeuroD1 
impairs insulin secretion through its effect on insulin gene expression.  Glucokinase 
mutations result in defective protein production and consequently defects in glucose 
sensing within the beta cell; increased plasma glucose levels are therefore necessary 
to stimulate normal insulin secretion in the pancreas (Tinto, et al., 2008; Zhang, et 
al., 2009).   
Extensive damage to the pancreas by diseases such as pancreatitis and cystic 
fibrosis, or by trauma, as well as endocrinopathies such as Cushing’s syndrome and 
glucagonoma can also lead to diabetes (American Diabetes Association, 2012).  In 
Cushing’s syndrome and glucagonoma excessive amounts of cortisol and glucagon 
respectively, antagonise the action of insulin and can cause diabetes (American 
Diabetes Association, 2004).  These rare forms of the disease highlight the 
fundamental importance of beta cell function to the maintenance of metabolic health, 
and highlight the complexity of its regulation.   
 
1.1.7. Diabetes insipidus 
 Diabetes insipidus is a rare condition unrelated to diabetes mellitus.  It is 
primarily a hormonal condition relating to a lack of or decreased sensitivity to anti-
diuretic hormone, and therefore leads to problems in the kidney and an inability to 
conserve water (Spanakis, et al., 2008).  Diabetes insipidus is unrelated to beta cell 
function; any further discussion of diabetes will therefore refer to diabetes mellitus 
and not to diabetes insipidus. 
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1.2. Complications of diabetes 
 There is a significant increase in morbidity and mortality as well as a 
financial cost of patient care associated with diabetes; 4.8 million deaths were 
attributed to diabetes in 2012 – equivalent to a death every 7 s, half of which were of 
people between the ages of 20 and 60 (Guariguata, 2012; International Diabetes 
Federation, 2012).  Additionally, treatment of diabetes accounted for 11% of global 
healthcare expenditure in 2011 (International Diabetes Federation, 2012).  Although 
good diabetes management can decrease the risk of complications, some studies 
show at least one complication present in more than 50% of people at the time of 
diagnosis with diabetes and consequently life expectancy is more than 8 years lower 
in patients with diabetes  (Franco, et al., 2007; International Diabetes Federation, 
2011). 
 Complications of diabetes include: microvascular complications – 
nephropathy, retinopathy and neuropathy; macrovascular complications – increased 
risk of CVD and cerebrovascular disease; and others – cataract and embryo 
malformations in pregnancy.  CVD is the major cause of morbidity and mortality for 
patients with diabetes; 50% of diabetes-associated deaths are attributed to CVD (The 
Lancet, 2008).  Although conditions which commonly coexist with T2DM, such as 
dyslipidaemia and hypertension, are also risk factors for CVD, diabetes is an 
independent risk factor for CVD (American Diabetes Association, 2013).  The global 
impact of beta cell dysfunction and diabetes, and the numerous complications, 
highlight the importance of maintaining glycaemic control and beta cell function; 
hence the necessity of improving our understanding of the factors which control it.   
 
1.3. Biology of beta cells 
1.3.1. Functional role and biochemistry  
The functional role of pancreatic beta cells is to secrete insulin in response to 
raising blood glucose levels – GSIS.  Insulin is an anabolic hormone involved in: 
carbohydrate metabolism – increasing glucose uptake in skeletal muscle, adipose 
tissue and liver, increasing the activity of glycogen synthase, glycolysis and the 
pentose-phosphate pathway and decreasing glycogenolysis and gluconeogenesis; 
lipid metabolism – increasing fatty acid and triglyceride synthesis in adipose tissue 
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and liver and decreasing lipolysis in adipose tissue and ketone body synthesis in the 
liver; and protein metabolism – increasing amino acid transport and protein synthesis 
in muscle, adipose tissue and liver, and decreasing protein degradation in muscle 
(Taniguchi, et al., 2006).  
Glucose enters pancreatic beta cells via the glucose transporter type 2 
(GLUT2).  These transporters are the lowest affinity and highest capacity glucose 
transporters, with a KM of 17 mM (Johnson, et al., 1990a).  This confers a high 
capacity for glucose uptake into beta cells by facilitated diffusion when plasma 
glucose levels increase, and therefore enables responses to subtle changes in plasma 
glucose concentration.  However, since glucose is taken up into beta cells in far 
higher quantities than can be metabolised – a 75% decrease in transport has been 
calculated to be necessary to limit glucose usage by islets, it is thought that GLUT2 
does not act directly as a glucose sensor but rather glucose transport beyond that 
required for sensing occurs (Efrat, 1997; Johnson, et al., 1990b).  It was rather 
suggested that phosphorylation of glucose by glucokinase to form glucose-6-
phosphate (G6P) acts as the mechanism by which extracellular glucose levels are 
coupled to insulin secretion (Matschinsky, 1990). 
The biochemical pathway by which glucose entry via GLUT2 into beta cells 
leads to insulin granule exocytosis is shown in Figure 1.  Glucose metabolism leads 
to an increase in the ATP:ADP ratio and the consequential closure of ATP sensitive 
potassium channels (K
+
ATP).  The subsequent membrane depolarisation activates 
voltage-gated calcium channels (VGCC), leading to calcium influx and hence an 
increase in the intracellular calcium concentration ([Ca
2+
]i) – the triggering signal for 
exocytosis (Muoio and Newgard, 2008).  The increase in intracellular calcium also 
activates the slow calcium-activated potassium channel (KCa,slow) which removes 
potassium ions from the cell, helping to repolarise the beta cells and prevent 
continuous calcium influx and insulin release (Nunemaker, et al., 2004).  It has also 
been suggested that increases in intracellular calcium may open K
+
ATP channels, and 
thus contribute to cell repolarisation (Nunemaker, et al., 2004). 
Medium and long chain fatty acids and amino acids act as physiological 
potentiators of insulin secretion (Itoh, et al., 2003; Newsholme, et al., 2005).  The G 
protein coupled receptor GPR40 functions as a receptor for free fatty acids in 
pancreatic islets; its expression is 17 times greater in the islets than in the total 
pancreas and it is non-specific for fatty acids (Briscoe, et al., 2006; Itoh, et al., 
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2003).  Activation of this receptor was shown to increase intracellular calcium 
through release from intracellular stores, such as the endoplasmic reticulum (ER), 
thereby amplifying the triggering signal for GSIS.  The stimulatory effects of both 
oleic and linoleic acids on insulin secretion were greater in high glucose conditions 
indicating that these fatty acids potentiate GSIS (Itoh, et al., 2003).  Fatty acids are 
necessary for insulin secretion; they function to maintain basal insulin secretion as 
well as ‘priming’ beta cells to respond to elevated glucose levels (Briscoe, et al., 
2006; Corkey, 2012). 
The mechanisms by which amino acids enhance insulin secretion vary.  
Arginine, in the presence of glucose, directly depolarises the plasma membrane.  
Other amino acids, such as alanine, are co-transported into the beta cells with sodium 
and consequently lead to depolarisation as a result of the sodium transport.  The 
metabolism of alanine also leads to an increase in the ATP:ADP ratio within the cell.  
Mitochondrial metabolism of glucose is crucial to the action of amino acids on 
insulin secretion.  Amino acids increase mitochondrial metabolism by increasing 
substrate availability for the Krebs cycle as well as by the activation of glutamate 
dehydrogenase by leucine (Newsholme, et al., 2005).  The effects of alanine and 
arginine on insulin secretion are illustrated in Figure 1. 
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Figure 1: The biochemical pathway of GSIS in the beta cell including the role of amino acids and free fatty acids.  Glucose metabolism 
generates an increase in the ATP:ADP ratio, which inhibits the ATP-sensitive potassium channels and leads to membrane depolarisation.  The 
resultant calcium influx acts as the triggering signal for insulin granule exocytosis. 
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1.3.2. Structure of pancreatic islets  
Beta cells form a central core within pancreatic islets of Langerhans in mice.  
Other cells, such as glucagon secreting alpha cells, form a peripheral mantle 
surrounding the beta cells.  This differs to the architecture of human islets where beta 
cells are interspersed with non-beta cells (Jain and Lammert, 2009).  Pancreatic islets 
have an extensive vascular supply ensuring that beta cells are supplied with the 
necessary nutrients and can regulate blood glucose levels appropriately.  It has been 
suggested that no part of the pancreatic islets is more than a cell away from the 
arterial blood supply and that all cells are surrounded by the structural basement 
membrane – the specialised extracellular matrix (ECM) (Olsson and Carlsson, 2011; 
Otonkoski, et al., 2008).  Up to 15 - 20% of the pancreatic blood flow is received by 
the pancreatic islets of Langerhans despite them representing approximately 1 - 2% 
of the total organ mass, distributed in clusters throughout the pancreas; this indicates 
how highly vascularised the islets are (Ahnfelt-Rønne, et al., 2012; Stendahl, et al., 
2009). 
 
1.3.3. ECM and cell-cell coupling  
Pancreatic beta cells function within an organ system; cell to cell coupling 
and interactions with other beta cells, other types of cells and with proteins of the 
basement membrane are vital to their integrated response to nutrient stimuli.  This 
was indicated by the calcium response to glucose stimuli being greater when cells 
were cultured as three-dimensional islet-like structures than when cultured as a 
monolayer (Hauge-Evans, et al., 1999).  Other studies, such as that of Hopcroft et al. 
(1985), indicated that basal insulin secretion could be increased by re-aggregation of 
dispersed islets.  Signalling between beta cells is therefore necessary for maintenance 
of normal beta cell function and insulin secretion.  A more recent study by 
Konstantinova et al. (2007) showed that when the cell density of the insulinoma cell 
line MIN6 was increased there was a decrease in the basal insulin secretion and an 
increase in GSIS.  This again indicates the importance of cell to cell communication 
to beta cells.  
Gap junctions are channels between cells composed of connexins which 
enable the transfer of cytoplasmic ions and metabolites.  They have been proposed to 
be involved in the coordination and synchronisation of cellular responses in beta 
cells (Jain and Lammert, 2009).  Vozzi et al. (1995) showed a causal link between 
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loss of gap junctional communication and impairment of insulin secretion.  It was 
demonstrated that separation of beta cells resulted in a decrease in both insulin 
biosynthesis and secretion, proposed to be due to connexin43 (Cx43) since insulin 
secreting cell lines with secretory defects often lack Cx43.  However, this conclusion 
has been more recently disputed.  Connexin36 (Cx36) has been shown to form gap 
junctional complexes in beta cells whilst Cx43 has not been found in either the 
insulin secreting cell line MIN6 or in primary beta cells (Cigliola, et al., 2013; Jain 
and Lammert, 2009; Serre-Beinier, et al., 2000).  It is therefore considered that 
connexins have a vital role in communication between beta cells and that Cx36 
underlies this communication.   
The role of Epithelial-cadherin (E-cadherin) in GSIS was indicated by studies 
showing that down regulation of E-cadherin in MIN6 cells decreased GSIS to similar 
levels as found in unattached cells.  This suggests that E-cadherin may be necessary 
for synchronisation of glucose stimulated calcium oscillations (Rogers, et al., 2007).  
Silencing cadherins in MIN6 cells using small interfering RNA also decreased GSIS, 
whilst exposure to an anti-cadherin antibody blocked the elevation of intracellular 
calcium in response to glucose stimulation (Jaques, et al., 2008; Yamagata, et al., 
2002).  
Interactions of beta cells with ECM proteins are also necessary for optimal 
beta cell function (Weber, et al., 2008).  Interactions with collagen IV and laminin 
improve MIN6 cell survival and the presence of ECM proteins in the extracellular 
environment also increased insulin secretion (Weber, et al., 2008).  ECM proteins in 
the basement membrane surrounding beta cells promote cell survival.  When cells 
are detached from their natural ECM environment in the pancreas they undergo 
apoptosis; this can be prevented in vitro by culturing cells on collagen IV or laminin 
(Pinkse, et al., 2006).  Beta cells interact with basement membrane proteins via 
integrins.  Heterodimers containing the β1-integrin have been suggested to affect 
insulin transcription and secretion, as well as cell proliferation (Kragl and Lammert, 
2010).  The expression of ECM proteins such as collagen IV has been suggested to 
regulate insulin secretion with the specific interaction between the α1β1-integrin 
heterodimer and collagen IV potentiating insulin secretion (Eberhard, et al., 2010; 
Kaido, et al., 2004; Kragl and Lammert, 2010).  The known components of the 
basement membrane surrounding pancreatic beta cells and the integrin receptors 
through which they interact with pancreatic beta cells are given in Table 2.   
34 
 
Table 2: Matrix proteins and their receptors on pancreatic beta cells 
Adapted from Weber et al. (2008). 
 
Recently syndecan-4, a cell-surface proteoglycan, has been shown by 
immunostaining to be present on insulin-positive but not glucagon-positive cells.  It 
has also been shown to be present in MIN6 cells and it was therefore suggested that 
beta cells form some of the basement membrane components (Cheng, et al., 2012a).  
The cytoplasmic domain of syndecan-4 binds to phosphatidylinositol 4,5-
bisphosphate and has intracellular effects through activation of protein kinase Cα in 
a calcium independent manner (Simons and Horowitz, 2001).  Syndecans have been 
described as co-receptors as they frequency work alongside other receptors, 
particularly integrins in interactions with ECM proteins.  Syndecans and integrins 
collaborate in mediating cell adhesion to ECM proteins and the processes these 
interactions regulate, including cell migration and cell spreading (Xian, et al., 2010).  
However, syndecan-4 knockout mice showed no significant impairments in 
pancreatic function; this may indicate that their role is limited, or alternatively, as 
suggested by Cheng et al. (2012a) that there is isoform redundancy and other 
syndecan isoforms are upregulated to compensate.  Whilst these proteoglycans have 
been suggested by Cheng et al. (2012a) to be the missing link to maintaining islet 
longevity after isolation, further work is required to fully understand their role and 
the interactions of syndecans with integrins in the basement membrane of the islets 
of Langerhans. 
 
 
 
 
Protein Localisation Integrin Receptor 
Collagen IV Basement membrane α1β1 
Laminin Basement membrane α1β1,  α3β1,  α5β1,  α6β1 
Collagen I ECM  αVβ3,  α2β1 
Fibrinogen Plasma αVβ3 
Fibronectin Plasma, ECM  αVβ1,  αVβ3,  α5β1 
Vitronectin Plasma, ECM  αVβ1,  αVβ3,  αVβ5 
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1.3.4. Insulin gene expression 
Humans have one insulin gene designated the abbreviation INS.  The primary 
translational product of INS is preproinsulin.  The signal peptide is cleaved in the 
ER, leaving proinsulin which is processed further to produce insulin (Støy, et al., 
2007).  This differs to the expression in rodents wherein insulin is expressed by two 
genes: Ins1 and Ins2.  Ins2 has the greater structural homology to other mammalian 
insulin genes with conservation of nucleotide sequence in the coding region and 
identical arrangement of introns and exons (Wentworth, et al., 1986).  Ins1 contains 
only one of the two introns present in Ins2 and other mammalian insulin genes and is 
considered to be a functional retroposon – a repetitive DNA fragment inserted into 
the DNA following reverse transcription from RNA (Kuroda, et al., 2009).  
Phylogenetic analysis has shown Ins1 to have originated before the separation of rat 
and mouse 15 million years ago and is a rodent specific retrogene (Hay and 
Docherty, 2006; Shiao, et al., 2008).   
Both Ins1 and Ins2 are expressed in mouse islets and contain homologous 
regulatory regions upstream of the gene itself.  However, as discussed by Roderigo-
Milne et al. (2002) this homology extends to approximately 500 base pairs upstream 
of the transcriptional start site; regulatory regions further upstream may contribute to 
differences in responsiveness of the genes.  Their studies of the murine MIN6 cell 
line indicated that Ins1 expression, but not Ins2 expression, is altered by both 
glucose stimulation and cell-cell contact, thereby indicating that in this system there 
is differential control of the expression of these 2 genes (Roderigo-Milne, et al., 
2002).  Previous studies using wild type and Ins1 and Ins2 knockout mice showed 
that the presence of either Ins1 or Ins2 is sufficient to prevent diabetes, with a similar 
level of pancreatic insulin observed in both single homozygous mutants and the wild 
type mouse.  The double homozygous mutant had severe insulin deficiency and 
diabetes (Leroux, et al., 2001).  Both the human insulin gene and the mouse Ins2 
gene have biallelic expression in the adult.  Demethylation of the insulin gene 
promoter region specifically in beta cells has been suggested to be an important step 
in the differentiation of insulin producing cells from embryonic stem cells (Kuroda, 
et al., 2009).  The insulin gene promoter spans approximately 400 base pairs 
upstream of the transcriptional start site.  The compact promoter region enables 
overlap of regulatory elements and synergistic interactions.  It is highly conserved in 
mammals with a decline in homology observed beyond 400 base pairs upstream of 
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the transcriptional start site (Hay and Docherty, 2006).  The regulatory sequences of 
the A3, C1 and E1 boxes and their flanking sequences are highly conserved between 
species, with 100% homology between the 5’ flanking region of the A3 box in 
mouse Ins2 and human INS.  The homology between INS and the mouse Ins1 is 
87% indicating a greater degree of homology between Ins2 than Ins1 and the single 
INS gene of other mammalian species (Hay and Docherty, 2006).  There are 
however differences between the promoter regions of human and rodent insulin 
genes, such as the spacing between the key regulatory elements, which will impact 
upon synergistic interactions – rodent insulin promoters contain insertions and 
deletions between the three regulatory domains (Hay and Docherty, 2006).  
Blood glucose regulates insulin production through its modulation of three 
beta cell specific transcriptional regulators – Pancreatic duodenum homeobox-1 
(Pdx-1), V-maf musculoaponeurotic fibrosarcoma oncogene homologue A (MafA) 
and NeuroD1 (Andrali, et al., 2008).  Pdx-1, MafA and NeuroD1 bind to the A3, C1 
and E1 sites of the insulin promoter respectively to stimulate insulin gene expression 
synergistically in response to elevated glucose levels.  It is suggested that the 
subcellular localisation of NeuroD1 is altered in response to changing glucose levels, 
being translocated from the cytoplasm to the nucleus when the glucose concentration 
is elevated (Andrali, et al., 2008).  The expression of MafA is regulated by glucose; 
transcription increases in response to high glucose concentrations.  The DNA-
binding activity of Pdx-1 and its interaction with both activators and repressors is 
modulated by glucose (Andrali, et al., 2008).  Glucose also increases the stability of 
the preproinsulin mRNA transcript through regulation of the binding of a binding 
protein to the pyrimidine-rich sequence in the 3’ untranslated region as well as 
promoting the translation of the preproinsulin transcript in beta cells (Poitout, et al., 
2006; Tillmar, et al., 2002; Welsh, et al., 1985; Wicksteed, et al., 2001).  In addition, 
glucose upregulates mRNA translation specifically in beta cells, particularly of 
granule proteins such as insulin (Bensellam, et al., 2012; Tillmar, et al., 2002; 
Vander Mierde, et al., 2007).  This ensures that enough insulin is available to meet 
the higher demands. 
 
1.3.5. Mechanisms of regulation of insulin secretion  
Production and secretion of insulin are independently regulated with insulin 
prepared and stored in granules in beta cells awaiting secretion upon stimulus.  As 
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well as nutritional stimuli (glucose, fatty acids and amino acids) insulin release is 
further modulated by a number of other factors including sympathetic and 
parasympathetic innervation, feedback mechanisms of insulin and glucagon and 
other environmental cues (interactions with other cells and the basement membrane).  
Parasympathetic innervation of beta cells, mediated by the action of acetylcholine 
through M3 muscarinic receptors, is stimulatory to both insulin secretion and 
synthesis.  Sympathetic innervation of beta cells, mediated by noradrenaline acting 
through adrenergic receptors, is inhibitory (Eberhard and Lammert, 2009; Gautam, et 
al., 2006).  The importance of this innervation was demonstrated by Gautam et al. 
(2006) who found mice lacking the M3 muscarinic receptor specifically in beta cells 
displayed IGT and reduced insulin release.  The same study also showed that if this 
receptor was overexpressed in beta cells mice displayed improved glucose tolerance 
and were resistant to diet-induced IGT and hyperglycaemia. 
There are interactions between the cells of the islets of Langerhans – some of 
these are paracrine, others occur through the systemic circulation.  In rodent islets, it 
has been shown that blood flows from beta cells to alpha and gamma cells, therefore 
whilst secretion from beta cells can directly affect other cell types within the islets, it 
is not believed that this is reciprocal.  Rather, glucagon and somatostatin pass 
through the systemic circulation before affecting beta cells (Kanno, et al., 2002).  
The inhibitory paracrine effect of insulin on alpha cells and glucagon production is 
well established and has been demonstrated in both rodents and humans.  The high 
level of insulin receptor expression in alpha cells, similar to that of the liver, 
indicates the importance of this paracrine interaction (Asplin, et al., 1981; 
Cooperberg and Cryer, 2010; Franklin, et al., 2005).  The negative effect of insulin 
secretion on glucagon production is thought to be due directly to the action of insulin 
and also due to zinc, which is co-released in insulin granules.  Zinc and insulin 
together increase K
+
ATP channel activation and thus inhibit glucagon secretion 
(Franklin, et al., 2005).  
 It has long been known that glucagon is stimulatory to insulin release 
(Samols, et al., 1966).  More recently evidence has suggested that this effect is 
through glucagon receptors on beta cells and intracellular cAMP increases (Huypens, 
et al., 2000; Kanno, et al., 2002).  Insulin also has an autocrine effect on its own 
production, as well as on beta cell survival and proliferation.  These effects are 
mediated by insulin binding to insulin receptors on beta cells (Jain and Lammert, 
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2009; Kulkarni, et al., 1999).  The study performed by Kulkarni et al. (1999) showed 
that knockout of the insulin receptor specifically in pancreatic beta cells in mice 
resulted in a loss of GSIS and progressive impairments in glucose tolerance – similar 
to observed in T2DM.  Research using a beta cell specific knockout of the insulin 
receptor has implicated the insulin receptor in beta cell proliferation, especially the 
compensatory islet growth of states of insulin resistance and obesity  (Okada, et al., 
2007).  This indicates that beta cell physiology is tightly regulated.  Changes in 
secretion of insulin, and the factors regulating it, as well as insulin resistance of the 
beta cells may be implicated in beta cell dysfunction. 
 
1.4. Maintenance of beta cell mass 
 Beta cell number is determined by the initial number of cells formed during 
development and by the rate of turnover.  The turnover of beta cells is determined by 
the rate of beta cell formation and the rate of beta cell loss by apoptosis (Taylor, 
2006).  Factors which affect either the rate of formation of beta cells or the rate of 
beta cell apoptosis will affect the beta cell mass and consequently the physiology and 
functionality of the endocrine pancreas. 
 
1.4.1. Growth and regeneration 
Growth of pancreatic islets could occur by either beta cell replication, 
neogenesis (formation from stem cells and progenitor cells) or a combination of 
both.  In 1911 it was suggested that islet growth occurred by both replication and 
differentiation (Bensley, 1911).  However at this early stage the function of islet cells 
was unknown.  Genetic studies, such as that performed by Dor et al. (2004) have 
questioned the role of neogenesis in the formation of pancreatic beta cells in adults.  
In this study a tamoxifen-inducible Cre-lox system was used to label beta cells; the 
proportion of these labelled cells that remained after 4, 6, 9 and 12 months was 
measured.  It was concluded that cells were either post-mitotic or derived from 
existing beta cells by self-duplication since this label was not diluted with time.  
However, this evidence has been disputed and the study criticised due to the low 
level of labelling used (approximately 30%) and that neogenesis was discounted on 
the basis of a lack of label dilution (Bonner-Weir, et al., 2010).  Indeed, these two 
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processes are not mutually exclusive, and it is possible, and indeed likely, that both 
duplication and neogenesis contribute to the maintenance of beta cell mass after 
birth.  These processes are not fully understood due largely to experimental 
limitations; in humans, evidence is predominantly based on observations at autopsies 
and surgery.  Recent studies indicate that in adult humans beta cell replication is 
negligible, although it may occur with significant impact on beta cell mass in 
children (In't Veld, et al., 2010; Perl, et al., 2010).  This is likely due to the slow 
turnover of beta cells in human adults wherein only about one per cent of beta cells 
enter into the mitotic phase from the resting G0 stage of mitosis (Skelin, et al., 2010).  
Given the current evidence, both replication and neogenesis are likely involved in 
maintaining beta cell mass after birth.  Contributions of the two factors vary 
depending on the conditions used and species studied. 
 
1.4.2. Beta cell decline with age  
The prevalence of both IGT and diabetes increases markedly with age from 
under 5% in individuals under the age of 30 to greater than 20% in individuals over 
the age of 70 (International Diabetes Federation, 2012; Shaw, et al., 2010; Szoke, et 
al., 2008).  The study by Szoke et al. (2008) examining the effect of ageing on 
glucose homeostasis and insulin secretion concluded that in healthy individuals with 
normal glucose tolerance, insulin secretion declined at a rate of approximately 0.7% 
per year.  This decline was more rapid in people with IGT at 1.2% per year.  The 
involvement of impairments in function or decreases in beta cell mass in the cause of 
this decline was not determined, although it was hypothesised to be due to a decrease 
in beta cell mass.  This is consistent with an earlier study which showed changes in 
both rates of apoptosis and proliferation in human pancreatic islets with ageing 
(Maedler, et al., 2006).  More recently, evidence has indicated that the age-related 
decrease in replication of beta cells is due to systemic circulating factors, although 
the identity of these factors is not known (Salpeter, et al., 2013).  However, it is 
estimated that beta cell area – the fractional beta cell area of the pancreas measured 
in a large representative section of the tissue removed at surgery - has declined by 
approximately 65% when diabetes develops.  Therefore, age alone cannot account 
for the deterioration in beta cell mass and function leading to the development of 
IGT and T2DM.  The decline in beta cell mass is far greater in individuals with 
diabetes (Meier, et al., 2012).  In addition, Szoke et al. (2008) demonstrated that 
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ageing has no apparent effect on insulin sensitivity – assessed using HOMA and 
hyperglycaemic clamp techniques, but rather has effects only on beta cell function 
and the ability of the islets to secrete sufficient insulin. 
 
1.4.3. Beta cell reserve capacity  
It is often assumed that anatomical and functional beta cell mass are the 
same.  Studies such as that of Chen et al. (2008) have used insulin as an indirect 
measure of beta cell mass, whereas this actually indicates the functional mass of beta 
cells producing and secreting insulin.  Weir and Bonner-Weir (2011) recently 
discussed evidence provided by Olsson and Carlsson (2011) that there may be 
differences between functional and actual beta cell mass.  Olsson and Carlsson 
(2011) indicated that there is a low-oxygenated population of islets which are 
functionally dormant, but act as a functional reserve of endocrine cells.  They 
showed, by means of partial pancreatectomy, that the number of low-oxygenated 
dormant islets could be altered and activated when demand increases.  Based on this, 
it was hypothesised that dormant islets are activated on demand – as desired in 
pregnancy and insulin resistance of pre-diabetes and T2DM and also inactivated 
when demand decreases – such as after weight loss (Weir and Bonner-Weir, 2011).  
However, the plasticity and adaptability of the endocrine pancreas varies between 
species; for example, the beta cell mass can be increased several fold in obese 
rodents whereas the capacity to increase beta cell mass is only 20 - 50% in human 
subjects (Henquin, et al., 2008).  Caution should therefore be taken in extrapolating 
conclusions across species; although this phenomenon has been demonstrated in 
rodents, it is not known whether it occurs in humans (Weir and Bonner-Weir, 2011).  
 
1.4.4. Factors promoting beta cell survival  
 Beta cells interact with other beta cells via processes involving E-cadherin 
and Cx36, as well as interacting with ECM proteins.  These interactions promote 
beta cell survival (Parnaud, et al., 2011; Pinkse, et al., 2006).  The protective nature 
of these interactions indicates the importance of not only individual beta cells, but 
also communication with other beta cells and between beta cells and the ECM.  
Damage to the ECM and associated loss of cell attachment may lead to either a 
decrease in insulin secretion from individual cells or a decrease in the beta cell mass.   
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1.5. Factors implicated in the beta cell decline of diabetes 
 The decrease in insulin secretion observed in diabetes is due to interplay 
between a loss of beta cell function and alterations in beta cell survival/growth.  The 
latter is due to impairments in the maintenance of beta cell mass – Figure 2.  It has 
been shown that beta cell replication is not altered in individuals with diabetes 
compared to healthy controls but rather that replication was low in both groups 
(Butler, et al., 2003).  Neogenesis was shown to increase in obesity, but was no 
different in weight match individuals with and without diabetes (Butler, et al., 2003).  
The study showed a significant increase in apoptosis of beta cells in people with 
diabetes.  This shift in the balance of beta cell formation and apoptosis prevents the 
maintenance of beta cell mass and likely contributes to the decrease in both beta cell 
mass and insulin secretion seen in diabetes.  Other studies, such as those discussed 
by Taylor (2006), showed a substantial decline in beta cell mass in T2DM.  
Estimates of beta cell mass at the onset of diabetes vary – from a 25 - 50% decline to 
a 65% decline (Chang-Chen, et al., 2008; Meier, et al., 2012).  The decrease in beta 
cell mass alone is not thought to be sufficient to cause T2DM – further beta cell 
dysfunction is involved in the deleterious effects of the pathogenesis of diabetes, of 
which numerous factors have been implicated, some of which are illustrated in 
Figure 2 (Chang-Chen, et al., 2008).  
The decline in functional activity of beta cells in diabetes may also be due to 
less effective insulin secretion.  The insulin secretion pathway is well characterised 
(Figure 1) and mutations or environmental factors affecting components of this 
pathway, or associated modulators and regulators, will affect insulin secretion.  
Reviews such as that by Muoio and Newgard (2008) have discussed the many 
factors implicated in the development of insulin resistance and T2DM.  These 
include hormonal and inflammatory factors, genetic susceptibility, nutritional 
overload – as occurs in obesity, ER stress and protein glycation – as given in Table 
3.  As can be seen from the numerous factors implicated in the pathogenesis of 
diabetes, there is no consensus as to a single pathway or mechanism by which 
chronic exposure of pancreatic islets to hyperglycaemia (and hyperlipidaemia) leads 
to the deleterious effects on the beta cell phenotype and consequential diabetes – the 
concept of glucotoxicity (or glucolipotoxicity) (Muoio and Newgard, 2008).  Rather, 
it is thought that the numerous stresses discussed are inter-related and act at multiple 
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levels to cause dysfunction through alterations in gene expression, function, survival 
and growth (Bensellam, et al., 2012; Jonas, et al., 2009; Muoio and Newgard, 2008).  
Indeed, detrimental effects of fatty acids on beta cell function have been shown to 
only occur if high glucose is also present – hence the concept glucolipotoxicity to 
describe the beta cell impairments of the combined metabolic overload (Muoio and 
Newgard, 2008; van Raalte and Diamant, 2011).  
 
 
Figure 2: Possible mechanisms of beta cell dysfunction from glucotoxicity.  
Exposure of beta cells to a number of metabolic stresses associated with elevated 
glucose can cause dysfunction through effects on gene expression and functionality 
as well as the balance of cell production and cell death (apoptosis) – the concept of 
glucotoxicity.  Adapted from Jonas et al. (2009).  
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Table 3: Factors implicated in development of diabetes 
Factor Implication in diabetes References 
Genetics Susceptibility factors (Table 1) and rare 
monogenic inheritance forms of diabetes are 
implicated.  Other genetic syndromes – such as 
Klinefelter, Turner, Down and Prader-Willi 
syndromes – are associated with increased 
incidence of diabetes. 
(American 
Diabetes 
Association, 
2012) 
Obesity Obesity may lead to insulin resistance in 
liver/skeletal muscle as well as accumulation of 
other factors implicated in the pathogenesis of 
diabetes (mitochondrial stress and increases in 
reactive oxygen species (ROS)) due to nutritional 
and metabolic overload.  Central obesity and an 
increased BMI correlate with loss of beta cell 
function and greatly increase the lifetime risk of 
developing diabetes. 
(Muoio and 
Newgard, 2008; 
Narayan, et al., 
2007; van 
Raalte and 
Diamant, 2011) 
Age Insulin secretion decreases at approximately 0.7% 
per year in healthy individuals. 
(Szoke, et al., 
2008) 
Inflammation High doses of aspirin (a salicylate) have been 
shown to reverse insulin resistance and diabetes.  
Inflammatory markers, such as C-reactive protein, 
IL-6 and TNF-α, are increased in insulin 
resistance and are suggestive of an increased risk 
of diabetes, although the underlying mechanisms 
are not determined. 
(Dandona, et 
al., 2004; 
Haffner, 2006; 
Kim, et al., 
2001; Muoio 
and Newgard, 
2008) 
ER stress An increased demand for insulin increases the 
workload for cellular components such as the ER.  
Beta cells are particularly susceptible to ER stress 
due to the high rate of proinsulin biosynthesis.  
Akita mice, a model of enhanced ER stress, have a 
decreased beta cell mass and increased apoptosis.  
Long chain saturated fatty acids have also been 
implicated in causing ER stress in beta cells – both 
(Back, et al., 
2012; 
Bensellam, et 
al., 2012; 
Muoio and 
Newgard, 2008; 
Nguidjoe, et al., 
2011; 
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by the unfolded protein response and by altered 
calcium handling in the ER.  Overexpression of 
the sodium-calcium exchanger, responsible for 
extruding calcium from cells is associated with ER 
stress through ER depletion of calcium.  
Activation of glucokinase has also been associated 
with ameliorating ER-stress induced apoptosis in 
beta cells. 
Shirakawa, et 
al., 2013) 
Oxidative 
stress 
Elevated levels of glucose and fatty acids are 
associated with increased production of ROS.  
ROS act as signalling intermediates in a variety of 
cellular processes.  When present in high levels 
ROS cause oxidative stress which can initiate 
apoptosis through MAPK pathways.  ROS-
mediated alteration of GSIS has been suggested to 
relate to down regulation of glyceraldehye-3-
phosphate dehydrogenase activity and increased 
formation of AGEs.  Islets are particularly 
vulnerable to oxidative stress since they contain 
low levels of ROS-scavenging enzymes and 
antioxidants and also have a poor capacity of 
DNA repair against oxidative damage.  Oxidative 
damage suppresses insulin gene transcription 
through its effects on the transcription factors Pdx-
1 and MafA.   
(Bensellam, et 
al., 2012; 
Grankvist, et 
al., 2012; 
Harmon, et al., 
2005; Modak, 
et al., 2009; Pi, 
et al., 2007; 
Robertson, et 
al., 2003; Sakai, 
et al., 2003) 
Glycative 
stress 
Protein glycation increases in hyperglycaemia and 
diabetes. 
Investigated in 
this project 
Infection/ 
Disease of 
exocrine 
pancreas  
Processes which injure the pancreas can cause 
diabetes.  This includes pancreatitis, cancers, 
trauma and infection.  Pancreatic damage must be 
extensive to cause diabetes – except in the case of 
cancers; adrenocarcinomas involving small 
sections of pancreas have been associated with 
diabetes.  Viral infections such as mumps have 
(American 
Diabetes 
Association, 
2012; 
Karjalainen, et 
al., 1988) 
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also been associated with T1DM. 
Endocrino-
pathies 
Hormones such as glucagon, cortisol, growth 
hormone and adrenaline antagonise the action of 
insulin.  Excesses of these in conditions such as 
glucagonoma can lead to diabetes. 
(American 
Diabetes 
Association, 
2012) 
Amylin 
fibrils 
Amylin fibrils have been suggested as a 
mechanism by which over-nutrition and increased 
beta cell stimulation can lead to beta cell 
dysfunction.  Amylin is secreted with insulin by 
beta cells.  Overexpression of human amylin has 
been associated with increased apoptosis and 
decreased beta cell mass in rats. 
(Matveyenko 
and Butler, 
2006; Muoio 
and Newgard, 
2008) 
In utero 
programming 
The thrifty phenotype hypothesis indicates that 
reduced foetal growth in utero is associated with 
metabolic conditions later in life.  An increase in 
nutrient availability potentially leads to similar 
consequences as obesity. 
(Hales and 
Barker, 1992) 
Leptin  Leptin is involved in appetite regulation in the 
hypothalamus; deficiency is associated with 
severe obesity and diabetes and is treated with 
exogenous leptin therapy.  Other studies have 
reported inhibitory effects of leptin on insulin 
secretion and insulin gene expression, indicating a 
more peripheral role for leptin.  Disruption of the 
leptin receptor in the pancreas indicates a critical 
role of leptin signalling in the islets, with IGT and 
poor compensatory islet growth in obesity. 
(McCarthy, 
2010; Morioka, 
et al., 2007) 
Impairments 
in autophagy 
Autophagy is known to be upregulated in beta 
cells in diet-induced diabetic rodents; this serves a 
crucial stress response to protect the cells against 
oxidative stress.  Loss of autophagy in beta cell 
specific knockouts of Atg7 in mice has shown 
impaired glucose tolerance and decreased serum 
insulin levels.  Impairments in autophagy could be 
(Ebato, et al., 
2008; Fujitani, 
et al., 2009; 
Jung, et al., 
2008; Meijer 
and Codogno, 
2008) 
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1.6. Stages of pathogenesis of diabetes 
 T2DM has been described as beta cell failure in the context of insulin 
resistance (Chang-Chen, et al., 2008).  In early stages of diabetes, beta cells are able 
to adapt to insulin resistance by increasing total beta cell mass and function.  
However, the associated stresses of these high nutritional demands have a negative 
impact on beta cell function, leading to impaired secretion and cell death.  The loss 
in insulin secretion will result in diminished inhibition of glucagon secretion from 
alpha cells; the consequential increase in glucagon release exacerbates the problem, 
with more glucagon counteracting the action of insulin and thus increasing the 
insulin resistance.  Indeed, both a decrease in beta cell number and an increase in the 
number of alpha cells have been reported in people with T2DM (Taylor, 2006).  
Weir and Bonner-Weir (2004) proposed a model of five stages of progressive beta 
cell dysfunction during the development of diabetes – these stages are summarised in 
a risk factor for T2DM.  
Branched-
chain amino 
acids 
(BCAAs)  
BCAAs (valine, isoleucine and leucine) are among 
the nine essential amino acids - they cannot be 
synthesised de novo but are provided by food 
intake.  Plasma concentrations of BCAAs are 
elevated in human and animal models of obesity 
and insulin resistance.  Both an increase in protein 
degradation and a decrease in BCAA catabolism 
has been implicated in this increase.  Levels of 
BCAAs in plasma increase in the fasting state, 
consistent with the suggestion of increased protein 
degradation.  Newgard et al. (2009) showed that 
elevated BCAAs contribute to the development of 
obesity-related insulin resistance using a rat model 
and demonstrated a similar association in humans.  
Whilst a number of studies have associated 
BCAAs with insulin resistance and diabetes, the 
underlying mechanism is not known and their role 
in beta cell (dys)function has not been reported. 
(Adeva, et al., 
2012; Lu, et al., 
2013; Sailer, et 
al., 2013; She, 
et al., 2007; 
Tom and Nair, 
2006) 
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Table 4.  Although this model shows progressive dysfunction, movement through 
stages 1 - 4 can be in either direction – for example with successful treatment 
individuals with T2DM can move back from stage 4 to stage 1 or 2, and likewise 
individuals with T1DM may move back to stage 2. 
 
Table 4: Stages of beta cell dysfunction in diabetes 
Information from Weir and Bonner-Weir (2004). 
Stage Details 
1: Compensation Insulin secretion increases to maintain normal glycaemic 
control in the face of decreased beta cell mass and/or 
insulin resistance.  GSIS function is maintained. 
2: Stable adaptation This stage often remains for a number of years.  Glucose 
concentrations start to rise; fasting glucose concentration is 
maintained at approximately 5.0 - 7.3 mM.  GSIS is 
diminished and individuals have IGT.  
3: Unstable early 
decompensation 
Glucose levels rise rapidly – this is an unstable transition 
stage.  The instability may be due to a greater decline in 
beta cell mass or to increases in insulin resistance. 
4: Stable 
decompensation 
Glucose levels rise again and stabilise at approximately 16 
- 20 mM; diabetes is apparent.   This stage usually lasts a 
lifetime for people with T2DM and symptoms may 
become more noticeable in undiagnosed cases. 
5: Severe 
decompensation 
This stage is rare in T2DM but typically occurs in people 
with T1DM.  The loss of beta cells is so severe that 
patients are dependent on insulin for survival.  Glucose 
levels can typically be greater than 22 mM. 
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2. Introduction: Glycation  
2.1. Protein glycation – a definition 
 The Biochemical Nomenclature Committee of the International Union of 
Biochemistry and the International Union of Pure and Applied Chemistry suggested 
in 1985 the term glycation for “all reactions that link a sugar to a protein or peptide” 
(Sharon, 1988).  Later, it was differentiated between enzymatic modification of 
proteins forming glycoproteins, by the process of glycosylation and non-enzymatic 
modification of proteins forming glycated proteins, by the process of glycation (Lis 
and Sharon, 1993).  Selective use of the term glycation for non-enzymatic 
modification of proteins by saccharides and saccharide derivatives is now the 
accepted nomenclature.  However, in older scientific literature, terms used to 
describe the glycated protein haemoglobin vary.  Terminology has included 
glycosylated haemoglobin, non-enzymatic glycosylated haemoglobin, 
glycohaemoglobin and glucosylated haemoglobin. 
Protein glycation involves the non-enzymatic addition of a reducing sugar or 
derivative to a protein.  A reducing sugar has a free aldehyde or ketone group and 
will therefore reduce Benedict’s solution to form green, yellow or red precipitates of 
the insoluble copper (I) oxide (Benedict, 1909).  It was initially thought that 
glycation was limited to amino groups of lysine side chains and N-terminal amino 
acid residues.  However, more recently glycation of arginine residues by dicarbonyls 
has been implicated in physiological systems, as discussed by Rabbani and 
Thornalley (2012b). 
Glycation occurs by a series of sequential and parallel reactions known 
collectively as the Maillard reaction.  This is named after the French chemist L.C. 
Maillard who pioneered work on the reactions between sugars and amino acids – he 
observed that brown pigments were formed when glucose was heated in the presence 
of proteins (Cerami, 1986; Maillard, 1912).  Historically, it was thought that 
glycation occurred first to early stage glycation adducts, known as Amadori products 
(or fructosamine adducts) via a Schiff’s base intermediate, before being degraded to 
more stable advanced glycation endproducts (AGEs), as is the case for glucose 
(Rabbani and Thornalley, 2012b; Thornalley, et al., 1999; Ulrich and Cerami, 2001).  
Glucose reacts with amino groups to form glycosylamines which dehydrate to form 
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Schiff’s bases.  N-(1-deoxy-D-fructos-1-yl)amino acids, or fructosamine, are 
consequently formed when the Schiff’s base undergoes the ‘Amadori rearrangement’ 
(Hodge and Rist, 1953).  Glycosylamine, Schiff’s bases and fructosamine are all 
known as early stage glycation adducts (Thornalley, 2008).  Further degradation of 
fructosamine to more stable adducts is known as advanced glycation and results in 
the formation of AGEs.  The term AGE was first used by Cerami (1986) to describe 
“yellow-brown fluorescent pigments that can crosslink proteins together,” but at this 
stage AGEs were not well characterised or understood. 
Reactive α-oxoaldehydes (dicarbonyls) also react directly with proteins to 
form AGEs, not necessarily via early stage glycation adducts (Rabbani and 
Thornalley, 2012b).  In addition, degradation of Schiff’s bases via a non-Amadori 
pathway (the Namiki pathway) forms dicarbonyls and subsequently leads to 
production of AGEs (Thornalley, 2008; Thornalley, 2005).  AGEs can therefore be 
formed in glycation from glucose from pre- (Schiff’s base) and post- Amadori 
product reactions as well as from processes where an Amadori product is not a 
precursor – as detailed in Figure 3.  This has consequently led to inconsistencies in 
the nomenclature and classification of AGEs, since AGEs are formed in both early 
and advanced stages of the Maillard reaction (Rabbani and Thornalley, 2012b).  The 
nomenclature of fructosamine and AGEs is now widely used and accepted. 
 
 
Figure 3: Formation of AGEs from glucose and physiological dicarbonyl 
metabolites (Rabbani and Thornalley, 2012b). 
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 Allen et al. (1958) first reported evidence of a glycated protein in vivo.  
However, at the time it was not understood that the heterogeneity they observed in 
haemoglobin was actually due to glycation.  It was characterised as glycated 
haemoglobin by Bookchin and Gallop (1968), whilst Rahbar (1968) described the 
increases observed in diabetes (Rabbani and Thornalley, 2012b).  The formation of 
glycated haemoglobin, as well as its relevance to diabetes was further described by 
Bunn et al. (1978; 1976). 
 
2.2. Dicarbonyls 
2.2.1. Physiological formation of dicarbonyls  
Dicarbonyls are compounds with two aldehyde or ketone functional groups 
or an aldehyde and ketone group.  In this study a particular type of physiological 
dicarbonyl is considered: α-oxoaldehydes or α-ketoaldehydes.  They are usually 
highly reactive and potentially toxic compounds formed endogenously as by-
products of cellular metabolism.  They are also present in many foods and beverages, 
increasing when foods and beverages are thermally processed in manufacture, 
pasteurisation, sterilisation and culinary processing.  Three major dicarbonyls have 
been studied for their role in protein glycation in physiological systems: 
methylglyoxal, glyoxal and 3-deoxyglucosone (3-DG) – the structures of which are 
displayed in Figure 4. 
Methylglyoxal (MG) is produced predominantly from degradation of the 
triose phosphate intermediates of the glycolytic pathway - glyceraldehyde-3-
phosphate (GA3P) and dihydroxyacetone-phosphate (DHAP), as well as in smaller 
amounts from oxidation of acetone and aminoacetone in the catabolism of ketone 
bodies and threonine respectively and from the degradation of glycated proteins and 
monosaccharides (Phillips and Thornalley, 1993; Rabbani and Thornalley, 2012a; 
Turk, 2010).  Although flux from triose phosphates is the major mechanism by 
which methylglyoxal is formed, formation of methylglyoxal is a minor or trace level 
fate of glucose metabolism – accounting for approximately 0.1% of the glucose flux.  
This low percentage flux increases in hyperglycaemia accounting for between 0.2% 
and 1% of glucose flux (Rabbani and Thornalley, 2011; Thornalley, 1988).  Since 
the whole body rate of formation of methylglyoxal has been calculated as 
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approximately 3 mmol per day and the urinary excretion rate of methylglyoxal 
glycation adducts is approximately 10 µmol/day in healthy individuals, this indicates 
that only a small proportion (less than 1%) of the methylglyoxal produced 
physiologically acts to modify the proteome (Rabbani and Thornalley, 2012a).  
However, a 15-fold increase in urinary excretion of methylglyoxal-derived glycation 
adducts has been measured in people with diabetes with a mean A1C of 8%, when 
compared to levels in healthy individuals, indicating a marked increase in protein 
glycation by methylglyoxal in clinical diabetes (Ahmed, et al., 2005a).  Some 
methylglyoxal-derived glycation adducts are also absorbed from food (Ahmed, et al., 
2005b). 
 
 
Figure 4: Structures of Glyoxal, MG and 3-DG in solution.  A. Unhydrated and 
hydrate structures of glyoxal. B. Unhydrated and hydrate structures of MG.  C. 
Acyclic unhydrated forms of 3-DG with related - and  anomers.  Adapted from 
Rabbani and Thornalley (2012c). 
 
Glyoxal is formed under physiological conditions by the slow, non-
enzymatic oxidative degradation of glucose and proteins glycated by glucose 
(Thornalley, et al., 1999).  It is also formed by the autoxidation of glycolaldehyde 
which is formed by oxidation of serine residues by hypochlorite in the phagocyte 
respiratory burst by myeloperoxidase (Rabbani and Thornalley, 2012c; Yang, et al., 
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2011).  Glyoxal is also formed by lipid peroxidation and degradation of nucleotides 
(Thornalley, 2005).  3-DG is formed by degradation of fructosamine-3-phosphate in 
the repair of early glycated proteins, degradation of fructose-3-phosphate and the 
slow non-enzymatic degradation of glucose and proteins glycated by glucose 
(Delpierre, et al., 2000; Lal, et al., 1997; Thornalley, et al., 1999). 
 
2.2.2. Levels of dicarbonyls in plasma of healthy people and 
patients with diabetes 
As methods for measuring dicarbonyls in plasma have improved to control 
and eliminate analyte formation in pre-analytic processing, reported estimates have 
decreased.  These lower estimates are probably closest to the true values.  Plasma 
glyoxal is ca. 200 nM in healthy people and increases 2 - 3 fold in patients with 
diabetes.  Plasma MG is 100 – 150 nM in healthy people and similarly increases 2 – 
5 fold in patients with diabetes.  Plasma 3-DG is 100 – 200 nM in healthy people and 
increases 2 – 3 fold in patients with diabetes (Agalou, et al., 2002; Hamada, et al., 
1997). 
 
2.2.3. Relative glycation reactivity  
The relative reactivity towards protein glycation in situ of different 
saccharides and derivatives varies, due to both their different plasma concentrations 
and also their different reactivity towards protein.  For example, the relative 
reactivity towards protein glycation in situ of methylglyoxal and glucose is similar 
and thus similar levels of glycation adducts are formed on proteins by glucose and 
methylglyoxal.  This is despite the plasma concentration of methylglyoxal being 
approximately 50,000 times lower than that of glucose (ca. 100 nM as opposed to 5 
mM (Beisswenger, et al., 1999; Rabbani and Thornalley, 2012a)).  This is explained 
by a much higher specific reactivity of methylglyoxal towards protein glycation than 
glucose: rate constants for glycation of proteins by methylglyoxal are 10,000 - 
50,000 fold higher than for glycation by glucose (Rabbani and Thornalley, 2012a; 
Thornalley, 2005).  The specific reactivity of glyoxal in glycation reactions is 
approximately 4-fold lower than methylglyoxal.  This is perhaps surprising as the 
dialdehyde structure is more electronically deficient and chemically reactive than 
methylglyoxal but for this reason it is also more highly hydrated than methylglyoxal 
which decreases its reactivity for protein glycation.  The specific reactivity of 3-DG 
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in glycation reactions is approximately 100-fold lower than methylglyoxal.  This is 
due to the existence of 3-DG in many cyclic and hydrated forms which stabilise it 
towards glycation reactions (Thornalley, et al., 1999).  
 
2.2.4. Clinical implications of dicarbonyls  
 Dicarbonyls react with proteins to form AGE residues and also with guanyl 
bases of nucleotides to form nucleotide AGEs.  Methylglyoxal is the precursor of the 
major protein and nucleotide AGEs quantitatively, methylglyoxal-derived 
hydroimidazolone Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) and 
imidazopurinone 3-(2’-deoxyribosyl)-6,7-dihydro-6,7-dihydroxy-6-
methylimidazo[2,3-b]purin-9(8)one (MGdG), respectively.  Formation of AGEs has 
been implicated in ageing and disease - including diabetes and its vascular 
complications, obesity, renal failure, CVD, neurological disorders such as 
Alzheimer’s disease, Parkinson’s disease and rare forms of schizophrenia, 
osteoarthritis, mutagenesis and multi-drug resistance in cancer chemotherapy 
(Brownlee, 2005; Kuhla, et al., 2005; Lüth, et al., 2005; Morcos, et al., 2008; 
Rabbani, et al., 2011; Sakamoto, et al., 2001).  MG modification of DNA increases 
DNA strand breaks and frameshift mutations (Murata-Kamiya, et al., 2000b; 
Thornalley, et al., 2010).  Protein modification by MG is directed to functional sites 
where it is associated with metabolic, structural and functional abnormalities: for 
example, mitochondrial dysfunction with increased formation of ROS (Rosca, et al., 
2002), cell detachment from the ECM by decreased integrin binding to MG-modified 
ECM proteins and anoikis (Dobler, et al., 2006; Pedchenko, et al., 2005) and 
induction of accelerated cell senescence (Sejersen and Rattan, 2009). 
 
2.3. Glycation by dicarbonyls 
2.3.1. Formation of AGE residues on DNA 
Dicarbonyls react with nucleic acids to form nucleotide AGEs (Brambilla, et 
al., 1985; Murata-Kamiya and Kamiya, 2001; Thornalley, 2008).  Deoxyguanosine 
(dG) is the most reactive nucleotide under physiological conditions.  Glyoxal and 
methylglyoxal react with deoxyguanosine under physiological conditions to form 
mainly imidazopurinone derivatives, 3-(2’-deoxyribosyl)-6,7-dihydro-6,7-
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dihydroxyimidazo[2,3-b]purin-9(8)one (dG-G) and MG-dG, respectively, – 6- and 7- 
methyl structural isomeric mixtures (Thornalley, 2008).  Glyoxal and methylglyoxal 
also form N2-carboxymethyl-deoxyguanosine (CMdG) and N
2
-(1,R/S-carboxyethyl)-
deoxyguanosine (CEdG) – the latter a stereoisomeric mixture of R/S-epimers at the 
N
2
-1-carboxyethyl chiral centre (Li, et al., 2006; Thornalley, et al., 2010).  The 
imidazopurinones are stabilised by incorporation into single and double stranded 
DNA.  Accumulation of nucleotide AGEs is associated with an increase in both the 
frequency of mutagenesis and cytotoxicity.  For glyoxal derived AGEs single-base 
substitutions primarily at C:G sites predominate, whereas for methylglyoxal multi-
base deletions of 8 - 320 base pairs predominate (50%) followed by base pair 
substitutions (35%), tandem mutations (8%), single base additions and deletions 
(4%), and multi-base additions (2%) (Murata-Kamiya, et al., 2000a; Thornalley, 
2008).  Studies have indicated that nucleotide excision repair suppresses and limits 
the effects of glycation damage (Murata-Kamiya, et al., 1999; Murata-Kamiya, et 
al., 1998). 
 
2.3.2. Formation of AGE residues on proteins 
 Dicarbonyls are predominantly arginine directed glycating agents (Dobler, et 
al., 2006; Queisser, et al., 2010).  Quantitatively the most important AGEs are the 
hydroimidazolones.  The hydroimidazolone MG-H1 formed from the reaction of 
methylglyoxal with arginine residues in proteins (Figure 5) accounts for more than 
90% of AGE adducts on proteins (Rabbani and Thornalley, 2012a).  The reaction of 
arginine and lysine residues with pentose and glucose-derived dicarbonyls forms the 
protein crosslinks, pentosidine and glucosepane, respectively (Sell and Monnier, 
2004).  Ornithine residues in proteins are formed from decomposition of 
hydroimidazolone AGEs (Sell and Monnier, 2004).  Examples and classification of 
glycation adducts are given in Figure 6.   
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Figure 5: Formation of the major hydroimidazolone MG-H1.  Glycation of 
arginine residues by methylglyoxal form the hydroimidazolone MG-H1 via the 
intermediate dihydroxyimidazolidine.  Figure reproduced from Rabbani and 
Thornalley (2012a). 
 
 
Nε-Carboxymethyl-lysine (CML) is one of the most studied AGEs since 
being reported in the 1980s.  CML is formed in physiological systems by the 
oxidative degradation of Nε-fructosyl-lysine (FL) (Ahmed, et al., 1986; Smith and 
Thornalley, 1992).  Other sources of CML are the oxidative degradation of L-
tetrulose-lysine formed in the protein glycation by ascorbic acid and the reaction of 
lysine residues with glyoxal (Dunn, et al., 1990).  CML is also formed as a minor 
AGE in glycation of proteins by glucose, ribose and other saccharides by oxidative 
fragmentation with formation of glyoxal during the Maillard reaction.  CML residues 
have been found in proteins of human cells in culture, cellular and ECM proteins of 
tissues and physiological fluids of laboratory rodents and human tissues and body 
fluids (Duran-Jimenez, et al., 2009; Karachalias, et al., 2010; Schleicher, et al., 
1997; Thornalley, et al., 2003).  CML is a chemically stable AGE and CML residue 
content of long-lived proteins such as lens protein and skin and cartilage collagen of 
human subjects increases with age (Dunn, et al., 1989; Dyer, et al., 1993).  CML 
content of collagen of skin and cartilage is related to the rate of collagen turnover 
(Verzijl, et al., 2000).  CML content of protein increases in diabetes in association 
with an increase in the protein content of the precursor FL (Dyer, et al., 1993; 
Karachalias, et al., 2010).  Proteolysis of CML modified proteins forms CML free 
adducts which are released into body fluids and excreted in urine.  Dietary content of 
CML residues in proteins ingested in food contributes to urinary excretion of CML 
free adducts (Knecht, et al., 1991; Liardon, et al., 1987).   Nε-Carboxymethyl-
hydroxylysine is found in collagen formed from hydroxylysine (Dunn, et al., 1991). 
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Figure 6: Protein glycation, oxidation and nitration adducts.  a. Early glycation adducts.  AGEs: b. Hydroimidazolones, c. Monolysyl, d. 
Fluorophores and e. Non-fluorescent crosslinks.  f. Oxidation adducts.  g. Nitration adduct.  Reproduced from Thornalley and Rabbani (2013). 
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Formation of MG-H1 residues results in a loss of the positive charge 
associated with the amino acid side chain.  This can lead to a loss of hydrogen 
bonding within parts of the protein and consequently rotation and separation of 
functional motifs, protein misfolding and changes in the tertiary structure of the 
protein (Dobler, et al., 2006; Xue, et al., 2011).  Therefore, protein glycation can 
lead to a loss of protein function, and consequently lower levels of the functional 
protein, or alternatively it can lead to alterations in the functional activity of the 
modified protein.  Since under 5% of a protein is typically glycated the decline in the 
amount of functional protein is unlikely to have severe functional effects (Rabbani 
and Thornalley, 2012a).  However, glycation is thought to target proteins for 
proteolysis and decrease protein half-life.  Without compensatory increases in 
protein expression, this may decrease the concentration of functionally active 
proteins significantly.  It is, perhaps, more likely that damaging effects occur when 
the modified protein has an altered physiology and functions differently (as is the 
case with the modification of collagen IV by methylglyoxal) as opposed to a loss of 
function (Dobler, et al., 2006).  
The modification of proteins by methylglyoxal forming MG-H1 residues is 
particularly damaging because it is usually focussed on functionally important 
arginine residues within the active site of the protein.  These arginine residues are 
often easily accessible for modification and have highly polarisable electronic charge 
(Rabbani and Thornalley, 2012a).  Between 0.1% and 3% of arginine residues on 
cellular proteins are known to be modified by methylglyoxal, and these 
modifications typically increase 2 - 5 fold in diabetes (Rabbani and Thornalley, 
2011; Thornalley, et al., 2003).  Arginine residues are frequently found in active 
sites of proteins – analysis of Swissprot database sequences and Protein Data Bank 
information has indicated that it is the most abundant amino acid residue within 
protein receptor binding domains, the most frequent residue within protein 
nucleotide binding sites and the third most frequent residue in enzyme active sites, 
behind histidine and aspartic acid (Bartlett, et al., 2002; Chetyrkin, et al., 2011; 
Gallet, et al., 2000; Lejeune, et al., 2005).  Analysis of residues involved in catalysis 
at 178 enzyme active sites indicated that 11% of residues were arginine, despite it 
only representing 4.9% of the total residues; this again highlights the accessibility of 
arginine to glycation and that this could have severe functional consequences 
(Bartlett, et al., 2002). 
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2.3.3. Repair of glycated proteins  
The major early stage glycation adduct of glucose, FL, can be de-glycated.  
Thus glycated proteins can be repaired in a pathway catalysed by fructosamine 3-
phosphokinase (Delpierre, et al., 2000; Pascal, et al., 2010).  However, there is no 
known de-glycation mechanism for hydroimidazolone-modified proteins – but there 
is slow dynamic reversibility of MG-H1 with a half-life of approximately 12 days 
(Rabbani and Thornalley, 2012a).  Proteins containing hydroimidazolone adducts 
have distorted and damaged structures and may therefore be targeted to the 
proteosome for proteolysis (Dobler, et al., 2006; Grune, et al., 1996; Hernebring, et 
al., 2006).  MG-H1 adduct residues are therefore released from proteins by cellular 
proteolysis.  MG-H1 free adducts are then cleared from cells and tissues and 
consequently MG-H1 free adducts are detectable in plasma and urine in both rodents 
and humans (Karachalias, et al., 2010; Thornalley, et al., 2003).  
 
2.3.4. Measurement of AGEs in physiological systems  
Quantification of glycation adducts has proved problematic with commonly 
used methods, namely immunoassay and fluorescence, having major limitations, as 
reviewed by Ahmed and Thornalley (2007).  Immunoassays have been widely used 
to detect AGEs (Chow, et al., 2013; Jung, et al., 2011; Sugimoto, et al., 1997; 
Yamaguchi, et al., 1998).  Limitations include a lack of antibody specificity – an 
antibody for CML has been shown to cross-react with CEL, high concentrations of 
AGEs in solutions used to block non-specific binding and interference caused by 
glycation free adducts (Ahmed and Thornalley, 2007).  Similarly, as discussed by 
Ahmed and Thornalley (2007), the use of total AGE fluorescence methods, as 
performed by Tajiri et al. (1997), has been questioned.  There are multiple 
fluorophores present in physiological samples contributing to total fluorescence and 
so quantitation is not possible, the major quantitative AGEs - hydroimidazolones - 
are not fluorescent and there are interferences from oxidative adducts such as N-
formylkynurenine (NFK).  Fluorescent adducts must be separated using HPLC or 
other techniques.   
 Mass spectrometric detection and quantification of the different AGEs using 
stable isotopic substituted standards is the more reliable method by which to quantify 
both glycation adducts on proteins and free adducts (Lieuw-A-Fa, et al., 2004; Niwa, 
2006; Thornalley, et al., 2003).  This method has been developed to measure 
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glycation, oxidation and nitration adducts concurrently.  Oxidative adducts include: 
methionine sulphoxide (MetSO) – formed by oxidation of methionine; NFK – 
formed by oxidation of tryptophan; dityrosine – formed by oxidation of tyrosine; α-
aminoadipic semialdehyde (AASA) - formed by oxidative deamination of lysine; and 
glutamic semialdehyde (GSA) - formed by oxidation of proline and arginine 
residues. 
 
2.4. Defence against dicarbonyls 
 The damaging effects of protein glycation by dicarbonyls on physiological 
systems are limited by the enzymatic defences which catalyse the metabolism of 
dicarbonyls.  The glyoxalase system in combination with other more minor defence 
systems, such as aldose reductase, is responsible for metabolising over 99% of 
dicarbonyls to less damaging metabolites (Rabbani and Thornalley, 2012a).  
Dicarbonyl damage to the genome and proteome is caused by less than one per cent 
of the methylglyoxal produced in the body; that such a small proportion of 
methylglyoxal can cause this damage indicates the importance of these enzymatic 
defences in lowering the levels of both dicarbonyls and the consequential AGEs. 
 
2.4.1. The glyoxalase system 
The glyoxalase system is estimated to account for over 97% of methylglyoxal 
metabolism in most human tissues (Rabbani and Thornalley, 2011).  It is a 
fundamental protective system found ubiquitously throughout biological life.     
 
2.4.1.1. Historical perspectives 
 Since the discovery of glyoxalase activity a century ago it has been known 
that the glyoxalase system catalyses the conversion of methylglyoxal to lactate 
(Dakin and Dudley, 1913).  However, this was originally thought to be L-lactate and 
act as a major metabolic process converting glucose to L-lactate, as discussed by 
Thornalley (1990).  The widespread distribution of glyoxalase in all studied 
organisms indicated that this enzymatic system performs an important cellular 
function (Hopkins and Morgan, 1945).  Racker identified that metabolism of 
methylglyoxal to lactate by the glyoxalase system occurred in a two-step process via 
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the intermediate S-D-lactoylglutathione (Racker, 1951).  In 1977 it was discovered 
that methylglyoxal and related aldehydes react with arginine residues, although the 
physiological significance of this was not understood (Takahashi, 1977).  A number 
of studies in the 1980s and 1990s began to implicate the glyoxalase system and 
dicarbonyl metabolism in diabetes.  An increase in dicarbonyl formation was shown 
in both hyperglycaemia and in patients with diabetes as well as overexpression of 
glyoxalase 1 (Glo1) preventing the increase in AGE formation in hyperglycaemia 
(Thornalley, 1988; Thornalley, et al., 1989).  Methylglyoxal was shown to be a 
protein glycating agent and MG-H1 a significant type of proteome damage and a 
significant AGE occurring in diabetes (Ahmed, et al., 2005a; Lo, et al., 1994; 
Thornalley, et al., 2003).  Overexpression of Glo1 in endothelial cells has been 
shown to prevent the increases in MG and associated AGEs observed in 
hyperglycaemia and to correct the cell dysfunction observed in diabetes (Shinohara, 
et al., 1998).  Recent studies have continued to show the impact of metabolism by 
the glyoxalase system and alterations therein in diabetes – for example 
methylglyoxal has been shown to be decreased by the glucose lowering drug 
metformin, and MG-H1 modification of both collagen IV and LDL has been shown 
to have functional impairments significant in states of diabetes (Beisswenger, et al., 
1999; Dobler, et al., 2006; Rabbani, et al., 2011).  Knockdown of Glo1 in mice, 
leading to a 45 - 65% decrease in the tissue Glo1 activity, resulted in an increase in 
proteasomal modification and impaired proteasomal activity (Queisser, et al., 2010).  
In addition, treatment of rodents with a cell permeable fusion protein construct of 
Glo1 has been shown to prevent the beta cell ablation induced by Streptozotocin 
treatment, indicative of its protective capacity (Kim, et al., 2013).   
 
2.4.1.2. Glyoxalase pathway 
The glyoxalase system consists of two cytosolic enzymes – Glo1 and 
glyoxalase 2 (Glo2) - which catalyse the conversion of methylglyoxal to D-lactate 
via the intermediate S-D-lactoylglutathione.  It thereby achieves metabolism of 
methylglyoxal, a detoxification function.  GSH binds non-enzymatically to 
methylglyoxal forming the methylglyoxal-glutathione hemithioacetal, and Glo1 then 
subsequently catalyses the isomerisation of the hemithioacetal to S-D-
lactoylglutathione (Thornalley, 2003a).  Glo2 is a thiolesterase which hydrolyses S-
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D-lactoylglutathione to D-lactate, reforming GSH (Rabbani and Thornalley, 2012a; 
Thornalley, 1994).  These sequential enzymatic reactions are illustrated in Figure 7. 
 
 
Figure 7: The glyoxalase system.  Adapted from Xue, et al. (2011). 
 
Glyoxalase 1 
Human glyoxalase 1 is a dimeric Zn
2+
-metalloenzyme, with one zinc ion per 
subunit, of molecular mass 42 kDa (Thornalley, 2003a).  The translation product of 
the gene consists of 184 amino acids, of which the amino acid residues tryptophan, 
lysine, tyrosine, histidine and glutamic acid lie within the active site situated at the 
dimer interface (Thornalley, 1993; Thornalley, 2003a).  Expression of Glo1 as a 
dimer has been reported in humans, other mammalian species, bacteria and plants 
(Xue, et al., 2011).  In yeast, however, Glo1 is a monomer, of size 32 and 37 kDa in 
Saccharomyces cerevisae and Schizosaccharomyces pombe, respectively (Xue, et al., 
2011).   
The human gene, GLO1, has three phenotypes – GLO 1-1, GLO 1-2 and 
GLO 2-2, representing the homozygous and heterozygous expression of the diallelic 
gene (Xue, et al., 2011).  GLO
2
 is the ancestral gene and GLO
1
 is thought to have 
arisen through mutation (Xue, et al., 2011).  The two alleles differ only in the amino 
acid at position 111 – an alanine in one allele and glutamic acid in the alternative 
allele (Kim, et al., 1995).  The diallelic gene is located on chromosome 6 in humans 
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and on chromosome 17 in mice, the locus of both are closely linked to the major 
histocompatability complex indicating conservation of linkage groups throughout 
evolution (Bender and Grzeschik, 1976; Minna, et al., 1978).   
 
Glyoxalase 2 
Glyoxalase 2 is a monomeric thiolesterase found in the cytosol of all 
eukaryotic and prokaryotic organisms (Thornalley, 1993).  It molecular mass is ca. 
29.5 and 29.0 kDa in mouse and human, respectively, estimated by SDS 
polyacrylamide gel electrophoresis (Oray and Norton, 1980; Thornalley, 1993).  
Glo2 contains a Fe(II)Zn(II) centre, with substrate hydrolysis linked to the Zn(II) site 
(Limphong, et al., 2009).  It is a basic protein which is competitively inhibited by the 
hemithioacetal substrate of Glo1 (Oray and Norton, 1980).  Arginine, histidine and 
lysine residues are present in the Glo2 active site, with histidine important to the 
enzyme catalysed mechanism (Thornalley, 1990).   
The gene for human glyoxalase 2 is hydroxyacylglutathione hydrolase, 
HAGH, or GLO2.  It is located on human chromosome 16 and on chromosome 17 in 
mice (Tan and Whitney, 1993).  There are no common polymorphisms for GLO2 
(Thornalley, 1993).  A rare polymorphism for GLO2 has been found in Micronesian 
and Japanese populations (Sugita and Takahama, 1983; Tan and Whitney, 1993; 
Thornalley, 1993). 
  
S-D-Lactoylglutathione 
S-D-Lactoylglutathione is formed from the catalytic action of Glo1 and is 
hydrolysed by Glo2 to form D-lactate.  Addition of S-D-lactoylglutathione to 
cultures of HL60 cells caused growth arrest and toxicity (Thornalley and Tisdale, 
1988).  Its formation has been shown to be elevated in hyperglycaemia and clinical 
complications of diabetes correlated with maintenance of higher cellular levels of S-
D-lactoylglutathione (Thornalley, et al., 1989).  The concentration of S-D-
lactoylglutathione in human blood is ca. 41 nmol per mL red blood cells, increasing 
to ca. 54 nmol per mL red blood cells in diabetic patients (Thornalley, 1993).  It has 
poor membrane permeability and therefore it is expected that it is produced and 
hydrolysed within the cytosol (Rae, et al., 1991). 
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D-Lactate 
D-Lactate is produced by the thiolesterase Glo2.  In physiological systems it 
is metabolised to pyruvate by the enzyme 2-hydroxyacid dehydrogenase (Thornalley, 
1993).  However, it is not metabolised by red blood cells (Thornalley, 1988).  
Activity of this enzyme is lacking in some immortalised cell lines, and therefore D-
lactate accumulates.  The concentration of D-lactate is ca. 10 and 20 nmol per g 
blood in healthy controls and diabetic patients, respectively (Thornalley, 1993).  
Increases in plasma D-lactate concentration are also observed after a meal and after 
exercise (Kondoh, et al., 1992; Ohmori and Iwamoto, 1988).  D-Lactate is 
membrane permeable, crossing membranes via a specific lactate transporter, the 
inorganic anion exchanger and by diffusion.  Approximately half the D-lactate 
membrane transport in human red blood cells is via the lactate transporter 
(Thornalley, 1993). 
 
2.4.1.3. The glyoxalase system in diabetes  
Since the in situ activity of Glo1 is proportional to the cellular concentration 
of GSH, GSH has a vital role in the glyoxalase system and cellular metabolism of 
methylglyoxal (and other α-oxoaldehydes) (Thornalley, 2003a).  Tissue 
concentrations of GSH decrease with age and recently chronic methylglyoxal 
infusion into Sprague-Dawley rats was shown to decrease the GSH levels within the 
pancreas (Dhar, et al., 2011; Meister, 1983).  In addition, GSH is depleted in states 
of oxidative stress (Abordo, et al., 1999).  This indicates that the in situ activity of 
Glo1 may become limited by GSH availability in the pancreas, particularly so with 
ageing or in pathogenic states.  This could intensify the problem with a decrease in 
cellular defences against glycation occurring in combination with an increase in 
glycative agents.  However, it has been reported that only minor decreases in GSH 
occur in most tissues and plasma of streptozotocin induced diabetic rats and no 
changes occur in GSH concentration of red blood cells in clinical diabetes.  
Consequently, it is suggested that GSH and glutathionylation do not alter the in situ 
activity of Glo1 in diabetes (Rabbani and Thornalley, 2011). 
Glyoxal and MG concentrations may be increased in diabetes as a 
consequence of impaired activity of Glo1.  Renal and vascular cell activity of Glo1 
may be decreased in diabetes by decreased concentration of GSH in oxidative stress, 
glutathionylation of Glo1 and decreased expression of Glo1 (Birkenmeier, et al., 
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2010).    Glo1 expression may be decreased by activation of the receptor for AGEs 
and by down regulation of signalling by transcription factor nuclear erythroid factor 
E2 related factor-2 (Nrf2) (Bierhaus, et al., 2005; Xue, et al., 2012).  Signalling by 
Nrf2 is impaired in diabetes which may lead to decreased metabolism and increased 
glyoxal and MG (Tan, et al., 2011). 
Studies of patients with T1DM and T2DM have indicated that methylglyoxal, 
S-D-lactoylglutathione and D-lactate were all elevated in blood, compared to healthy 
controls.  The activity of Glo1 was also shown to increase in red blood cells in 
diabetic patients, likely as a response to sensing a higher methylglyoxal 
concentration – exposure to dicarbonyl stress (Rabbani and Thornalley, 2011). 
 
2.4.1.4. Chemical Inhibitors of the glyoxalase system 
 Chemical inhibitors of Glo1 and Glo2 have been used experimentally to 
examine the effects of endogenous increases in dicarbonyls.  Some of the earlier 
studies demonstrated that S-conjugates of glutathione could be used as inhibitors of 
Glo1 and linked these inhibitors to potential uses as anticancer drugs (Vince and 
Daluge, 1971; Vince, et al., 1971).  Similarly, inhibitors of Glo2 were developed, but 
as discussed by Lo and Thornalley (1992) these still had some inhibitory activity 
towards Glo1 (Bush and Norton, 1985).  These early studies did not appreciate that 
conjugates had to be diesterified to be delivered into cells and to be stable to 
decomposition by γ-glutamyl transferase (Lo and Thornalley, 1992).  The effects of 
different S-conjugates of glutathione on growth and viability of cells were 
investigated (Lo and Thornalley, 1992).  This indicated that GSH conjugate 
inhibitors did not enter cells.  Diester derivatives were shown to be resistant to 
cleavage by the enzyme γ-glutamyl transferase and also permeable to cells.  Inside 
cells, ester groups were cleaved by non-specific esterases forming the active 
inhibitor (Thornalley, 2003a).  Consequently, the compound S-p-bromobenzyl-
glutathione cyclopentyl diester (BrBzGSHCp2) was shown to be a cell permeable 
inhibitor of Glo1, suitable for use in cell based experiments and also suggested to be 
of use in inhibiting tumour growth and inducing apoptosis (Thornalley, et al., 1996).   
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2.4.2. Metabolism of dicarbonyls by aldoketo reductases and 
aldehyde dehydrogenase 
When the glyoxalase system is impaired, aldoketo reductase (AKR) isozymes 
1B1, 1B3 and 1B8 may metabolise glyoxal to glycolaldehyde and AKR isozymes 
1A4, 1B1 and 1B3 may metabolise MG to mainly hydroxyacetone (Baba, et al., 
2009).  Aldose reductase (AKR 1B1) was claimed to have an important role in MG 
metabolism by Baba et al. (2009).  However, since the Glo1 activity measurement 
was made incorrectly - without preformation of the hemithioacetal substrate, making 
non-enzymatic formation of hemithioacetal rate-limiting in this study - it is likely 
that the Glo1 activity was underestimated, as discussed by Rabbani and Thornalley 
(2011).  Metabolism by AKR 1B1 may be a major fate of glyoxal and MG in the 
renal medulla where high expression of AKR 1B1 outcompetes Glo1 (Larsen, et al., 
1985; Nishimura, et al., 1993).  AKRs 1A4, 1B1, 1B3 and 1B8 are antioxidant-
response element-linked genes with expression regulated by the transcription factor 
Nrf2 (Kwak, et al., 2003; MacLeod, et al., 2009; Nishinaka and Yabe-Nishimura, 
2005; Thimmulappa, et al., 2002).  3-DG is metabolised to 3-deoxyfructose by 
AKRs 1A4, 1B1 and 1B3 (3-DG reductase activity) and to 3-deoxy-2-ketogluconate 
by aldehyde dehydrogenase 1A1 (3-DG dehydrogenase activity) (Baba, et al., 2009; 
Collard, et al., 2007).  All genes encoding these enzymes have expression regulated 
by Nrf2 and hence may be down-regulated in diabetes leading to an increased 3-DG 
concentration (Kwak, et al., 2003; MacLeod, et al., 2009; Nishinaka and Yabe-
Nishimura, 2005; Reisman, et al., 2009). 
Aldose reductase, in conjunction with sorbitol dehydrogenase, mediates the 
conversion of glucose to fructose – the polyol pathway (Lindstad and McKinley-
McKee, 1993).  Methylglyoxal is however a better substrate than glucose for human 
aldose reductase (aldoketo reductase isoform 1B1), as is indicated by the much lower 
KM value – 8 µM compared to 70 mM (Lindstad and McKinley-McKee, 1993; 
Vander Jagt, et al., 1992).  Aldose reductase catalyses the NADPH-dependent 
reduction of methylglyoxal to produce hydroxyacetone (95%) and D-lactaldehyde 
(5%) (Thornalley, 1994).  Both hydroxyacetone and L-1,2-propanediol, formed from 
further reduction of hydroxyacetone, are known to accumulate in states of 
uncontrolled diabetes (Vander Jagt, et al., 1992).  It is reported that these increases 
are due to increases in ketone body metabolism when insulin is lacking and fat is 
therefore used as an energy source, consistent with the ketoacidosis observed in 
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undiagnosed or uncontrolled diabetes (Wolfsdorf, et al., 2009).  An increase in the 
metabolism of methylglyoxal by aldose reductase could also lead to such increases.  
However, since aldose reductase also metabolises flux through the polyol pathway it 
can act to increase triose phosphate formation and thereby increase methylglyoxal 
formation.  Indeed, the use of the aldose reductase inhibitor, Statil, has been shown 
to prevent some of the increases in methylglyoxal observed in diabetic rats (Phillips, 
et al., 1993). 
 Methylglyoxal may also be metabolised in some mammalian tissues by 
aldehyde dehydrogenase.  Activity of methylglyoxal dehydrogenase has been 
detected in the liver of sheep; it catalyses the conversion of methylglyoxal to 
pyruvate in a NAD
+
 dependent process (Monder, 1967).   
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3. Project Specific Background 
3.1. Implications of glycation in beta cells and diabetes 
 Increased protein glycation and formation of AGEs has been linked to 
dysfunction in T1DM and T2DM.  Both concentrations of dicarbonyls in the plasma 
and their flux through the glyoxalase system increase in hyperglycaemia and in 
diabetes (Beisswenger, et al., 1999; McLellan, et al., 1994).  Plasma concentrations 
of methylglyoxal and 3-DG increase in postprandial hyperglycaemia, indicating that 
dicarbonyl concentrations are responsive to short term hyperglycaemia in vivo 
(Beisswenger, et al., 2001; Masterjohn, et al., 2012).  In contrast, glycation by 
glucose with formation of A1C and other proteins modified by fructosamine residues 
is relatively unresponsive to short term hyperglycaemia. 
The glyoxalase system is known to be modified in diabetes, although it is not 
known whether these changes are implicated in causing or are a consequence of the 
dysfunctional state.  Development of insulin resistance, impaired fasting glucose and 
IGT leading to T2DM likely lead to increased methylglyoxal formation which, 
without compensatory increased expression and activity of Glo1, will lead to 
increased formation of MG-derived AGEs.  Moreover, insulin resistance and the 
metabolic syndrome are associated with increased expression of the inflammatory 
mediators S100 proteins (Yamaoka, et al., 2013).  S100 proteins are likely important 
activators of RAGE in vivo which may down-regulate expression of Glo1 
(Thornalley, 2007). 
Modifications of dicarbonyl metabolism in pre-diabetes and diabetes 
therefore likely include: increased flux of formation of methylglyoxal - proportional 
increase due to down-regulation of glyceraldehyde-3-phosphate dehydrogenase and 
increased concentrations of intermediates GA3P and DHAP; and decreased in situ 
activity of the glyoxalase system due to decreased GSH and/or down-regulation of 
Glo1 expression via inflammatory signalling  (Rabbani and Thornalley, 2011).  
An increase in protein damage by reactive dicarbonyls is associated with 
diabetes.  Protein glycated by methylglyoxal has been reported to increase 2 - 5 fold 
in people with diabetes (Ahmed, et al., 2005a; Hegab, et al., 2012; Karachalias, et 
al., 2010; Nicolay, et al., 2006; Rabbani and Thornalley, 2011).  Accumulation of 
AGE residues on both extracellular and intracellular proteins is a risk factor for 
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diabetic complications such as diabetic neuropathy and nephropathy (Duran-
Jimenez, et al., 2009; Matafome, et al., 2013; Perkins, et al., 2012; Thornalley, et al., 
2003).  Whilst this 2 - 5 fold increase is damaging, it still represents a low extent of 
modification, typically 0.1 - 1% of arginine and lysine residues (Thornalley, 2008).  
It is therefore crucial to interpret the physiological relevance of literature showing 
the importance of protein glycation with caution and in context.  Many articles such 
as Fiory et al. (2011) and Riboulet-Chavey et al. (2006) use methylglyoxal 
concentrations which far exceed physiological levels to show an effect, or use highly 
glycated proteins which would not occur physiologically.  The study by Fiory et al. 
(2011) used aminoguanidine as a dicarbonyl scavenger; it reacts rapidly with 
dicarbonyls and thereby inhibits the actions of methylglyoxal.  However, it is highly 
reactive and at higher concentrations will react with other physiological metabolites 
such as glucose and pyruvate - caution should therefore be taken in its use, and an 
appropriate concentration used so that it acts as a selective scavenger of dicarbonyls 
(Thornalley, 2003b).  The 4 mM aminoguanidine used in this study was of too high a 
concentration to act as a selective scavenger.  The reported impairments in GSIS as a 
result of methylglyoxal treatment cannot be reliably concluded from experiments 
using a scavenger at levels sufficient to scavenge other essential metabolites. 
It has been known for a number of years that insulin can be glycated by 
glucose (Dolhofer and Wieland, 1979; Lapolla, et al., 1988).  These earlier studies 
used highly glycated insulin formed by incubation with 222 mM glucose, and whilst 
this glycated insulin had decreased biological activity, its physiological relevance 
was not known.  More recently, studies have again indicated that insulin can be 
glycated by glucose or glucose metabolites, both in vitro and in vivo, and that this 
may have physiological effects (Abdel-Wahab, et al., 1997; Abdel-Wahab, et al., 
1996; O'Harte, et al., 1996).  Abdel-Wahab et al. (1996) observed glycated insulin 
within pancreatic islets of both insulin-deficient and insulin-resistant rodent models 
of diabetes.  It was suggested that G6P was the glycating agent and not glucose, 
since G6P is more reactive and of an elevated concentration in the ER.  In addition, 
both proinsulin and insulin were glycated, as would be expected if this glycation 
occurred in the ER of beta cells (Abdel-Wahab, et al., 1996).  However, the specific 
sites of glycation and the glycating agent were not identified in this in vivo study.  
More recently the extent of glycated insulin in the pancreas and circulating plasma of 
ob/ob mice was shown to be decreased by vitamin C supplementation, resulting in 
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improvements in insulin sensitivity and glycaemic control (Abdel-Wahab, et al., 
2002).  It was identified by O’Harte et al. (1996) that glycation of insulin by glucose 
occurs in vitro on the phenylalanine residue at the amino terminus of the beta chain, 
however it is not known if this glycation occurs physiologically.  This in vitro 
glycated insulin was shown to have impaired biological activity compared to non-
glycated insulin when injected by intraperitoneal injection into mice (Abdel-Wahab, 
et al., 1997).  Insulin has also been shown to be glycated on arginine-22 of the beta 
chain by methylglyoxal in vitro (Jia, et al., 2006).  This resulted in decreased insulin-
mediated glucose uptake as well as impaired insulin secretion.  However, this is 
unlikely to be of physiological relevance, since the half-life of insulin in plasma is 
approximately 4 - 6 min.  Glycation of insulin by methylglyoxal is unlikely to lead to 
the functional impairments observed in clinical diabetes (Rabbani and Thornalley, 
2011; Sherwin, et al., 1974).  Indeed, it was suggested that due to the short half-life 
of insulin, any glycation which occurs will predominantly occur during synthesis and 
storage of insulin within beta cells and not post secretion (Abdel-Wahab, et al., 
1996).  However, glycation may lead to some functional impairment in synthetic 
long-acting insulin derivatives.  
Supraphysiological concentrations of methylglyoxal (0.5 mM and 1 mM) 
have long been shown to have effects on pancreatic beta cells, as discussed by 
Rabbani and Thornalley (2011).  It was shown using patch-clamping techniques that 
methylglyoxal caused depolarisation of isolated rat pancreatic beta cells and that in 
intact islets methylglyoxal increased the intracellular calcium concentration (Cook, 
et al., 1998).  This was associated with a transient stimulation of insulin secretion, 
followed by inhibition of GSIS.  It was then reported that the depolarisation was due 
to activation of a volume-sensitive anion channel due to cell swelling following 
exposure to methylglyoxal and the formation of D-lactate (Best, et al., 1999).  As 
discussed by Cook et al. (1998) the concentration of methylglyoxal used in these 
studies far exceeds physiological or patho-physiological levels to which beta cells 
may be exposed, and consequently methylglyoxal is unlikely to induce 
depolarisation of beta cells.  However, this work was indicative of the potential role 
of methylglyoxal in the physiology of beta cells and their dysfunction in diabetes.  
Studies infusing high levels of methylglyoxal into rats indicate the 
significance of methylglyoxal and protein glycation in diabetes (Berlanga, et al., 
2005; Dhar, et al., 2011).  The study by Berlanga et al. (2005) exposed Wistar rats to 
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a progressively increasing continuous infusion of methylglyoxal (from 50 - 75 mg/kg 
of body weight/day) for a period of 7 weeks.  They demonstrated the development of 
diabetes-like vascular damage and impaired wound healing following chronic 
exposure – even with the maintenance of normal glycaemic control.  A more recent 
study (Dhar, et al., 2011) continuously infused 60 mg/kg body weight/day 
methylglyoxal into Sprague-Dawley rats for 28 days.  They showed functional 
effects of dicarbonyls on pancreatic beta cells in vivo, such as decreased insulin 
secretion, decreased GSH and increased apoptosis as well as increased plasma 
glucose.  The increased plasma glucose differs to the maintenance of normal 
glycaemic control in the earlier study (Berlanga, et al., 2005).  It was suggested by 
Dhar et al. (2011) that their observed effects may be tissue specific, with effects 
observed in the pancreatic, skeletal and adipose tissue.  However, they make no 
mention of which other tissues were studied wherein effects were not seen.  
Although these studies infused high levels of methylglyoxal, the use of continuous 
infusion makes them of more physiological relevance than other studies (such as 
Jung, et al., 2011; Zhao, et al., 2009) which spiked high bolus doses of dicarbonyls 
or AGEs into plasma, leading to a sudden increase in the plasma levels, which would 
not occur physiologically. 
 Recently, a study using a cell permeable fusion protein construct of Glo1, 
Tat-Glo1, showed that Glo1 protected against chemical induction of toxicity to 
insulinoma cells in vitro and diabetes in vivo.  The expression vector contained 
consecutive cDNA sequences for human Glo1, Tat peptide and six histidine residues 
at the amino-terminus.  Purified Tat-Glo1 protein protected RINm5F cells against 
sodium nitroprusside induced cell death and DNA fragmentation.  It also protected 
against induction of diabetes by streptozotocin (STZ) in mice (Kim, et al., 2013).  It 
was shown that injection of Tat-Glo1 into mice was equally effective in partially 
suppressing the development of diabetes when given 12 h before or 1 day after STZ 
injection.  This was associated with increased serum insulin and decreased free fatty 
acids in Tat-Glo1 treated animals compared to STZ-treated animals.  Although the 
mechanism is yet to be elucidated, the study indicates the potential role of Glo1 and 
dicarbonyls in pancreatic beta cell destruction by STZ and potentially other types of 
beta cell toxicity.  However, a limitation of this study is that neither the amount of 
Glo1 protein reaching the beta cells nor the activity of this protein was determined.  
It is therefore unknown how the amount of protein providing protection to beta cells 
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in this study compares to physiological levels observed in beta cells.  The protective 
nature of Tat-Glo1 reported by Kim et al. (2013) is in agreement with other recent 
publications which suggest a decrease in AGEs and oxidative stress in diabetic rats 
following overexpression of Glo1 (Brouwers, et al., 2011).  Brouwers et al. (2011) 
indicated that a 10 - 50 fold overexpression of Glo1 decreased the elevations of both 
dicarbonyls and AGEs observed in diabetes and this has been shown to protect 
against retinopathy (Berner, et al., 2012).  These studies further highlight the 
protective nature of the glyoxalase system and the importance of maintaining 
metabolic control – limiting the effects of damaging reactive metabolites such as the 
dicarbonyls. 
 
3.2. Collagen and ECM proteins 
3.2.1. Beta cell mass and ECM proteins  
Decreases in beta cell mass have been repeatedly associated with the 
development of diabetes.  Loss of beta cells by apoptosis is implicated in beta cell 
dysfunction and the pathogenesis of T2DM (Chang-Chen, et al., 2008; Meier, et al., 
2012; Szoke, et al., 2008; Taylor, 2006).  The mechanism of apoptosis activation is 
not known, although potential causes have been postulated (detailed in Figure 2 and 
Table 3).  Interaction of beta cells with ECM proteins of the basement membrane 
have been shown to be important in maintaining beta cell mass as well as in 
regulation of insulin secretion.  Loss of these interactions was associated with 
detachment-stimulated cell death – a phenomenon termed ‘anoikis’ (Frisch and 
Francis, 1994).  The loss of functional ECM interactions when islets are removed 
from the pancreas results in integrin-mediated anoikis unless islets are cultured on 
ECM proteins, such as collagen IV and laminin.  This indicates the clinical 
significance of studies into beta cell-ECM interactions (Pinkse, et al., 2006). 
 
3.2.2. Collagen IV 
Collagen IV was first discovered and isolated by Kefalides (1966).  It is a 
trimeric protein present exclusively in the basement membrane of all tissues 
(Khoshnoodi, et al., 2008; Kühn, 1994).  Collagen IV is commonly composed of two 
α1 subunits and one α2 subunit; subunit structure (α1)2(α2)1, (Khoshnoodi, et al., 
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2008).  Whilst two other distinct collagen IV heterotrimers are known to exist, 
α3α4α5 and (α5)2(α6)1, these have specific spatial and temporal regulation and occur 
in specific tissues – such as the kidney, eye and skin - during development 
(Khoshnoodi, et al., 2008).   
The two genes for the α1 and α2 subunits are a bidirectional gene pair located 
on chromosome 13 in humans.  The other four α subunits form two other 
bidirectional gene pairs on chromosome 2 (α3 and α4) and X (α5 and α6).  These 
bidirectional gene pairs are arranged head-to-head and transcribed from opposite 
DNA strands.  They share a short promoter region which separates the 
transcriptional start sites by 127 base pairs (Khoshnoodi, et al., 2008; Pöschl, et al., 
1988).  This shared promoter region with symmetrical arrangement of sequence 
elements and shared enhancers enables co-ordinated control of transcription of the 
two subunits of the heterotrimeric collagen IV (Burbelo, et al., 1988; Pöschl, et al., 
1988). 
Collagen IV is a 500 kDa protein with three distinct functional domains: an 
amino terminal signal peptide rich in cysteine and lysine, a collagenous domain and 
a long carboxy-terminal noncollagenous domain (NC1) (Hudson, et al., 2003; 
Khoshnoodi, et al., 2008).  The structural features of the α1 and α2 chains are 
detailed in Table 5.  The NC1 domain is important in determining chain specificity 
and acts as the folding origin for the triple helical assembly, and hence initiates the 
molecular assembly of collagen IV molecules (Khoshnoodi, et al., 2008).  The 
collagenous domain forms a supercoiled triple helical structure with glycine residues 
frequently repeating every third amino acid residue (Cameron, et al., 1991; Dobler, 
et al., 2006; Stendahl, et al., 2009).  Glycine is essential to this tightly coiled triple 
helix because it is the only amino acid which will fit in the centre of the triple helix.  
Interruptions in the collagenous triple helical structure provide molecular flexibility 
and enable cell-binding and interchain crosslinking (Khoshnoodi, et al., 2008).  
Collagen IV is secreted by cells into the ECM and self-associates into a network of 
triple-helical molecules which provide a molecular scaffold for other ECM 
components such as laminin (Khoshnoodi, et al., 2008).  Cell attachment is mediated 
at specific binding sites within both the collagenous and NC1 domains, with both 
integrin receptors and non-integrin receptors implicated; the specific receptors 
involved in interactions with pancreatic beta cells are detailed in section 1.3.3. 
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Table 5: Structural features of α1 and α2 chains of human collagen IV 
Adapted from Khoshnoodi, et al. (2008) 
  
3.2.3. Modification of ECM proteins  
Agents that react with and modify ECM proteins and thus impair integrin-
mediated binding to beta cells may prove detrimental to beta cell survival through 
activation of anoikis.  ECM proteins are particularly susceptible to damage because 
protective enzymatic defence systems, such as the glyoxalase system, are located 
within the cell cytosol; increases in methylglyoxal are therefore larger in 
extracellular medium and plasma than observed within cells (Dobler, et al., 2006).  
Furthermore, functionally important arginine residues lie within integrin binding 
sites in ECM proteins (Chetyrkin, et al., 2011).  The plasma concentration of 
methylglyoxal is known to increase in hyperglycaemia and diabetes, and 
consequently levels of AGE residues on proteins also increase.  In addition, the half-
life of aortal collagen – including collagen IV - is estimated to be 60 - 70 days and so 
modifications by glycation may accumulate (Nissen, et al., 1978). 
Collagen IV is susceptible to modification by methylglyoxal with functional 
consequences (Cameron, et al., 1991; Dobler, et al., 2006).  Arginine residues within 
the integrin binding site motifs of RGD on the α2 chain and GFOGER on the α1 
chain were specifically modified by methylglyoxal, leading to impairments in 
endothelial cell binding to collagen and subsequent cell detachment and anoikis.  
Dobler et al. (2006) additionally showed that these modifications resulted in a 
decrease in angiogenesis within endothelial cells in vitro.  This study identified the 
specific hotspots for glycation within collagen IV and indicated in endothelial cells 
that this modification impaired cell-ECM interactions and subsequently resulted in 
anoikis.  Similar effects of the modification of collagen with methylglyoxal were 
observed earlier by Paul and Bailey (1999), again indicative of the deleterious 
 α1 α2 
Residues after translation (procollagen) 1669 1712 
Residues in signal peptide 27 36 
Residues in collagenous domain 1413 1449 
Residues in NC1 domain 229 227 
Number of interruptions to collagenous domain 21 23 
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changes in tissues in both ageing and disease.  Since both cell-ECM interactions and 
the maintenance of beta cell mass are known to be vital for normal beta cell 
functioning, it is possible that similar modifications within the basement membrane 
of the islets of Langerhans may have a role in beta cell dysfunction. 
 
3.2.4. Culture of beta cells on collagen  
 ECM proteins have been utilised for cell culture studies of cell-ECM 
interactions in vitro (Kleinman, et al., 1987).  ECM proteins regulate cell function as 
well as enabling survival of some cell lines and primary cultures.  Indeed, primary 
beta cells require matrix components to survive out of their natural environment 
(Pinkse, et al., 2006; Wang and Rosenberg, 1999).  The interactions between ECM 
proteins and the MIN6 insulinoma cell line have been investigated by a number of in 
vitro studies.  These studies have indicated that matrix proteins provide a suitable 
surface for cell growth (Iino, et al., 2004; Nikolova, et al., 2006; Weber, et al., 
2008).  They also highlight the importance of interactions between beta cells and 
basement membrane proteins and suggest that interactions with collagen IV and 
laminin predominate for beta cells.  Modifications of ECM proteins at functional 
sites involved in these interactions may impair cell metabolism, signalling and 
viability. 
   
3.3. Experimental models of beta cells and diabetes 
 Beta cell function has been characterised experimentally by studying isolated 
mammalian beta cells in vitro. The difficulties in isolating and maintaining 
mammalian beta cells in primary culture has led to the development and use of 
insulinoma cell lines which exhibit some characteristics of the beta cell phenotype.  
Beta cell function in vivo has been studied in animal models of pre-diabetes, insulin 
resistance and diabetes.  There are limitations to extrapolating conclusions from in 
vitro and in vivo rodent models to human physiological systems, particularly due to 
the differences in the arrangement of islet cells between the different species 
(Stendahl, et al., 2009).  These models are, however, useful tools in furthering 
understanding of both beta cells and diabetes, with similar mechanisms and 
molecular events underlying these processes in both humans and rodents. 
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3.3.1. Beta cells in culture 
A number of beta cell lines have been developed for research into beta cells 
and diabetes.  The changing characteristics that they display with continued culture 
and abnormal protein expression are their main limitations.  The main advantage is 
their availability and susceptibility to genetic modification (Skelin, et al., 2010).  
Characteristics of the commonly used beta cell lines are given in Table 6.  The 
glucose responsiveness varies greatly and many cell lines have defects in the insulin 
secretion pathway.  Methods used to transform beta cells and overcome replicative 
senescence have included induction of tumours by irradiation, viral infection and 
development of transgenic mice with targeted expression of a recombinant oncogene 
in beta cells (Skelin, et al., 2010).  Expression of the Simian vacuolating virus 40 
(SV40) has been successful in adapting primary cells to continuous growth in culture 
and transforming cells into a tumourigenic condition.  It is believed to suppress the 
tumour-suppressor p53, and so lead to uncontrolled proliferation and a tumour 
(Skelin, et al., 2010). 
The cell lines MIN6 and INS-1 are considered to provide the best models of 
physiological beta cell function (Skelin, et al., 2010).  They are both glucose 
responsive in the physiological range and express the glucose sensor glucokinase.  
The glucose responsiveness of MIN6 cells does, however, deteriorate with passage 
and it is therefore important to use lower passage cells for a model of healthy beta 
cells (Cheng, et al., 2012b).  Primary rodent beta cells are also grown in culture.  
These do not easily proliferate and are usually cultured for approximately a week 
(Skelin, et al., 2010).  The main limitation of their use is availability due to the 
reliance on fresh animal material.  Although the rodent pancreatic beta cell lines 
have enabled many advances in the study of beta cell physiology, the current 
developments in human cell lines will provide a new, more clinically relevant source 
of experimental beta cells and enable testing of advances in human-derived tissue 
(McCluskey, et al., 2011; Vasu, et al., 2013). 
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 Table 6: Insulin secreting cell lines 
Cell line and origin  Characteristics 
MIN6 –C57BL6 mouse 
insulinoma (SV40 T-
antigen transgenic mouse) 
Expresses GLUT-2 and glucokinase and responds to 
glucose within the physiological range.  Developed by 
Miyazaki et al. (1990). 
INS-1 – rat insulinoma 
(radiation induced) 
Displays many of the characteristics of beta cells – 
glucose responsive (express GLUT-2 and glucokinase) 
and has a high insulin content compared to some other 
cell lines.  Dependent on mercaptoethanol.  Developed 
by Asfari et al. (1992). 
Rat insulinoma cell line 
(RINm) (radiation 
induced) 
Physiology differs to beta cells.  Abnormal glucose 
metabolism, poor sensitivity to glucose insulin (Halban, 
et al., 1983). 
Hamster pancreatic beta 
cells (HIT) (SV40 T-
antigen transformed) 
GSIS similar to observed in hamster islets.  Responds 
to known modulators of insulin release (glucose and 
glucagon).  Insulin content 2.5 - 20 fold lower than 
hamster islets (Santerre, et al., 1981). 
Beta-tumour cells – 
transgenic rodents (SV40 
T-antigen transgenic 
rodents) 
Maintains the features of differentiated beta cells for 
approximately 50 passages in culture.  Secretes insulin 
but with a lower threshold for maximal stimulation than 
normal beta cells.  Developed by Efrat et al. (1988). 
Beta-hyperplastic islet-
derived cells (HC), e.g. 
βHC-9 from hyperplastic 
mice islets (SV40 T-
antigen transgenic mouse) 
Displays normal concentration dependent GSIS – 
expresses both GLUT-2 and glucokinase.  Kinetics of 
glucose metabolism are determined by glucokinase 
activity (Liang, et al., 1996).  Developed by Radvanyi 
et al. (1993) 
Human pancreatic beta 
cell line 1.1B4 
(electrofusion of freshly 
isolated beta cells and the 
immortal human PANC-1 
epithelial cell line) 
Novel human cell lines were developed by McCluskey 
et al. (2011) and characterised further (Vasu, et al., 
2013).  This cell line was shown to demonstrate glucose 
sensitivity and respond to known insulin modulators, 
such as glucose and alanine.  Implantation of the 1.1B4 
cell line into STZ-induced diabetic mice improved 
glucose tolerance.    
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Insulin release by MIN6 cells has been compared to that of mouse islets 
(Kelly, et al., 2010).  It was found that although islets have greater insulin content, 
insulin release was higher from MIN6 cells cultured as pseudo-islets than from 
primary mouse islets.  However, the underlying functional and molecular features of 
MIN6 cells (glucose responsiveness and expression of adhesion molecules such as 
E-cadherin and Cx36) are similar to beta cells.  In addition, when MIN6 cells are 
cultured as pseudo-islets they contain a similar number of cells to in the islets of 
Langerhans in mice (approximately 4,000 cells per pseudo-islet), indicating the 
suitability of MIN6 as a beta cell line. 
 
3.3.2. Animal models of diabetes 
3.3.2.1. Streptozotocin induced diabetes  
STZ is synthesised by Streptomycetes achromogenes and is used to 
chemically induce diabetes (Szkudelski, 2001).  STZ has selective toxicity to 
pancreatic beta cells.  It induces beta cell necrosis which can be detected by electron 
microscopy within hours of treatment (Rossini, et al., 1977; Szkudelski, 2001).  STZ 
enters beta cells via the GLUT2 glucose transporter and induces alkylation of DNA 
and subsequent activation of poly ADP-ribosylation.  This leads to depletion of 
cellular ATP as well as formation of ROS.  Since STZ ablates the beta cell mass and 
induces diabetes it is useful for studies investigating the consequences, 
complications and treatments for diabetes.  It is not usually of use in studying 
changes within the pancreas in the normal pathogenesis of T2DM.  The study 
injecting Tat-Glo1 into STZ-induced diabetic mice and observing changes in beta 
cell ablation is a clear exception to this (Kim, et al., 2013).  In addition, a treatment 
combining nicotinamide with STZ has been used to induce a moderate decrease in 
beta cell mass as a model of T2DM (Masiello, et al., 1998; Szkudelski, 2012).   
 
3.3.2.2. Animal models of diabetes and obesity  
Selective inbreeding of mice for a number of generations has led to the NOD 
mouse model of T1DM.  Hyperglycaemia has specifically been selected for and so 
not all the genes and phenotypes which have become enriched will be relevant to the 
pathogenesis of diabetes in either rodents or humans (Rees and Alcolado, 2005).  In 
addition, NOD mice suffer less ketoacidosis and animals can survive for weeks 
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without insulin administration, unlike humans with T1DM.  This mouse model is 
useful in improving understanding of the genetic and immunological basis of T1DM. 
Models of T2DM are more complex due to the heterogeneity of the disorder 
– the interplay of insulin resistance and aspects of beta cell dysfunction and impaired 
insulin secretion.  Animals with single gene mutations, such as the leptin deficient 
and leptin resistant models of obesity, ob/ob and db/db mice respectively, have been 
used to gain insights into T2DM.  A number of tissue specific gene deletions or 
“knockout” animal models have also been utilised to identify the role of genes in 
specific tissues.  For example knockout of the insulin receptor specifically in 
pancreatic beta cells in mice indicated insulin resistance within beta cells (Kulkarni, 
et al., 1999). 
 
3.3.2.3. HFD model of insulin resistance  
The HFD fed mouse is a model of impaired glucose tolerance, insulin 
resistance and the early stages of T2DM (Hancock, et al., 2008; Souza-Mello, et al., 
2010; Winzell and Ahrén, 2004).  It is the most clinically relevant model of T2DM.  
This model was introduced in 1988 with suggestions of genetic predisposition to 
develop diabetes in diet-induced obese mice (Surwit, et al., 1988).  A combination of 
higher dietary intake and lower metabolic efficiency increases body weight as well 
as plasma glucose after a week of HFD feeding in C57BL6J mice.  Insulin increases 
more progressively with time, although insulin release in response to glucose stimuli 
was shown to be impaired after a week of HFD feeding (Winzell and Ahrén, 2004).   
It has been shown that HFD feeding of rodents for 16 weeks leads to changes 
within the pancreas suggestive of changes in morphology and impairments in 
function – these include an increase in islet mass, insulin content and glucagon 
content as well as a decrease in immunodensity for GLUT2 (Souza-Mello, et al., 
2010).  Drugs used to treat T2DM, such as metformin, were shown to prevent these 
changes in the pancreas, with similar levels of insulin, glucagon and GLUT2 
observed in mice treated with a combination of HFD and metformin as seen in mice 
fed a standard chow diet (Souza-Mello, et al., 2010).  Another recent study 
demonstrated similar effects as well as indicating that HFD feeding of C57BL6J 
mice leads to decreased insulin secretion - due to the functional dissociation of 
VGCC from exocytosis in beta cells (Collins, et al., 2010).  This was suggested to be 
because calcium entry in beta cells becomes more dispersed following HFD.  It is 
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therefore less efficient and intracellular increases in calcium occur too far from 
release-competent granules to trigger release.  Additionally, it was reported that the 
inhibitory effect of prolonged non-esterified fatty acid (NEFA) treatment on GSIS 
involves a redistribution of VGCC such that the granule pool close to the calcium 
channels are lost (Hoppa, et al., 2009; Rorsman and Braun, 2013).  These studies are 
suggestive of a direct link between increased dietary lipids – a high fat diet – and 
pancreatic beta cell dysfunction; this indicates the importance of this model for not 
only studying insulin resistance, but also beta cell dysfunction during the 
pathogenesis of diabetes. 
 Further studies have replaced some of the dietary fats with n-3 long-chain 
polyunsaturated fatty acids (LC-PUFA), namely eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which are abundant in fish oils.  These LC-PUFA 
have been shown to be hypolipidaemic in both humans and rodents and prevent 
obesity and insulin resistance in rodents fed a HFD (Jilkova, et al., 2013; Rossmeisl, 
et al., 2009).  Plasma lipid levels were decreased, further weight gain prevented and 
glucose tolerance improved when these LC-PUFA were fed to dietary obese mice, 
the treatment did not however decrease the plasma insulin levels (Rossmeisl, et al., 
2012).  The role of LC-PUFA in beta cell dysfunction or maintenance of healthy beta 
cell physiology remains to be determined. 
 
3.4. Aims and Objectives 
 The aim of this investigation is to investigate the effect of protein glycation 
by methylglyoxal on pancreatic beta cell dysfunction and the subsequent 
development of diabetes.  The MIN6 cell line and HFD-induced diabetic mouse 
model were used in this study. 
 
Objective 1: To characterise the glyoxalase system and dicarbonyl 
metabolism in MIN6 cells in vitro  
There are few publications on the glyoxalase system and the associated 
dicarbonyl metabolism in beta cells or relevant cell lines.  It is therefore important to 
characterise this enzymatic system in a relevant cell type.  To achieve this objective, 
MIN6 cells were used as a model to characterise the glyoxalase system in both basal 
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glucose concentration (5.5 mM) and high glucose concentration (20 mM) conditions.  
Activities of the glyoxalase enzymes and concentrations of the associated 
metabolites - dicarbonyls, D-lactate and glutathione - were determined.  The 
glyoxalase pathway flux was determined and the glucose consumption used to 
calculate the proportional flux from triosephosphates in cells cultured in basal and 
high glucose.  Cellular protein was analysed for glycation, oxidation and nitration 
adducts to assess whether exposure to higher concentrations of glucose has an impact 
on the level of cellular protein damage.  A cell permeable inhibitor of Glo1, 
BrBzGSHCp2, was utilised to induce dicarbonyl stress.  In this model dicarbonyls 
and glutathione were measured, as well as the mRNA expression of insulin and Glo1 
to characterise changes in dicarbonyl metabolism and beta cell function. 
 
Objective 2: To study the effect of modification of collagen IV with 
methylglyoxal on the function and adhesion of MIN6 cells in vitro 
The functional effect of modifying collagen IV with methylglyoxal has been 
previously demonstrated in endothelial cells (Dobler, et al., 2006).  The sites of 
modification were identified – specific arginine residues within integrin binding 
sites, necessary for cell-ECM binding in both endothelial cells and beta cells.  To 
achieve this objective MIN6 cells were cultured on control and methylglyoxal-
modified collagen IV coated plates and adhesive interactions assessed.  Controls 
were performed using both an anti-integrin β1 antibody and RGD peptide to confirm 
that any observed binding is specific to collagen.  The force and energy underlying 
adhesion between collagen and MIN6 cells was determined using atomic force 
microscopy force spectroscopy (AFM-FS).  Analysis of gene expression in MIN6 
cells following culture on uncoated, collagen coated and methylglyoxal-modified 
collagen coated plates was used to assess MIN6 cell function and any impairment 
therein.  Genes analysed were Ins1, Ins2, Glo1, E-cadherin, Cx36 and integrin beta 1 
(Itgb1).  This enabled the effect of methylglyoxal modification of collagen IV on 
binding to MIN6 cells, and related effects on insulin expression and cell-cell 
adhesion and cell-ECM adhesion to be determined. 
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Objective 3: To characterise and evaluate the effect of diet induced 
insulin resistance on dicarbonyls and the associated metabolism in an 
in vivo model of T2DM 
 Feeding C57BL6 mice a HFD for 6 - 12 weeks induces insulin resistance and 
diabetes (Surwit, et al., 1988).  The effects of this have been well studied, 
particularly in organs susceptible to insulin resistance such as skeletal muscle and the 
liver, and with regards to potential treatments (Hancock, et al., 2008; Souza-Mello, 
et al., 2010; Winzell and Ahrén, 2004).  However, relatively little is known about the 
pancreas in this model, especially with regard to the glyoxalase system and 
dicarbonyl metabolism.  To achieve this objective, diabetes was induced by feeding a 
HFD to C57BL6 mice.  An additional treatment group in which mice were fed a 
HFD supplemented with EPA and DHA was maintained.  Previous work has 
suggested that this supplementation prevents the detrimental effects of HFD in the 
development of obesity and insulin resistance (Jilkova, et al., 2013; Rossmeisl, et al., 
2009; Rossmeisl, et al., 2012).  The activity of the glyoxalase system enzymes and 
the amount of related metabolites was measured in the pancreas from control diet 
fed, HFD fed and omega-3 fatty acid supplemented HFD fed mice.  Glycation, 
oxidation and nitration adduct residues were quantified on the cytosolic and ECM 
pancreatic protein and the plasma protein.  The concentration of glycation, oxidation 
and nitration free adducts in the pancreas and plasma was determined.  This data 
enabled an understanding and comparison of dicarbonyl metabolism and associated 
protein glycation in control and insulin resistant diabetic mice.  Immunostaining was 
also used to observe changes in localisation of collagen IV, insulin and the glycation 
adduct MG-H1 in the pancreas of mice fed these different diets. 
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4. Materials and Methods 
4.1. Materials 
4.1.1. Cell line and cell culture reagents  
MIN6 cells were originally obtained from Professor Jun-ichi Miyazaki 
(Osaka Medical School, Japan).  Dulbecco’s Modified Eagles Medium (DMEM), 
CO2-independent medium and 0.25% Trypsin-EDTA solution were purchased from 
Invitrogen Life Technologies (Paisley, UK) and Fetal Bovine Serum (FBS) from 
Biosera (Boussens, France).  Penicillin-Streptomycin solution (10,000 units 
penicillin and 10 mg streptomycin per mL in 0.9% sodium chloride), trypan blue and 
thiazolyl blue tetrazolium bromide (MTT) were all purchased from Sigma Aldrich 
(Gillingham, Dorset, UK).  Trypsin neutralising solution (0.05% trypsin inhibitor, 
0.1% BSA) was from Promocell (Heidelberg, Germany).  Neubauer 
haemocytometers for cell counting were purchased from Paul Marienfeld GmbH & 
Co. KG (Lauda-Königshofen, Germany).  
 
4.1.2. Enzymes, peptides and proteins  
L-Arginyl-glycyl-L-aspartic acid (RGD), human fibronectin purified from 
plasma and human placental collagen IV were obtained from Sigma Aldrich and 
mouse Engelbreth-Holm-Swarm (EHS) lathrytic tumour derived collagen IV was 
obtained from BD Bioscience (San Jose, USA).  Collagenase from Clostridium 
histolyticum (type VII), pronase E from Streptomyces griseus (type XIV), pepsin 
from porcine gastric mucosa, prolidase from porcine kidney, leucine aminopeptidase 
from kidney microsomes (type VI-S), L-lactic dehydrogenase from rabbit muscle 
and D-lactic dehydrogenase from Staphylococcus epidermidis were all purchased 
from Sigma Aldrich.  
 
4.1.3. Antibodies 
Armenian hamster anti-mouse Itgb1 (functional grade purified) monoclonal 
antibody was from eBioscience (Hatfield, UK).  Chicken polyclonal anti-insulin 
antibody and rabbit polyclonal anti-collagen IV antibodies were obtained from 
Abcam (Cambridge, UK).  Mouse anti-MG-H1 monoclonal antibody clone 1H7G5 
was a gift from Professor Michael Brownlee (Albert Einstein College of Medicine, 
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Bronx, NY).  Alexa Fluor 555 goat anti-chicken IgG, Alexa Fluor 488 goat anti-
mouse IgG, Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-
rabbit IgG were all obtained from Molecular Probes (Invitrogen, Eugene, Oregon, 
USA). 
 
4.1.4. Analytical and preparative kits  
RNeasy Mini Kit was from Qiagen (Manchester, UK).  CBQCA protein 
quantitation kit was purchased from Invitrogen Life Technologies (Paisley, UK) and 
the protein assay dye concentrate from BioRad (Hemel Hempstead, Hertfordshire, 
UK).  Glucose assay kits were obtained from Sigma Aldrich.  Strong anion exchange 
solid phase extraction cartridges were from Alltech Associates Ltd. (Carnworth, 
Lancashire, UK) and 3,000 and 10,000 molecular weight cut-off centrifugal filters 
were from Millipore (Watford, UK). 
 
4.1.5. Immunohistochemistry reagents  
Microscope slides were from Fisher Scientific (Loughborough, UK) and 
cover glass from VWR International (Lutterworth, Leicestershire, UK).  Embedding 
matrix was from Shandon Cryomatrix (ThermoFisher, Epsom, Surrey, UK).  
Mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI) and an 
ImmEdge hydrophobic barrier pen were purchased from Vector Laboratories 
(Peterborough, UK). 
 
4.1.6. Chromatographic reagents 
Hypercarb columns (50 x 2.1 mm, 150 x 2.1 mm and 250 x 2.1 mm) and 
octadecyl silane (ODS) columns (100 x 2.1 mm) for HPLC were purchased from 
Thermofisher (Epsom, Surrey, UK) and Waters (Elstree, Hertfordshire, UK) 
respectively.  HPLC grade and Optima grade solvents were obtained from Fisher 
Scientific (Loughborough, UK). 
 
4.1.7. Other analytical reagents  
Nuclease-free water and 18S reference primers were from Qiagen 
(Manchester, UK).  All other primers were ordered from Invitrogen custom primer 
service (Paisley, UK).  dNTP mix was from Fermentas (Thermo Scientific, Epsom, 
Surrey, UK).  Bioscript, RiboSafe RNase Inhibitor, Oligo (dT)18 Primer Mix and 
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SensiMix Sybr Low-ROX were all purchased from Bioline (London, UK).  [glycine-
13
C2
15
N]GSH, 98% 
15
N and 99% 
13
C was purchased from Sigma Aldrich.  
[
13
C4
15
N2]GSSG was synthesised from [glycine-
13
C2
15
N]GSH.  Standards and 
isotopic standards for dicarbonyl assay were available in house.  3-DG and [
13
C6]3-
DG were synthesised from glucose and [
13
C6]glucose respectively.  Glyoxal and 
[
13
C2]glyoxal were synthesised by oxidation of ethylene glycol and [
13
C2]ethylene 
glycol respectively using alcohol oxidase and catalase.  High purity methylglyoxal 
and [
13
C2]methylglyoxal were available in house, prepared and purified as described 
(McLellan and Thornalley, 1992).  Isotopically labelled citrulline and amino acids 
were purchased from Cambridge Isotope Laboratories (Andover, MA, USA) and 
glycation, oxidation and nitration adducts were available in house, prepared and 
purified as described (Ahmed, et al., 2002; Thornalley, et al., 2003).  2,5,5[
2
H3]DL-
α-Aminoadipic acid ([2H3]-AAA) was purchased from CDN Isotopes (Quebec, 
Canada).  ε-(γ-L-Glutamyl)–L-lysine was purchased from Bachem AG (Bubendorf, 
Switzerland) and [
13
C5]ε-(γ-L-glutamyl)–L-lysine was available in house, prepared 
and purified as described (Bertholet, et al., 1977).  S-p-Bromobenzyl-glutathione 
cyclopentyl diester (BrBzGSHCp2) was available in house, prepared and purified as 
described (Thornalley, et al., 1996).  All other analytical reagents and buffers were 
purchased from either Sigma Aldrich or Fisher Scientific. 
 
4.1.8. Instrumentation 
Water used for all experiments was filtered through a Milli-Q Advantage A-
10 System from Millipore (Watford, UK).  Microplate assays were quantified using a 
FLUOstar Optima plate reader (BMG Labtech, Aylesbury, Buckinghamshire, UK) 
and enzymatic activity assays and stock calibrations performed using UVIKON XS 
spectrophotometer (NorthStar Scientific Ltd. Potton, Bedfordshire, UK).  Liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed 
using  Waters Acquity ultra HPLC systems with a Quattro Premier XE Tandem mass 
spectrometer and Xevo triple quadrupole mass spectrometer (Waters, Elstree, 
Hertfordshire, UK).  Enzymatic hydrolysis was performed using a CTC-PAL 
Automation System (CTC-Analytics, Zwingen, Switzerland).  The centrifugal 
evaporator was a Savant Instruments SpeedVac (Thermo Scientific, Waltham MA). 
Quantification of RNA stocks was performed using a ND-1000 Nanodrop 
spectrophotometer (Nanodrop, Wilmington, USA).  RNA expression analysis was 
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performed using a 7500 Fast Real-Time PCR machine from Applied Biosystems 
(Carlsbad, California, USA).  A Sonics Vibra-Cell sonicator from Jencons Scientific 
(Leighton Buzzard, Bedfordshire, UK) was used for lysis of cell culture samples and 
a Lab Gen 7 homogeniser from Cole Parmer (Vernon Hills, USA) was used for 
isolation of protein and soluble extracts from pancreatic tissue samples.  Pancreas 
samples were sectioned for immunohistochemistry using a CM1850 Cryostat from 
Leica Microsystems (Milton Keynes, UK).  Confocal microscopy was performed 
using an AxioVert 200M laser scanning confocal microscope from Carl Zeiss 
Microscopy (Thornwood, NY, USA).  AFM-FS was performed using a CellHesion 
module (JPK Instruments, Berlin, Germany). 
 
4.1.9. Software 
 Mass spectrometry data was processed using MassLynx software Version 4.1 
(Waters, Elstree, Hertfordshire, UK).  Atomic force spectroscopy data was processed 
using CellHesion 200 software (JPK Instruments, Berlin, Germany).  Confocal 
microscopy images were viewed using LSM Image Browser (Carl Zeiss Microscopy, 
Thornwood, NY, USA).  Microplate assays were analysed using Optima software 
version 2.10 R2 (BMG Labtech, Aylesbury, Buckinghamshire, UK).  Real-time PCR 
analysis was performed using 7500 Fast System Software version 1.4.0.  RNA 
primers were designed using the Oligo perfect design tool (Invitrogen Life 
Technologies, Paisley, UK) with mRNA and genomic sequences obtained using the 
University of California, Santa Cruz genome browser tool (Genome Bioinformatics 
Group, University of California, Santa Cruz).  ChemDraw Pro version 13.0 was used 
for chemical structures and associated analysis. Statistical analysis was performed 
using SPSS Statistics version 21. 
 
4.2. Cell culture methods 
4.2.1. MIN6 cell culture 
MIN6 cells were maintained in DMEM supplemented with 15% FBS and 
200 U/mL penicillin and 200 µg/mL streptomycin at 37 °C under aseptic conditions 
and an atmosphere of air/5% carbon dioxide.  Cells were passaged approximately 
every 7 days with a seeding density of ca. 30,000 cells/cm
2
.  Cells were harvested 
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using 0.25% trypsin-EDTA, subsequently neutralised by media addition.  For 
experiments performed in high glucose conditions, culture media was supplemented 
with β-D-glucose to a final concentration of 20 mM using a sterile aqueous solution.  
Unless stated otherwise, all experimental cultures were performed for 5 days on cells 
between passages 40 and 45, following which cell pellet samples (collected by 
trypsinisation) and media samples were stored for subsequent analysis.  Cell viability 
was ≥ 98% at the start of all experiments determined using trypan blue dye 
exclusion. 
 
4.2.2. Assessment of cell viability  
Cell viability was assessed by the trypan blue dye exclusion technique 
(Strober, 2001) and also by the redox staining MTT method (Mosmann, 1983).  For 
the MTT method, medium was removed from cells plated in 96 well cell culture 
plates.  Wells were washed with 2 x 100 µL fresh medium and 2 x 100 µL PBS.  
MTT (100 µL; 0.5 mg/mL) in medium was added and the plate incubated for 2 h at 
37 °C in a cell culture incubator.  The MTT solution was removed, wells washed (2 
x 100 µL medium) and cells lysed with 100 µL DMSO.  Plates were mixed for 5 min 
until lysis solutions were of homogenous appearance and absorbance at 595 nm was 
measured using a reference wavelength of 650 nm.   
 
4.2.3. Coating of plates with collagen  
Type IV collagen was diluted in PBS and added to 24 well cell culture plates 
(Costar, Corning) to give a coating concentration of 10 µg/cm
2
.  Plates were 
incubated at room temperature overnight, the solution carefully aspirated off and 
wells washed with 500 µL PBS. 
 
4.2.4. Modification of plated collagen  
Methylglyoxal was diluted in PBS to a final concentration of 10 µM, sterile 
filtered through a 0.2 µm cellulose acetate filter and 500 µL added per well of the 24 
well plate.  Plates were incubated at 37 °C for 24 hours.  Methylglyoxal solutions 
were removed and wells washed with 500 µL PBS. 
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4.2.5. Quantification of collagen adhered to wells  
Plates were coated overnight with collagen as described in section 4.2.3.  
Collagen was removed from wells and wells washed twice with 500 µL PBS; PBS 
wash.  Wells were then washed with 6 x 500 µL 0.1% Triton X-100 in PBS to 
remove the collagen from the well; the first three washes Triton wash 1 and the 
second three washes Triton wash 2.  Samples were quantified by 3-(4-
carboxybenzoyl)quinoline-2- carboxaldehyde (CBQCA) assay. 
 
4.2.6. Cell adhesion assay 
MIN6 cells at a density of 570,000 cells/mL in HEPES buffer (9.7 mM, pH 
7.4, containing 5.4 mM KCl, 1 mM CaCl2, 136.9 mM NaCl, 0.34 mM Na2HPO4 and 
5.6 mM D-glucose) were seeded into wells of collagen coated plates to give 
coverage of 150,000 cells/cm
2
.  Plates were incubated at 37 °C for 2 h after which 
time non-adherent cells were removed and the adhered cells were trypsinised and 
counted.  Cells were incubated with 5 µg/mL anti-Itgb1 antibody and 2 µg/mL RGD 
for 15 minutes at 37 °C prior to plating for the cell adhesion assay. 
 
4.2.7. Atomic force microscopy force spectroscopy 
AFM-FS was used to measure the detachment energy and initial force 
necessary to uncouple cells from collagen IV.  The experimental set up is illustrated 
in Figure 8. 
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Figure 8: AFM experimental set-up. 
 
Cantilevers were functionalised by sequential incubations in solutions of 2 
µg/mL poly-L-lysine in PBS (30 min at room temperature), 20 µg/mL fibronectin in 
PBS (2 h at 37 °C) and PBS (overnight at 4 °C).  Each cantilever was calibrated 
before use.  MIN6 cells were removed from culture flasks into fresh CO2-
independent media using a cell scraper.  Cell suspensions were incubated with 2 
µg/mL RGD for 15 min at 37 °C prior to use as RGD treated cells.  A single MIN6 
cell was bound to a cantilever and brought into contact with collagen IV with a force 
of 3 nN.  The cell remained in contact with the collagen substrate for 15 s while 
adhesion occurred.  The cantilever was then retracted at a constant speed of 5 µm/s 
and the force (nN) and displacement - deflection of the cantilever - were measured 
using a laser until the cell was completely separated from the collagen (a maximum 
pulling length of 90 µm).  Measurements, approximately 50, were performed with 
multiple cells and plates of collagen in separate experiments (n=3).  Detachment 
energy (fJ) was calculated as force (nN) x displacement (µm). 
 
 
Collagen substrate 
 
 
 
 
Quadrant 
photodiode 
detector 
Attraction force 
Cantilever 
Detection laser 
MIN6 cell 
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4.3. Analytical methods 
4.3.1. Bradford assay (samples)  
Protein concentrations in cell lysates and tissue homogenates were 
determined by the Bradford method (Bradford, 1976) using BSA for calibration 
standards.  Stock solutions of BSA were calibrated on a spectrophotometer using 
absorbance at 279 nm and the stock concentration deduced.   
 
4.3.2. CBQCA protein assay 
The CBQCA assay for proteins was performed according to the 
manufacturer’s instructions to quantify collagen adhered to wells of a 24 well plate.  
This assay has higher sensitivity than the Bradford assay and quantifies protein 
concentrations in the ng range in the presence of detergents such as Triton X-100.  
Collagen was quantified against a collagen standard curve.  All standards and 
samples were prepared using low binding pipette tips and glass tubes to minimise 
loss of protein during sample processing and to improve assay performance. 
 
 
4.3.3. Calibration of stock solutions  
4.3.3.1. MG 
Stock solutions of MG were calibrated by derivatisation of MG with 
aminoguanidine at 37 °C and pH 7.4 which forms isomeric triazines, 3-amino-5-
methyl-1,2,4-triazine and 3-amino-6-methyl-1,2,4-triazine with characteristic 
absorbance at 320 nm for which ε320 = 2.41 mM
-1
cm
-1
.  MG was diluted to 
approximately 50 µM and 1 mM aminoguanidine added and incubated in 50 mM 
sodium phosphate buffer, pH 7.4 and 37 °C for 4 h.  Control samples, containing 1 
mM aminoguanidine in 50 mM sodium phosphate buffer, were incubated alongside.  
The absorbance of the product mixtures was measured and the concentration of the 
MG was deduced assuming a 1:1 reaction of MG with aminoguanidine to form 
triazine products. (Thornalley, et al., 2000).     
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4.3.3.2. S-D-Lactoylglutathione 
Stock solutions of S-D-lactoylglutathione were calibrated by absorbance at 
240 nm using the extinction coefficient Δε240 = 3.30 mM
-1
cm
-1 
(Clelland and 
Thornalley, 1991). 
 
4.3.4. Enzymatic activity assays 
4.3.4.1. Sample preparation 
MIN6 cells were collected after trypsinisation, washed in PBS and 
resuspended in 10 mM sodium phosphate buffer, pH 7.0, sonicated on ice at 110 
Watts for 30 sec, and centrifuged at 20,000 g for 30 min at 4°C.  The supernatant 
was removed and retained for enzymatic activity assays.  Pancreas samples (5 - 10 
mg) were homogenised on ice in 250 µL 10 mM sodium phosphate buffer, pH 7.0.  
Homogenates were centrifuged at 20,000 g for 30 min at 4°C and the supernatant 
used for enzymatic activity assays. 
 
4.3.4.2. Glyoxalase 1 
The activity of Glo1 was determined by measuring the initial rate of 
formation of S-D-lactoylglutathione from the GSH-MG hemithioacetal formed non-
enzymatically from MG and GSH and followed spectrophotometrically at 240nm; 
Δε240 = 2.86 mM
-1
cm
-1
 (Allen, et al., 1993b).   
              Glo1 
CH3COCHO + GSH            CH3COCH(OH)-SG  →  CH3CH(OH)CO-SG 
 
2 mM MG and 2 mM GSH were incubated in 50 mM sodium phosphate 
buffer, pH 6.6 for 10 min at 37°C to form the GSH-MG hemithioacetal.  Cell lysate, 
or lysate buffer for the blank, was added at a 50-fold dilution to a final volume of 1 
mL, the solution mixed well by inversion and absorbance at 240 nm monitored for 
five min at 37°C.  The initial rate of change in absorbance was determined and the 
activity of Glo1 deduced.  Glo1 activity was expressed as units per mg of protein 
where one unit is the amount of enzyme which catalyses the formation of 1 µmol of 
S-D-lactoylglutathione from the hemithioacetal substrate per minute under assay 
conditions. 
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4.3.4.3. Glyoxalase 2 
The activity of Glo2 was determined by measuring the initial rate of 
hydrolysis of S-D-lactoylglutathione to D-lactate and GSH, followed 
spectrophotometrically at 240 nm; Δε240 = 3.10 mM
-1
cm
-1
.  This extinction 
coefficient equates to the difference between the extinction coefficients of the 
substrate, S-D-lactoylglutathione, 3.3 mM
-1
cm
-1
, and the hydrolysed product GSH, 
0.2 mM
-1
cm
-1
 (Ball and Vander Jagt, 1979). 
 
            Glo2 
CH3CH(OH)CO-SG + H2O   →  CH3CH(OH)CO2
-
 + H
+ 
 
S-D-Lactoylglutathione (0.3 mM) was incubated in 50 mM Tris/HCl, pH 7.4 
and 37°C, and the cell lysate or lysate buffer for the blank was added at a 20-fold 
dilution to a final volume of 1 mL.  The solution was mixed by inversion and 
absorbance at 240 nm monitored for 5 min at 37°C.  The initial rate of change in 
absorbance was deduced (Allen, et al., 1993a).  One unit of Glo2 activity is the 
amount of enzyme which catalyses the hydrolysis of 1 µmol of S-D-
lactoylglutathione per minute under assay conditions. 
 
4.3.5. Assay of D-lactate 
4.3.5.1. Assay of D-lactate in cell culture media  
Since D-lactate is freely membrane permeable the cellular levels of D-lactate 
were established by measuring the amount in culture media.  The end-point 
enzymatic assay was based on the fluorimetric assay developed by McLellan et al. 
(1992).  D-Lactate is converted to pyruvate by the enzyme D-lactic dehydrogenase 
during incubation at 37 °C.  This is associated with the reduction of NAD
+
; the 
accumulation of NADH is measured by fluorescence, with 340 nm and 460 nm the 
excitation and emission wavelengths respectively. 
 
D-Lactate + NAD
+
                             pyruvate + NADH 
 
The reaction is driven to endpoint in the forward reaction by the presence of 
hydrazine, removing pyruvate from the equilibrium as pyruvate hydrazine.  Media 
samples (0.5 mL) were de-proteinised by the addition of 1 mL ice-cold 0.6 M 
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perchloric acid (PCA).  The suspension was vortex mixed, incubated on ice for 10 
min to enable the protein to precipitate and centrifuged (7,000 g, 4 °C, 5 min) to 
sediment the protein precipitate.  An aliquot of supernatant (700 µL) was taken and 
neutralised to pH 7 by the addition of 2 M potassium bicarbonate (200 µL).  Samples 
were again vortex mixed and centrifuged (7,000 g, 4 °C, 5 min) to sediment the 
potassium perchlorate precipitate.  The supernatant was removed and placed in a 
centrifugal evaporator under vacuum (20 mm Hg) at room temperature for 5 min to 
remove dissolved carbon dioxide. 
An aliquot of the resulting neutralised sample (100 µL) or D-lactate standard 
solution was added to each well of a black microplate together with 100 µL of 
glycine hydrazine buffer (1.2 M glycine, 0.5 M hydrazine hydrate, 2.5 mM 
diethylenetriaminepentaacetic acid (DETAPAC), pH 9.2) and 25 µL 4 mM NAD
+
.  
The reaction was initialised by the addition of 25 µL D-lactic dehydrogenase (250 
U/mL), the plate sealed and incubated in the dark at 37 °C for 2 h.  A control without 
addition of enzyme was run for each sample.  A standard curve over the range 0.5 – 
3.0 nmol D-lactate was prepared as detailed in Table 7.  A representative calibration 
curve is displayed in Figure 9. 
 
Table 7: Solutions for preparing the calibration curve in the assay of D-lactate  
 
 
Calibration 
solution 
D-Lactate 
(nmol) 
Volume of 100 µM 
D-lactate stock (µL) 
Water 
 (µL) 
0 0 0 100 
1 0.5 5 95 
2 1.0 10 90 
3 1.5 15 85 
4 2.0 20 80 
5 2.5 25 75 
6 3.0 30 70 
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Figure 9: Standard curve for assay of D-lactate (fluorescence method).  
Regression of fluorescence on D-lactate (nmol) gave Fluorescence = ((16075 ± 169) 
x D-lactate (nmol)) + 6088 ± 304; r
2 
= 0.998; n = 21. 
 
4.3.5.2. Assay of D-lactate in mouse pancreas 
Snap frozen mouse pancreas tissue (approximately 10 mg) was homogenised 
in 250 µL ice-cold 0.6 M PCA.  Suspensions were incubated on ice for 10 min to 
enable the protein to precipitate and centrifuged (7,000 g, 4 °C, 5 min) to sediment 
the protein precipitate.  The supernatant (200 µL) was removed and neutralised to 
pH 7 by the addition of 2 M potassium bicarbonate (60 µL).  Samples were vortex 
mixed and centrifuged (7,000 g, 4 °C, 5 min) to sediment the potassium perchlorate 
precipitate.  The supernatant was removed and placed in a centrifugal evaporator 
under vacuum (20 mm Hg) at room temperature for 5 min to remove dissolved 
carbon dioxide. 
Samples were assayed in a clear microplate as described for cell culture 
media samples (section 4.3.5.1) against a calibration curve from 0.5 – 14 nmol D-
lactate prepared as described in Table 8.  A specimen calibration curve is shown in 
Figure 10.  The resulting increase in NADH was monitored by absorbance at 340 
nm. 
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Table 8: Solutions for preparing the calibration curve in the assay of D-lactate 
(absorbance detection) 
 
 
 
Figure 10: Standard curve for D-lactate (absorbance).  Regression of absorbance 
on amount of D-lactate (nmol) gave Absorbance = ((0.018 ± 0.0007) x D-lactate 
(nmol)) + 0.0157 ± 0.0050; r
2 
= 0.968; n = 24. 
 
 
4.3.6. Assay of L-lactate 
L-Lactate was assayed as described for D-lactate except using L-lactic 
dehydrogenase.  Sample content of L-lactate is 50 - 100 fold higher than D-lactate 
and so media samples were diluted with water prior to assay.  L-Lactate calibration 
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D-Lactate 
(nmol) 
Volume of 100 µM 
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Water 
 (µL) 
0 0 0 100 
1 0.5 2.5 97.5 
2 1.0 5 95.0 
3 2.0 10 90.0 
4 4.0 20 80.0 
5 6.0 30 70.0 
6 8.0 40 60.0 
7 10.0 50 50.0 
8 14.0 70 30.0 
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standards were prepared over the range 1-10 nmol - Figure 11.  Samples were 
prepared and assayed according to the protocol for D-lactate (section 4.3.5).  
 
 
Figure 11: Standard curve for assay of L-lactate (fluorescence method).  
Regression of fluorescence on amount of L-lactate (nmol) gave: Fluorescence = 
((5275 ± 86) x L-lactate (nmol)) + 3431 ± 484; r
2
 = 0.995; n = 21. 
 
4.3.7. D-Glucose assay 
The concentration of glucose in culture media was determined using an end-
point enzymatic assay using a commercial assay reagent containing 1.5 mM NAD
+
, 
1 mM ATP, 1 unit/mL hexokinase and 1 unit/mL G6P dehydrogenase.  It was 
calibrated by assay of 0 – 37.5 nmol D-glucose standard.  The D-glucose assay was 
performed according to the manufacturer’s instructions; the enzymatic principle of 
the coupled assay is illustrated by the following equations: 
 
         Hexokinase 
Glucose + ATP    G6P + ADP 
 
G6PDH 
G6P + NAD
+
     6-Phosphogluconate + NADH 
  
The formation of NADH is measured by endpoint measurement 
spectrophotometrically at 340 nm.  Since one nmol glucose leads to the formation of 
one nmol NADH in this reaction, the increase in absorbance at 340 nm is directly 
proportional to the concentration of glucose.  A standard curve was constructed over 
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the range 0 – 37.5 nmol glucose, incubated for 15 min at room temperature alongside 
diluted test samples and the absorbance at 340 nm measured spectrophotometrically. 
 
4.3.8. Assay of cellular thiols  
The amount of total thiols in cell cytosolic extracts (mainly protein cysteine 
thiols, GSH, γ-glutamyl-cysteine and free cysteine) was determined by measuring 
the absorbance produced by the reaction of cytosolic extracts with 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB).  The reaction between DTNB and protein thiols results 
in the formation of the chromophore 2-nitro-5-thiobenzoate anion (TNB) and a 
consequent increase in absorbance at 410 nm. 
 
 
 
DTNB solution (125 µL, 1 mM DTNB in 100 mM sodium phosphate buffer, 
containing 0.2 mM DETAPAC, pH 7.4) and 100 µL of water were added to wells of 
a 96 well plate.  Sample or standard (25 µL) was added and the absorbance at 410 
nm was recorded after incubation for 20 min at room temperature.  The assay was 
calibrated using GSH over the range 2 - 30 nmol and the measured absorbance used 
to deduce the amount of cellular thiols.  A specimen calibration curve is displayed in 
Figure 12. 
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Figure 12: Standard curve for assay of thiols in cytosolic extracts of cells.  
Regression of absorbance on amount of Thiols (nmol) gave: Absorbance = ((0.0407 
± 0.0002) x GSH (nmol)) + 0.0708 ± 0.0035; r
2
 = 0.999; n = 24. 
 
 
4.3.9. Real-time quantitative PCR 
4.3.9.1. Principle of assay 
Real-time quantitative PCR (qPCR) was used to compare mRNA transcript 
copy number of specific genes in cell and tissue samples.  Briefly, the cellular RNA 
was extracted and reverse transcribed into cDNA.  cDNA was used as a template for 
the primers during real-time PCR analysis.  SYBR green I dye was used for 
detection; it fluoresces when bound to double stranded DNA.  This fluorescence was 
measured on each PCR cycle. 
 
4.3.9.2. Primer design and testing 
Primers were designed using the Invitrogen oligo perfect designer tool using 
mRNA and genomic DNA sequences obtained from the University of California, 
Santa Cruz genome browser.  Multiple primer pairs were selected for each gene.  
Amplicon length (optimal 100 - 150 base pairs) was considered and primers 
spanning exon-exon junctions were chosen when possible; this acted as an additional 
quality control since any contaminant genomic DNA would not act as a template for 
amplification.  All primer sequences used are given in Appendix A. 
Dissociation plots were performed for all primers to test performance and 
MgCl2 concentration was optimised further when necessary.  Example dissociation 
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plots are shown in Figure 13.  Dissociation plots were routinely performed for each 
assay plate; this ensured that the primers performed consistently. 
 
Figure 13: Representative dissociation plots for primers.  A: Itgb1 in MIN6 cell 
sample.  B: ICAM-1 in pancreas sample. 
 
 
4.3.9.3. RNA extraction 
RNA was extracted from both cell and pancreas samples using the Qiagen 
RNeasy Mini Kit.  Extraction was performed according to the manufacturer’s 
protocol.  For pancreas samples 3 - 6 mg tissue was homogenised in 350 µL RLT 
lysis buffer using a micropestle before continuing according to the provided 
protocol.  Quantity and quality of RNA was determined using a Nanodrop 
spectrophotometer; a pure solution of RNA should give a value of between 1.9 and 
2.1 for the ratio of the absorbance at 260 nm and 280 nm. 
 
4.3.9.4. Reverse transcription 
Oligo-(dT)18 primer (270 ng) was added to RNA (200 ng) and the volume 
made up to 12 µL with nuclease free water.  Samples were incubated at 70 °C for 5 
min to enable the primer to hybridise to the poly-adenylated tail at the 3’ end of 
mRNA.  Solutions were then cooled on ice before 8 µL of a master mix containing 
200 U Bioscript Reverse Transcriptase, 10 U RNase inhibitor, 4 µL of 5x buffer and 
1 µL of 10mM dNTP mix in nuclease free water was added.  Samples were 
incubated for 60 min at 42 °C, heated at 72 °C for 10 min to terminate the reaction 
and then cooled at 4 °C.  Samples were stored at -20 °C until analysis.  Amounts of 
A. B. 
99 
 
RNA used for cDNA preparation was scaled up to 500 ng and 1 µg, as necessary, for 
tissue samples. 
 
4.3.9.5. Sample analysis 
 PCR plates were loaded with 2 µL sample, 10 µL SensiMix SYBR Low-
ROX, 2.5 pmol of forward and reverse primers and MgCl2 to the optimised 
concentration in a final volume of 20 µL/well.  Plates were sealed and analysed 
using a real-time PCR machine.  Plates were heated to 95 °C for 10 min to activate 
the hot-start DNA polymerase, 40 cycles of 95 °C x 15 s and 60 °C x 60 s then 
followed.  A standard curve of serially diluted pooled cDNA over the range 0.1 pg – 
1000 ng was run alongside assay samples and used for quantification using 18S as a 
reference gene.  RNA was quantified as a ratio to 18S RNA in the sample. 
 
4.4. LC-MS/MS methodologies 
4.4.1. Dicarbonyl assay 
4.4.1.1. Principle of assay 
The amount of MG, glyoxal and 3-DG in cultured cells and media, pancreas 
and plasma samples was determined by derivatisation with 1,2-diaminobenzene and 
quantification of the resulting quinoxaline adducts by stable isotopic dilution 
analysis LC-MS/MS (Figure 14). 
 
 
Figure 14: Derivatisation reaction in the dicarbonyl assay.  For glyoxal, MG and 
3-DG, R = H, CH3, and CH2(CHOH)2CH2OH, respectively. 
 
4.4.1.2. Sample preparation 
For collection of MIN6 cell culture samples, cells were trypsinised and then 
neutralised with trypsin neutralising solution (0.05% trypsin inhibitor, 0.1% BSA).  
N
N R
NH2
NH2
+
O
O R
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Cell suspensions were immediately centrifuged to pellet the cells, the supernatant 
removed and cell pellet samples frozen. 
For analysis of cell pellets, 10 µL of cold 20% trichloroacetic acid (TCA) 
containing 0.9% sodium chloride solution (TCA-saline) was added to cell pellets to 
de-proteinise the samples and samples were vortex mixed well.  An aliquot of water 
(40 µL) was added.  For media samples, an aliquot of culture medium (20 µL) was 
taken, and 10 µL of TCA-saline and 20 µL of water were added.  For plasma 
samples, an aliquot of plasma (5 µL) was taken, and 10 µL of TCA-saline and 35 µL 
of water were added.  Subsequent preparation was identical for all three types of 
sample.  An aliquot of 3% sodium azide in water (5 µL) was added to inhibit 
peroxidise activity and isotopic standard cocktail (5 µL containing 2 pmol of each 
[
13
C]dicarbonyl) was added to each sample.  The samples were vortex mixed and 
centrifuged (6,000 g, 10 min, 4°C).  Supernatant (45 µL) was removed and added to 
10 µL derivatisation agent solution (0.5 mM 1,2-diaminobenzene in 200 mM HCl 
containing 0.5 mM DETAPAC).  Pancreas samples (5 - 10 mg) were homogenised 
using a micropestle in 100 µL TCA-saline and 5 µL of [
13
C]dicarbonyl standard 
cocktail was added.  Samples were vortex mixed and centrifuged (6,000 g, 10 min, 
4°C).  An aliquot of supernatant (40 µL) was transferred and 5 µL of 3% sodium 
azide was added to it.  The derivatisation agent solution was added (10 µL 0.5 mM 
1,2-diaminobenzene in 200 mM HCl containing 0.5 mM DETAPAC).  Samples and 
standards were left at room temperature in the dark for 4 h for derivatisation to 
quinoxaline adducts and then analysed by LC-MS/MS.  Standards (2 - 20 pmol for 
MG and 3-DG and 0.2 – 2.0 pmol for glyoxal) were derivatised concurrently with 
the samples for calibration of the analyte/isotopic standard response ratio. 
 
4.4.1.3. Preparation of calibration standards  
 Cocktails of dicarbonyl normal standards containing 800 nM MG and 3-DG 
and 80 nM glyoxal and stable isotopic substituted dicarbonyls containing 400 nM 
[
13
C3]MG, [
13
C2]glyoxal and [
13
C6]3-DG were prepared and used to prepare 
standards over the range 0.2 - 2.0 for glyoxal and 2 - 20 pmol for MG and 3-DG - 
Table 9. 
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Table 9: Preparation of calibration standards in the assay of dicarbonyls 
Calibration 
solution 
MG, 3-DG 
(pmol) 
Glyoxal 
(pmol) 
20% TCA-
0.9% NaCl 
(µL) 
Water 
(µL) 
3% 
sodium 
azide (µL) 
800 nM MG and 
3-DG, 80 nM 
glyoxal (µL) 
400 nM 
[
13
C]Dicarbonyl  
(µL) 
0.5 mM 1,2-
diaminobenzene in HCl-
DETAPAC (µL) 
0 0 0 10 25 5 - 5 10 
1 2 0.2 10 22.5 5 2.5 5 10 
2 4 0.4 10 20 5 5 5 10 
3 8 0.8 10 15 5 10 5 10 
4 12 1.2 10 10 5 15 5 10 
5 16 1.6 10 5 5 20 5 10 
6 20 2.0 10 - 5 25 5 10 
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4.4.1.4. LC-MS/MS conditions 
LC was performed using a reversed phase ODS BEH C18, 1.7 µm particle 
size column (100 x 2.1 mm) fitted with a 5 x 2.1 mm pre-column.  The column 
temperature was 30 °C.  Solvents used were 0.1% trifluoroacetic acid (TFA) in water 
(solvent A) and 0.1% TFA in 50:50 acetonitrile (MeCN): water (solvent B).  The 
elution profile is shown in Table 10. 
 
Table 10: Elution profile for dicarbonyl analysis 
Injection Run     
Time (min) 
Flow rate 
(mL/min) 
Solvent A (%) Solvent B (%) Gradient 
Initial 0.2 100 0  
10 0.2 0 100 Linear 
15 0.4 0 100 Immediate 
30 0.4 100 0 Immediate 
 
LC eluate was eluted into the electrospray source of the Waters Quattro 
Premier XE tandem mass spectrometer.  For mass spectrometric detection, the 
capillary voltage was 0.6 kV, the ion source temperature 120 °C, the desolvation gas 
temperature 350 °C and cone and desolvation gas flows 146 and 900 L/h 
respectively.  Table 11 lists the optimised multiple reaction monitoring (MRM) 
conditions used for detection, along with their retention times, cone voltage and 
collision energy. 
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Table 11: Optimised MRMs for dicarbonyl analysis 
Analyte 
Parent ion 
(Da) 
Fragment 
ion (Da) 
Retention 
time (min) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
MG 145.1 77.1 7.8 24 24 
[
13
C3]MG 148.0 77.1 7.8 24 24 
Glyoxal 131.0 77.1 7.1 24 23 
[
13
C2]Glyoxal 133.0 77.1 7.1 24 23 
3-DG 235.2 199.0 5.8 21 15 
[
13
C6]3-DG 241.2 205.0 5.8 21 15 
 
4.4.1.5. Data analysis 
LC-MS/MS data was integrated using MassLynx software.  Representative 
chromatograms of standard solutions of dicarbonyls are shown in Figure 15.  Peak 
area ratios of analyte/isotopic standard were plotted against analyte amount to 
construct calibration curves - Figure 16.  The amount of dicarbonyls in aliquots 
assayed was deduced from the peak area ratio using the calibration curves and the 
amount in original samples was calculated using appropriate dilution factors. 
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Figure 15: Chromatograms of dicarbonyl compounds in mouse pancreas.  A: 
MG. B: [
13
C3]MG (2 pmol). C: Glyoxal. D: [
13
C2]Glyoxal (2 pmol). E: 3-DG. F: 
[
13
C6]3-DG (2 pmol).   
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Figure 16: Typical calibration curves of dicarbonyls by LC-MS/MS.  A. 
Standard curve for MG.  Regression of Peak area ratio on amount of MG (pmol) 
gave: Peak area ratio = ((0.544 ± 0.030) x MG (pmol)) + 1.75 ± 0.007; r
2
 = 0.988; n 
= 6.  B. Standard curve for Glyoxal.  Regression of Peak area ratio on amount of 
glyoxal (pmol) gave: Peak area ratio = ((0.211 ± 0.007) x glyoxal (pmol)) + 0.027 ± 
0.0074; r
2
 = 0.995; n = 7.  C. Standard curve for 3-DG.  Regression of Peak area 
ratio on amount of 3-DG (pmol) gave: Peak area ratio = ((0.0971 ± 0.0050) x 3-DG 
(pmol)) ± 0.0515; r
2
 = 0.984; n = 6.   
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4.4.2. Glutathione assay 
4.4.2.1. Principle of assay 
 A stable isotopic dilution analysis LC-MS/MS method for the detection and 
quantification of GSH, GSSG and S-D-lactoylglutathione in cell culture samples was 
developed. 
 
4.4.2.2. Synthesis of [13C4
15
N2]GSSG 
Stable labelled [glycine-
13
C2
15
N1]GSH was oxidised using diamide 
(Kosower, et al., 1969) to obtain stable labelled [
13
C4
15
N2]GSSG for use in the 
LC-MS/MS method to quantify cellular GSSG.   
 
An aliquot of [
13
C2
15
N1]GSH solution (3.2 mM, 100 µL) and 10 mM diamide 
in methanol (30 µL) were added to 100 µL of 10 mM sodium phosphate buffer, pH 
7.4 and incubated at 37°C for 30 min.  The reaction mixture was purified by elution 
onto a 500 mg strong anion-exchange solid-phase extraction (SAX SPE) cartridge in 
the formate form.  [
13
C4
15
N2]GSSG was retained on the SAX-SPE cartridge but 
diamide and reduced diamide were not.  The SAX-SPE cartridge was washed with 
10 mL water to remove the diamide and reduced diamide.  [
13
C4
15
N2]GSSG was 
collected by eluting off the SAX-SPE cartridge with 5 mL 100 mM formic acid.  The 
solution was lyophilised to dryness, reconstituted in water (1 mL) and filtered 
through a 0.2 µm nylon filter.  The concentration of [
13
C4
15
N2]GSSG was deduced 
by isotopic dilution analysis with known amounts of GSSG.  The synthesis yield was 
28%.  
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4.4.2.3. Preparation of calibration standards  
Stock solutions of GSH, GSSG, S-D-lactoylglutathione and [glycine-
13
C2
15
N1]GSH were prepared in filtered water to 1 mg/mL.  Further dilutions of these 
stocks were prepared in 0.1% TFA in water.  Calibration standards were prepared for 
sample analysis over the range 100 - 2000 pmol and 5 - 100 pmol for GSH and 
GSSG respectively (Table 12) by the protocol detailed in Table 13.   
 
Table 12: Calibration range for glutathione analysis 
Calibration 
solution 
GSH (pmol) GSSG (pmol) 
[
13
C2
15
N1]GSH 
(pmol) 
[
13
C4
15
N2]GSSG 
(pmol) 
0 0 0 100 20 
1 100 5 100 20 
2 200 10 100 20 
3 400 20 100 20 
4 1000 50 100 20 
5 1600 80 100 20 
6 2000 100 100 20 
 
 
Table 13: Preparation of glutathione standards 
Calibration 
solution 
GSH (µL) GSSG (µL) 
0.1% TFA 
in water 
(µL) 
12.5% TCA 
(µL) 
Isotopic 
cocktail 
(µL) 
 
40 
µM 
200 
µM 
2 
µM 
10 
µM 
   
0 - - - - 20 20 10 
1 2.5 - 2.5 - 15 20 10 
2 5 - 5 - 10 20 10 
3 10 - 10 - - 20 10 
4 - 5 - 5 10 20 10 
5 - 8 - 8 4 20 10 
6 - 10 - 10 - 20 10 
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4.4.2.4. Preparation of samples 
Pelleted cells were resuspended in 40 µL of a solution containing 10% TCA, 
0.15% NaCl and 0.25% sodium azide in water.  This solution precipitates proteins 
and acts as a preservative by inhibiting peroxidase activity in the sample; residual 
peroxidase activity otherwise remains in TCA extracts.  Samples were centrifuged at 
20,000 g for 30 min at 4 °C and aliquots of supernatant (10 µL) transferred to vials 
for LC-MS/MS analysis with the addition of 10 µL isotopic standard cocktail. 
 
4.4.2.5. LC-MS/MS conditions 
Two graphite Hypercarb HPLC columns were used in series (50 x 2.1 mm 
and 250 x 2.1 mm, particle size 5 µm) with column temperature of 30 °C.  Solvents 
used were 0.1% TFA in water (Solvent A) and 0.1% TFA in 50:50 MeCN: water 
(Solvent B1) and 0.1% TFA in 50:50 Tetrahydrafuran (THF): water (Solvent B2).  
The gradients used during the analytical run and post run are displayed in Table 14. 
 
Table 14: Elution profile for glutathione analysis 
Injection Run 
Time (min) 
Flow rate 
(mL/min) 
Solvent A1 
(%) 
Solvent B1 
(%) 
Solvent B2 
(%) 
Gradient 
Initial 0.2 100 0 -  
1 0.2 100 0 - Isocratic 
15 0.2 40 60 - Linear 
16 0.2 40 60 - Isocratic 
Postrun      
Initial 0.4 0 - 100  
10 0.4 0 - 100 Isocratic 
25 0.4 100 - 0 Immediate 
 
Flow from the column was eluted into the electrospray source of the MS/MS 
detector between 4 and 16 min for data collection.  Mass spectrometric analysis was 
performed using electrospray positive ionisation mode.  For mass spectrometric 
detection, the capillary voltage was 3.4 kV, the ion source temperature 120 °C, the 
desolvation gas temperature 350 °C and cone and desolvation gas flows 146 and 550 
L/h respectively.  Table 15 shows the optimised MRM conditions used for detection, 
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along with their retention times, cone voltage and collision energy.  Fragmentation 
analysis of the MRM transitions is detailed in Figure 17.  
  
Table 15: Optimised MRMs for glutathione analysis 
Analyte 
Parent 
ion (Da) 
Fragment 
ion (Da) 
Retention 
time 
(min) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
GSH 308.2 179.1 11.7 30 13 
[
13
C2
15
N1]GSH 311.2 182.1 11.7 30 13 
GSSG 613.2 483.7 14.4 52 18 
[
13
C4
15
N2]GSSG 619.2 489.7 14.4 52 18 
S-D-lactoylglutathione 380.2 76.2 13.1 32 35 
 
 
Figure 17: Fragmentation of glutathione.  MRM mass transition fragmentations: 
A. GSH, B. GSSG and C. S-D-lactoylglutathione. 
 
A. 
B. 
C. 
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4.4.2.6. Data analysis 
 Data analysis was performed using MassLynx software.  Specimen 
chromatograms of GSH and GSSG are shown in Figure 18.  Calibration curves were 
constructed plotting peak area ratio of analyte/isotopic standard against analyte 
concentration as shown in Figure 19.  The amount of glutathione in assayed aliquots 
was deduced using the peak area ratio and the appropriate calibration curve and the 
amount in the original sample calculated taking account of any dilution factors.   
 
 
Figure 18: Representative chromatograms in of glutathione in MIN6 cells.  A: 
GSH. B: [
13
C2
15
N1]GSH (100 pmol). C: GSSG. D: [
13
C4
15
N2]GSSG (20 pmol).  
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Figure 19: Typical calibration curves of glutathione by LC-MS/MS.  A: Standard 
curve for GSH.  Regression of Peak area ratio on amount of GSH (pmol) gave: Peak 
area ratio = ((0.0145 ± 0.002) x GSH (pmol)) ± 0.180; r
2
 = 0.999; n = 7.  B: Standard 
curve for GSSG.  Regression of Peak area ratio on amount of GSSG (pmol) gave: 
Peak area ratio = ((0.1072 ± 0.0027) x GSSG (pmol)) ± 0.124; r
2
 = 0.998; n = 6.  C: 
Standard curve for S-D-lactoylglutathione.  Regression of Peak area ratio on amount 
of S-D-lactoylglutathione (pmol) gave: Peak area ratio = ((0.1711 ± 0.0032) x S-D-
lactoylglutathione (pmol)) ± 0.167; r
2
 = 0.998; n = 7.   
 
4.4.2.7. Limit of detection, recovery and intra-batch 
coefficient of variation  
The calibration curves for GSH, GSSG and S-D-lactoylglutathione were 
linear (see Figure 19) and reproducible when prepared and assayed on different days.  
The limit of detection (LoD) was 0.92 pmol, 1.46 pmol and 0.54 pmol for GSH, 
GSSG and S-D-lactoylglutathione respectively.  Example chromatograms of GSH 
and GSSG in MIN6 cells are shown in Figure 18.  Analytical recovery was assessed 
by addition of 500 pmol GSH and 50 pmol GSSG and S-D-lactoylglutathione to cell 
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samples. Analytical recoveries were: GSH, 97.1 ± 1.6%; GSSG, 92.7 ± 5.7%; and S-
D-lactoylglutathione, 99.3 ± 14.1%.  Intra-batch coefficient of variation was 
determined by analysis of replicate samples.  Intra-batch coefficient of variation was: 
GSH, 8.8% (n = 6); and GSSG, 10.9% (n = 6).  
 
4.4.3. Assay of protein glycation, oxidation and nitration 
adducts 
4.4.3.1. Principle of assay 
The glycation, oxidation and nitration adduct and the corresponding amino 
acid residue content of cytosolic protein extracts of cultured cells and mouse 
pancreas and plasma protein were measured, after exhaustive enzymatic hydrolysis, 
by stable isotopic dilution analysis LC-MS/MS as described (Thornalley, et al., 
2003).  Glycation, oxidation and nitration free adduct concentration of culture 
medium, mouse pancreas and plasma were measured similarly without exhaustive 
enzymatic hydrolysis. 
 
4.4.3.2. Sample preparation 
Extraction of soluble protein  
Trypsinised MIN6 cells were washed 3 times in PBS and then resuspended in 
250 µL 10 mM sodium phosphate buffer, pH 7.4, sonicated on ice (110 W, 30 sec) 
and centrifuged (20,000 g, 30 min, 4°C).  The supernatant was transferred to a 10 
kDa ultrafilter and washed by diafiltration - 4 cycles of dilution to 500 µL with 
argon-purged water and concentration to 50 µL by centrifugation (14,000 g, 20 min, 
4 °C).  The resultant washed protein concentrate was quantified by Bradford assay 
and subjected to exhaustive enzymatic hydrolysis.  Culture media samples were 
filtered through 3 kDa ultrafilters (14,000 g, 20 min, 4 °C) and the resulting 
ultrafiltrate analysed for protein glycation, oxidation and nitration free adducts. 
Pancreas samples (approximately 10 mg wet weight) were homogenised in 
250 µL 10 mM sodium phosphate buffer, pH 7.4 and 4 °C and centrifuged (20,000 g, 
30 min, 4 °C) to sediment the membranes.  The resulting supernatants were 
transferred to 10 kDa ultrafilters.  Plasma samples (5 µL) were diluted with 45 µL 
water and transferred to 10 kDa ultrafilters.  Samples were washed by diafiltration.  
The resultant protein was quantified by Bradford assay and hydrolysed by exhaustive 
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enzymatic hydrolysis.  The first filtrates were retained for analysis as pancreatic and 
plasma filtrate.   
 
Enzymatic hydrolysis of soluble protein  
Protein (100 µg) was transferred to vials for hydrolysis and all 
samples/controls in a sample set were made up to the same volume (20 - 40 µL) 
using argon-purged filtered water.  Samples were argon-purged using a centrifugal 
evaporator and the remaining procedure carried out on the CTC-PAL sample 
preparation automation system.  Aliquots of HCl (100 mM, 10 µL), pepsin (2 
mg/mL in 20 mM HCl, 5 µL) and the antioxidant thymol (1 mg/mL in 20 mM HCl, 
5 µL) were added and the samples incubated for 24 h at 37 °C.  Samples were 
buffered and neutralised by the additions of potassium phosphate buffer (100 mM, 
pH 7.4, 12.5 µL) and potassium hydroxide (260 mM, 5 µL) respectively.  Pronase E 
(2 mg/mL in 10 mM potassium phosphate buffer, pH 7.4, 5 µL) and prolidase (2 
mg/mL in 10 mM potassium phosphate buffer, pH 7.4, 5 µL) were added and the 
samples incubated for a further 24 h at 37 °C.  Aliquots of aminopeptidase (2 mg/mL 
in 10 mM potassium phosphate buffer, pH 7.4, 5 µL) and prolidase (2 mg/mL in 10 
mM potassium phosphate buffer, pH 7.4, 5 µL) were added, the samples incubated 
for a further 48 h at 37 °C and frozen at -20 °C until subsequent LC-MS/MS 
analysis.  Triplicate samples of water and human serum albumin (HSA) (100 µg) 
were hydrolysed alongside analytical samples as hydrolysis controls.  These were 
made up to the same volume as protein samples. 
 
Extraction of ECM protein  
 Pancreas samples (approximately 2 mg) were homogenised in 100 µL of ice-
cold PBS and centrifuged at 10,000 g for 30 min at 4 °C.  The supernatant was 
removed and pellets were washed with two cycles of 500 µL PBS addition and 
centrifugation (6,000 g, 15 min, 4 °C).  Lipid components were then extracted with 
500 µL chloroform: methanol (2:1 v/v) for 24 h at 4 °C whilst shaking continuously 
(Dobler, et al., 2006; Folch, et al., 1957).  Samples were centrifuged (6,000 g, 15 
min, 4 °C) and the chloroform-methanol mixture removed.  Pellets were washed 
with two cycles of 500 µL water addition and centrifugation (6,000 g, 15 min, 4 °C) 
and the pellets stored at -20 °C until subsequent enzymatic hydrolysis.  
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Enzymatic hydrolysis of ECM protein  
The enzymatic hydrolysis protocol used for soluble cellular proteins was 
adapted for hydrolysis of insoluble matrix proteins.  Argon-purged filtered water (40 
µL) was added to the pelleted protein.  Aliquots of thymol (1 mg/mL in 10 mM TES 
buffer, pH 7.4, 5 µL) and bacterial collagenase (1 mg/mL in 50 mM TES buffer, pH 
7.4 with 5 mM CaCl2, 10 µL) were added, the sample purged with argon in a 
centrifugal evaporator and incubated for 24 h at 37 °C with shaking.  Pronase E 
solution (2 mg/mL in 10 mM TES buffer, pH 7.4, 5 µL) and penicillin/streptomycin 
(1000 U/mL and 1 mg/mL in 10 mM TES buffer, pH 7.4, 5 µL) were added, the 
samples again argon purged in a centrifugal evaporator and incubated for 24 h at 37 
°C with shaking.  Further aliquots of aminopeptidase (2 mg/mL in 10 mM TES 
buffer, pH 7.4, 5 µL) and prolidase (2 mg/mL in 10 mM TES buffer, pH 7.4, 5 µL) 
were added to give a final hydrolysate volume of 75 µL.  Samples were purged with 
argon in a centrifugal evaporator and incubated, shaking, at 37 °C for 48 h.  
Hydrolysates were frozen at -20 °C until subsequent LC-MS/MS analysis.  
Additional control samples were run: water alone (no protein), 100 µg and 200 µg 
HSA in 40 µL of argon purged water – to investigate the effect of protein 
concentration on autohydrolysis of hydrolytic enzymes.   
 
Preparation of samples for analysis  
Samples were prepared for LC-MS/MS analysis as detailed in Table 16.  
MIN6 culture samples and pancreatic hydrolysed protein were analysed on the 
Quattro Premier mass spectrometer.  Pancreatic filtrates, plasma filtrates and plasma 
samples were all analysed on the Xevo TQ-S system. 
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Table 16: Sample preparation for analysis of protein glycation, oxidation and 
nitration adducts  
Sample type Sample (µL) 
Isotopic 
standard 
cocktail (µL) 
0.1% TFA in 
water (µL) 
MIN6 protein hydrolysate 25 25 - 
MIN6 Culture media filtrate 25 25 - 
Pancreatic protein hydrolysate 25 25 - 
Pancreatic ECM protein 12.5 25 12.5 
Pancreatic filtrate 10 25 15 
Plasma hydrolysate 5 25 20 
Plasma filtrate 10 25 15 
 
4.4.3.3. Preparation of calibration standards  
Calibration cocktail stocks of both analytes and isotopically labelled analytes 
were prepared.  These were diluted as shown in Table 17.  Different stocks were 
prepared for calibrations and samples to be run on the Quattro Premier and the more 
sensitive Xevo TQ-S system, enabling the same dilutions to be used for both.  
Details of the calibration range for all analytes for the two instruments are listed in 
Table 18 and Table 19 for the Quattro Premier and Xevo TQ-S respectively. 
 
Table 17: Preparation of calibration standards for analysis of protein glycation, 
oxidation and nitration adducts 
Calibration 
solution 
Standard 
cocktail (µL) 
0.1 % TFA in 
water (µL) 
Isotopic 
cocktail (µL) 
Total volume 
(µL) 
0 0 25.0 25.0 50.0 
1 1.25 23.75 25.0 50.0 
2 2.5 22.5 25.0 50.0 
3 6.3 18.7 25.0 50.0 
4 12.5 12.5 25.0 50.0 
5 18.8 6.2 25.0 50.0 
6 25.0 0 25.0 50.0 
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Table 18: Calibration range for analysis of protein glycation, oxidation and nitration adducts (Quattro Premier) 
Calibration 
solution 
0 1 2 3 4 5 6 Isotopic 
standard  
Analyte pmol pmol pmol pmol pmol pmol pmol pmol 
MG-H1 0 2.50 5.00 12.5 25.0 37.5 50.0 25.0 
CEL 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
MOLD 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
G-H1 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
CML 0 1.25 2.50 6.25 12.5 18.75 25.0 5.0 
CMA 0 0.50 1.00 2.5 5.0 7.5 10.0 2.5 
3DG-H 0 2.50 5.00 12.5 25.0 37.5 50.0 25.0 
FL 0 5.00 10.0 25.0 50.0 75.0 100.0 6.0 
Glucosepane 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
Pentosidine 0 0.05 0.10 0.25 0.50 0.75 1.00 n/a 
MetSO 0 2.50 5.00 12.5 25.0 37.5 50.0 25.0 
Dityrosine 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
NFK 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
Ornithine 0 2.50 5.00 12.5 25.0 37.5 50.0 50.0 
3-NT 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
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AASA 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
GSA 0 0.50 1.00 2.5 5.0 7.5 10.0 5.0 
 nmol nmol nmol nmol nmol nmol nmol nmol 
Arginine 0 1.0 2.0 5.0 10.0 15.0 20.0 5.0 
Lysine 0 1.0 2.0 5.0 10.0 15.0 20.0 5.0 
Methionine 0 1.0 2.0 5.0 10.0 15.0 20.0 5.0 
Tyrosine 0 0.2 0.4 1.0 2.0 3.0 4.0 2.0 
Tryptophan 0 0.2 0.4 1.0 2.0 3.0 4.0 1.0 
Valine 0 1.0 2.0 5.0 10.0 15.0 20.0 5.0 
 
 
Table 19: Calibration range for analysis of protein glycation, oxidation and nitration adducts (Xevo TQ-S) 
Calibration 
solution 
0 1 2 3 4 5 6 Isotopic 
standard  
Analyte pmol pmol pmol pmol pmol pmol pmol pmol 
MG-H1 0 0.125 0.250 0.625 1.250 1.875 2.500 1.25 
CEL 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
MOLD 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
G-H1 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
CML 0 0.125 0.250 0.625 1.250 1.875 2.500 0.25 
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CMA 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
3DG-H 0 0.125 0.250 0.625 1.250 1.875 2.500 1.25 
FL 0 0.250 0.500 1.250 2.500 3.750 5.000 0.30 
Glucosepane 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
Pentosidine 0 0.0025 0.005 0.0125 0.025 0.0375 0.050 n/a 
MetSO 0 0.125 0.250 0.625 1.250 1.875 2.500 1.25 
Dityrosine 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
NFK 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
Ornithine 0 0.125 0.250 0.625 1.250 1.875 2.500 2.50 
3-NT 0 0.025 0.050 0.125 0.250 0.375 0.500 0.25 
AASA 0 0.025 0.050 0.125 0.250 0.375 0.500 2.50 
GSA 0 0.025 0.050 0.125 0.250 0.375 0.500 2.50 
 nmol nmol nmol nmol nmol nmol nmol nmol 
Arginine 0 0.05 0.10 0.25 0.50 0.75 1.00 0.25 
Lysine 0 0.05 0.10 0.25 0.50 0.75 1.00 0.25 
Methionine 0 0.05 0.10 0.25 0.50 0.75 1.00 0.25 
Tyrosine 0 0.01 0.02 0.05 0.10 0.15 0.20 0.10 
Tryptophan 0 0.01 0.02 0.05 0.10 0.15 0.20 0.05 
Valine 0 0.05 0.10 0.25 0.50 0.75 1.00 0.25 
119 
 
4.4.3.4. LC-MS/MS conditions (Quattro Premier)  
 Two graphite Hypercarb HPLC columns were used in series (50 x 2.1 mm 
and 250 x 2.1 mm, particle size 5 µm) with column temperature of 30 °C.  Solvents 
used were 0.1% TFA in water (Solvent A) and 0.1% TFA in 50:50 MeCN: water 
(Solvent B1) and 0.1% TFA in 50:50 THF: water (Solvent B2).  The gradients used 
during the analytical run and post run are detailed in Table 20.  Flow went through 
both columns in series until 10.8 min.  From 10.8 min until 26 min eluate from the 
50 x 2.1 mm column was eluted into the mass spectrometer detector, and for the 
remainder of the analytical run eluate was from both columns in series. 
 
Table 20: Elution profile for analysis of protein glycation, oxidation and 
nitration adducts (Quattro Premier) 
Injection Run 
Time (min) 
Flow rate 
(mL/min) 
Solvent A1 
(%) 
Solvent B1 
(%) 
Solvent B2 
(%) 
Gradient 
Initial 0.2 100 0 -  
5 0.2 100 0 -  
8 0.2 97 3 - Linear 
12 0.2 97 3 - Isocratic 
15 0.2 83 17 - Linear 
18 0.2 83 17 - Isocratic 
24 0.2 20 80 - Linear 
26 0.2 97 3 - Linear 
27 0.2 50 50 - Linear 
35 0.2 50 50 - Isocratic 
Postrun      
Initial 0.4 0 - 100  
10 0.4 0 - 100 Isocratic 
20 0.2 0 - 100 Immediate 
25 0.2 100  0 Immediate 
40 0.4 100  0 Immediate 
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Flow from the column was eluted into the electrospray source of the MS/MS 
detector between 4 and 35 min for data collection.  Mass spectrometric analysis was 
performed using electrospray positive ionisation mode.  For mass spectrometric 
detection, the capillary voltage was 1.0 kV, the ion source temperature 120 °C, the 
desolvation gas temperature 350 °C and cone and desolvation gas flows 96 and 900 
L/h respectively.  Table 21 lists the optimised MRM conditions used for detection, 
along with their retention times, cone voltage and collision energy.  
 
Table 21: Optimised MRM mass transitions for analysis of protein glycation, 
oxidation and nitration adducts (Quattro Premier) 
Analyte Parent ion 
(Da) 
Fragment 
ion (Da) 
Retention 
time (min) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
Arginine 175.1 70.1 31.2 30 24 
[
15
N2]Arginine 177.1 70.1 31.2 30 24 
Lysine 147.1 84.1 5.7 20 18 
[
13
C6]Lysine 153.1 89.1 5.7 20 18 
Methionine 150.1 104.0 31.4 21 13 
[
2
H3]Methionine 153.1 107.0 31.4 21 13 
Tyrosine 181.9 136.0 18.8 20 16 
[
2
H4]Tyrosine 185.9 140.0 18.8 20 16 
Tryptophan 205.2 158.8 23.8 20 20 
[
15
N2]Tryptophan 207.2 160.8 23.8 20 20 
Valine 117.8 72.0 8.5 19 8 
[
2
H8]Valine 125.8 80.0 8.5 19 8 
MG-H1 229.0 114.0 11.3 30 18 
[
15
N2]MG-H1 231.0 116.0 11.3 30 18 
CEL 219.0 130.0 30.7 25 16 
[
13
C6]CEL 225.0 136.0 30.7 25 16 
MOLD 341.0 84.1 14.8 48 33 
[
2
H8]MOLD 349.0 88.1 14.8 48 33 
G-H1 214.9 100.2 12.9 25 18 
[
15
N2]G-H1 216.9 102.2 12.9 25 18 
CML 204.9 84.1 30.5 24 19 
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[
13
C6]CML 210.9 89.1 30.5 24 19 
CMA 233.0 70.1 12.4 30 27 
[
13
C2]CMA 235.0 70.1 12.4 30 27 
3DG-H 319.0 70.1 11.3 45 34 
[
15
N2]3DG-H 321.0 70.1 11.3 45 34 
FL 291.0 84.1 30.5 35 32 
[
2
H4]FL 295.0 88.1 30.5 35 32 
Glucosepane 429.2 269.2 16.4 49 30 
[
13
C6]Glucosepane 435.2 275.1 16.4 49 30 
MetSO 166.1 56.2 8.6 21 20 
[
2
H3]MetSO 169.1 56.2 8.6 21 20 
Dityrosine 361.0 315.1 20.5 35 22 
[
2
H6]Dityrosine 367.0 321.1 20.5 35 22 
NFK 237.0 191.1 21.7 20 11 
[
15
N2]NFK 239.0 193.1 21.7 20 11 
Ornithine 133.1 70.1 5.2 20 13 
[
2
H6]Ornithine 139.1 76.1 5.2 20 13 
3-NT 226.9 180.9 23.5 25 18 
[
2
H3]3-NT 229.9 183.9 23.5 25 18 
AASA 127.9 82.0 31.3 26 12 
[
2
H3]-AAA 164.9 146.8 31.7 17 10 
GSA 113.8 67.9 31.0 26 12 
Pentosidine Ex 320 nm Em 365 nm 20.7   
NFK Ex 320 nm Em 424 nm 21.2   
Dityrosine Ex 284 nm Em 407 nm 20.3   
 
 
4.4.3.5. LC-MS/MS conditions (Xevo TQ-S) 
A similar HPLC elution gradient and postrun wash was optimised as used 
with the Quattro Premier system – section 4.4.3.4 above.  Mass spectrometric 
analysis was performed using electrospray positive ionisation mode.  For mass 
spectrometric detection, the capillary voltage was 0.5 kV, the ion source temperature 
150 °C, the desolvation gas temperature 500 °C and cone and desolvation gas flows 
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150 and 1000 L/h respectively.  Similar MRM mass transitions were optimised and 
established for quantification on the Xevo TQ-S system as optimised on the Quattro 
Premier (Table 21). 
 
4.4.3.6. Data analysis 
 Data analysis was performed using MassLynx software.  Calibration curves 
were constructed by plotting peak area ratio of analyte/isotopic standard against 
analyte concentration as shown in Figure 20.  Example chromatograms are displayed 
in Figure 21.  The amounts in assayed aliquots were deduced using the peak area 
ratio and the appropriate calibration curve.  Concentrations of glycation, oxidation 
and nitration free adducts in filtrates (from culture media, plasma and pancreas) were 
calculated using appropriate dilution factors.  Glycation, oxidation and nitration 
adduct residues in hydrolysed protein samples were normalised to the appropriate 
amino acid, taking into account any necessary correction factors for hydrolysis.   
 In the analysis of protein glycation, oxidation and nitration adduct residues of 
proteins, a robust basis for correction of the contribution to protein glycation, 
oxidation and nitration adducts by autohydrolysis of proteases is required.  
Hydrolysis in protein free blanks overestimates this contribution since 
autohydrolysis of proteases is faster when no protein substrate is present.  An initial 
strategy employed was correction from digestion of a polypeptide that could not 
contain protein glycation, oxidation and nitration adduct residues – such as 
polythreonine.  This however, only presents the proteases with one type of peptide 
bond – different from all other samples.  The current method uses triplicate digests 
of zero protein blanks and a known amount of HSA to quantify an amino acid that is 
not modified – valine.  In the HSA digests the amount of valine detected is that from 
HSA + autohydrolysis of proteases (VHSA + VProteases (Protein)).  In the zero protein 
blanks the valine detected is only from autohydrolysis (VProteases (Blank)). The valine 
liberated from proteases in the presence of HSA is decreased by the suppression of 
autohydrolysis by presence of HSA.  The factor VProteases (Protein)/ VProteases (Blank), 
typically ca. 0.7, is applied to the amount of protein glycation, oxidation and 
nitration adducts quantified in the blank to produce correction factors to apply to 
sample protein digests.  That is, the presence of protein substrate slows 
autohydrolysis of proteases by ca. 30%.  This correction factor is determined for 
each batch of samples for enzymatic hydrolysis. 
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Figure 20: Typical calibration curves for glycation and oxidation adduct 
residues and amino acids by LC-MS/MS.  A: Standard curve for arginine.  
Regression of Peak area ratio on amount of arginine (nmol) gave: Peak area ratio = 
(0.175 ± 0.001 x arginine (nmol)) ± 0.0105; r
2
 = 1.00 (n = 7).  B: Standard curve for 
MG-H1.  Regression of Peak area ratio on amount of MG-H1 (pmol) gave: Peak area 
ratio = (0.0605 ± 0.0008 x MG-H1 (pmol)) ± 0.0220; r
2
 = 0.998 (n = 7).  C: Standard 
curve for 3DG-H.  Regression of Peak area ratio on amount of 3DG-H (pmol) gave: 
Peak area ratio = (0.093 ± 0.001 x 3DG-H (pmol)) ± 0.0378; r
2
 = 0.998 (n = 7).  D: 
Standard curve for FL.  Regression of Peak area ratio on amount of FL (pmol) gave: 
Peak area ratio = (0.101 ± 0.003 x FL (pmol)) ± 0.150; r
2
 = 0.996 (n = 7).  E: 
Standard curve for CML.  Regression of Peak area ratio on amount of CML (pmol) 
gave: Peak area ratio = (0.183 ± 0.003 x CML (pmol)) ±0.0340; r
2
 = 0.999 (n = 7).  
F: Standard curve for MetSO.  Regression of Peak area ratio on amount of MetSO 
(pmol) gave: Peak area ratio = (0.0536 ± 0.0008 x MetSO (pmol)) ± 0.0219; r
2
 = 
0.997 (n = 7). 
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Figure 21: Representative chromatograms of glycation and oxidation adduct 
residues and amino acids in mouse pancreas.  Chromatograms are: A. arginine; B. 
[
15
N2]arginine; C. MG-H1 (2 epimers); D. [
15
N2]MG-H1 (2 epimers); E. 3DG-H (3 
isomers); F. [
15
N2]3DG-H (3 isomers); G. FL; H. [
2
H4]FL; I. CML; J. [
13
C6]CML; K. 
MetSO; L. [
2
H3]MetSO. 
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4.4.4. Assay of ε-(γ-Glutamyl)lysine  
4.4.4.1. Principle of assay 
The amount of ε-(γ-glutamyl)lysine (GEEK) in pancreas homogenates was 
measured by LC-MS/MS assay. 
 
4.4.4.2. Sample preparation 
Hydrolysates of soluble and ECM pancreatic protein prepared as in section 
4.4.3.2 were used.  Soluble pancreatic protein digest (25 µL) was added to a solution 
of [
13
C5]GEEK (10 pmol, 25 µL) for analysis.  ECM pancreatic protein digest (12.5 
µL) was diluted with 0.1% TFA in 3.75% MeCN (12.5 µL) and added to 
[
13
C5]GEEK (10 pmol, 25 µL) for analysis. 
 
4.4.4.3. Preparation of calibration standards 
Stocks of GEEK (0.5 µM and 10 µM) and γ-[13C5]GEEK (0.4 µM) were 
prepared.  Aliquots of [
13
C5]GEEK (25 µL) were mixed with GEEK diluted to 25 µL 
with 0.1% TFA in 3.75% MeCN.  Standards were prepared over the range 1 - 200 
pmol as detailed in Table 22. 
 
4.4.4.4. LC-MS/MS conditions 
Special LC elution conditions were required to resolve GEEK 
chromatographically from isobaric interferences of α-Glu-Lys, α-Lys-Glu and γ-Glu-
α-Lys.  A graphite Hypercarb HPLC column was used (150 x 2.1 mm, particle size 3 
µm) with column temperature of 30 °C.  Solvents used were 0.1% TFA in 3.75% 
MeCN (Solvent A) and 0.1% TFA in 50:50 THF: water (Solvent B).  The elution 
profile is detailed in Table 23.  
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Table 22: Preparation of GEEK calibration standards 
Calibration 
solution 
GEEK 
(pmol) 
GEEK (µL) 0.1% TFA in 
3.75% 
MeCN (µL) 
[
13
C5]GEEK 
(0.4 µM) (µL) 
Total 
volume 
(µL) 
0.5 
µM 
10 
µM 
0 0 - - 25.0 25.0 50.0 
1 1 2 - 23.0 25.0 50.0 
2 5 10 - 15.0 25.0 50.0 
3 10 20 - 5.0 25.0 50.0 
4 25 - 2.5 22.5 25.0 50.0 
5 50 - 5.0 20.0 25.0 50.0 
6 100 - 10.0 15.0 25.0 50.0 
7 150 - 15.0 10.0 25.0 50.0 
8 200 - 20.0 5.0 25.0 50.0 
 
 
Table 23: Elution profile for GEEK analysis 
Injection Run     
Time (min) 
Flow rate 
(mL/min) 
Solvent A (%) Solvent B (%) Gradient 
Initial 0.2 100 0  
5 0.2 100 0 Isocratic 
15 0.2 100 0 Isocratic 
35 0.2 0 100 Immediate 
40 0.2 100 0 Immediate 
55 0.4 100 0 Immediate 
 
Flow from the column was eluted into the electrospray source of the MS/MS 
detector between 2 and 15 min for data collection.  Mass spectrometric analysis was 
performed using electrospray positive ionisation mode.  For mass spectrometric 
detection, the capillary voltage was 1.0 kV, the ion source temperature 120 °C, the 
desolvation gas temperature 350 °C and cone and desolvation gas flows 96 and 900 
L/h respectively.  The optimised MRM conditions used for detection, along with 
their retention times, cone voltage and collision energy are listed in Table 24. 
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Table 24: Optimised MRM mass transitions for GEEK analysis 
Analyte 
Parent ion 
(Da) 
Fragment 
ion (Da) 
Retention 
time (min) 
Cone 
Voltage 
(V) 
Collision 
Energy 
(eV) 
GEEK 276.1 147.1 10.0 32 12 
[
13
C5]GEEK 281.1 147.1 10.0 32 12 
 
4.4.4.5. Data analysis 
Specimen chromatograms are shown in Figure 22.  Calibration curves were 
constructed by plotting peak area ratio of GEEK / [
13
C5]GEEK against GEEK 
concentration (Figure 23).  The amounts in assayed aliquots were deduced using the 
peak area ratio and the appropriate calibration curve.  The amount of GEEK in 
hydrolysed samples was normalised to the lysine measured in the corresponding 
assay of glycation, oxidation and nitration adduct residues. 
 
   
Figure 22: Representative chromatograms of GEEK in pancreatic protein 
digest.  A: GEEK. B: [
13
C5]GEEK (10 pmol). 
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Figure 23: Typical calibration curve for GEEK by LC-MS/MS.  Regression of 
Peak area ratio on amount of GEEK (pmol) gave: Peak area ratio = ((0.0873 ± 
0.0013) x GEEK (pmol)) ± 0.119; r
2
 = 0.998; n = 9.  
 
 
4.4.5. Citrulline assay 
4.4.5.1. Principle of assay 
The amount of free citrulline in pancreatic and plasma filtrates was measured 
by an established stable isotopic dilution analysis LC-MS/MS assay. 
 
4.4.5.2. Sample preparation 
Pancreatic and plasma ultra-filtrates prepared for analysis of glycation, 
oxidation and nitration free adducts were diluted for analysis to measure citrulline 
free adducts.  Pancreatic filtrates (10 µL) and plasma filtrates (2.5 µL) were diluted 
with 0.1% TFA in water to a final volume of 25 µL and added to [
13
C6]citrulline (2.5 
pmol, 25 µL) for analysis.   
 
4.4.5.3. Preparation of calibration standards  
Stocks of citrulline (0.2 µM and 2 µM) and [
13
C6]citrulline (0.1 µM) were 
prepared.  Aliquots of [
13
C6]citrulline (25 µL) were mixed with known amounts of 
citrulline diluted to 25 µL with 0.1% TFA in water.  Standards were prepared over 
the range 0.25 – 50.0 pmol as detailed in Table 25. 
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Table 25: Preparation of citrulline calibration standards 
Calibration 
solution 
Citrulline 
(pmol) 
Citrulline 
(µL) 
0.1% TFA 
in water 
(µL) 
[
13
C6]Citrulline 
(0.1 µM) (µL) 
Total 
volume 
(µL) 
0.2 
µM 
2 
µM 
0 0 - - 25.00 25 50 
1 0.25 1.25 - 23.75 25 50 
2 0.50 2.50 - 22.50 25 50 
3 1.25 6.25 - 18.75 25 50 
4 2.50 12.5 - 12.50 25 50 
5 3.75 18.75 - 6.25 25 50 
6 5.00 25.0 - - 25 50 
7 10.0 - 5.00 20.00 25 50 
8 25.0 - 12.5 12.50 25 50 
9 50.0 - 25.0 - 25 50 
 
 
4.4.5.4. LC-MS/MS conditions 
Special LC elution conditions were required to clearly resolve citrulline from 
arginine chromatographically as a minor fraction of arginine degrades to citrulline in 
the electrospray source of the mass spectrometer.  Although minor for arginine 
detection this would overestimate citrulline significantly if arginine and citrulline 
were not resolved chromatographically.  A graphite Hypercarb HPLC column was 
used (150 x 2.1 mm, particle size 3 µm) with column temperature of 30 °C.  Solvents 
used were 0.1% TFA in water (Solvent A), 0.1% TFA in 50% MeCN (Solvent B1) 
and 0.1% TFA in 50% THF (Solvent B2).  The elution profile for the analytical run 
and postrun is detailed in Table 26.  Eluate from the column was eluted into the 
electrospray source of the Quattro Premier MS/MS detector between 4 and 20 min 
for data collection.  Mass spectrometric analysis was performed using electrospray 
positive ionisation mode.  For mass spectrometric detection the capillary voltage was 
1.0 kV, the ion source temperature 120 °C, the desolvation gas temperature 350 °C 
and cone and desolvation gas flows 96 and 900 L/h respectively.  The optimised 
MRMs used for detection and quantification of citrulline, along with their retention 
time, cone voltage and collision energy are displayed in Table 27. 
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Table 26: Elution profile for citrulline analysis 
Injection Run 
Time (min) 
Flow rate 
(mL/min) 
Solvent A1 
(%) 
Solvent B1 
(%) 
Solvent B2 
(%) 
Gradient 
Initial 0.2 100 0 -  
5 0.2 100 0 -  
20 0.2 95 5 - Linear 
Postrun      
Initial 0.2 0 - 100  
20 0.2 0 - 100 Isocratic 
25 0.2 100 - 0 Immediate  
40 0.4 100 - 0 Immediate 
 
 
Table 27: Optimised MRM mass transitions for citrulline analysis 
Analyte 
Parent 
ion (Da) 
Fragment 
ion (Da) 
Retention 
time (min) 
Cone 
Voltage (V) 
Collision 
Energy (eV) 
Citrulline 176.1 158.9 11.8 20 8 
[
13
C6]Citrulline 181.1 163.9 11.8 20 8 
 
 
4.4.5.5. Data analysis 
Specimen chromatograms are shown in Figure 24.  Calibration curves were 
constructed by plotting the peak area ratio of citrulline/ [
13
C6]citrulline against 
citrulline concentration (Figure 25).  The amount in assayed samples was deduced 
using the calibration curve and the concentration in the original filtrate calculated 
with use of appropriate dilution factors.  The amount of citrulline in pancreatic 
filtrates was normalised to the wet weight of the pancreas sample. 
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Figure 24: Representative chromatograms of citrulline in mouse pancreas.   
A: Citrulline.  B: [
13
C6]Citrulline (2.5 pmol). 
 
 
 
Figure 25: Typical calibration curve for citrulline by LC-MS/MS.  Regression of 
Peak area ratio on amount of citrulline (pmol) gave: Peak area ratio = ((0.5673 ± 
0.0059) x citrulline (pmol)) ± 0.107; r
2
 = 0.999; n = 10. 
 
4.5. Immunohistochemistry 
 Frozen mouse pancreas samples were covered in cryomatrix embedding resin 
and placed on dry ice to solidify.  Samples were sectioned into 0.8 µm slices and 
mounted onto glass slides.  Sections were air dried and fixed using 4% 
paraformaldehyde (PFA) in PBS for 10 min.  PFA was removed, sections washed 
with PBS and permeabilised with 0.1% Triton X-100 in PBS for 10 min.  Triton X-
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100 was removed and sections were washed with TBS for 10 min and blocked with 
1% poly-L-asparagine for 1 h at room temperature.  Sections were washed again 
with PBS and incubated with primary antibodies overnight at 4 °C.  Antibodies were 
10 ng/mL mouse anti-MG-H1 monoclonal antibody, 11 µg/mL chicken anti-insulin 
polyclonal antibody and 2.5 µg/mL rabbit anti-collagen IV polyclonal antibody.  
Sections were then washed with PBS (2 x 5 min) and incubated with the Alexa 
labelled secondary antibodies for 1 h at room temperature.  Secondary antibodies 
were goat anti-mouse IgG-Alexa488 conjugate, goat anti-chicken IgG-Alexa555 
conjugate, goat anti-rabbit IgG-Alexa555 conjugate and goat anti-rabbit IgG-
Alexa488 conjugate; all diluted to 5 µg/mL.  Samples were then mounted using 
mounting medium containing 4’,6-diamidino-2-phenylindole (DAPI).  Images were 
acquired under a 63x NA oil immersion objective using a laser scanning Zeiss 
confocal microscope at 1x zoom.  Additional pancreas sections were incubated with 
PBS without antibody addition and with secondary antibodies only as controls for 
tissue auto-fluorescence and non-specific antibody binding respectively. 
 
4.6. Animal Study 
 The in-life study was performed by Professor Jan Kopecky and co-workers, 
Institute of Physiology, Academy of Sciences of the Czech Republic.  Experiments 
were conducted under the guidelines for the use and care of laboratory animals of the 
Institute of Physiology and followed the ‘Principles of laboratory animal care’.  
C57BL6/N male mice were randomised into control chow fed (3.4% fat) and HFD 
(approximately 35% fat) fed groups at the age of 3 months.  Control animals 
remained on a standard chow diet whilst HFD animals were fed high fat chow for 
one week.  Following this one week of adaptation, HFD fed animals were again 
randomised, into HFD and omega-3 fatty acid supplemented HFD groups.  HFD and 
control groups continued on the same chow diet, whilst supplemented animals were 
fed HFD with 15% dietary lipids replaced by fish oils for a further 9 weeks.  Details 
of the macronutrient composition of these diets are given by Kuda et al. (2009).  The 
mice were sacrificed by cervical dislocation under anaesthesia following overnight 
access to food.  All mice were caged separately throughout.  Fasting glucose and 
insulin levels and the glucose tolerance test were performed after 8 weeks of the 
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dietary regimes – one week prior to sacrifice.  Blood glucose and insulin were 
measured using calibrated glucometers and radioimmunoassay respectively.  Plasma 
triglycerides and cholesterol were measured using a clinical analyser.  NEFA were 
measured using a commercial kit (Waco Chemicals, Neuss, Germany).  Glucose 
tolerance was assessed by measuring blood glucose after an overnight fast and 
following injection of D-glucose and expressed as “area under the curve”.  Food 
consumption over a 24 h period was measured weekly and used to calculate the 
cumulative food intake over the study period.  Pancreas and plasma samples were 
sent on dry ice for subsequent analysis.   
 
4.7. Statistical Analysis  
 Experiments were performed using analysis in replicates of triplicates or 
greater.  Difference between normally distributed experimental groups was tested 
using Student’s t-test assuming equal or unequal variance as appropriate based on the 
result of the F-test two sample for variance.  Significance was defined as P≤0.05.  
Regression analysis was performed and used to determine the statistical LoD; using 
3 x standard error at the intercept to calculate the LoD.  Normality of data was tested 
using Kolmogorov-Smirnov test and difference between non-parametric data groups 
determined using Mann Whitney U test.  Where smoothing has been applied to 
chromatograms it is based on the number of scans for peak width at half-height. 
 
134 
 
5. Results: The glyoxalase system and dicarbonyl 
metabolism in MIN6 cells in vitro 
5.1. Growth of MIN6 cells in vitro 
 A growth curve was constructed to assess the growth and viability of MIN6 
cells in vitro. The growth of MIN6 cells was studied in low and high glucose 
concentrations, 5.5 mM and 20 mM, respectively - Figure 26.  When MIN6 cells 
were seeded at a density of 32,200 cells/cm
2
 or 322,000 cells per well in medium 
containing 5.5 mM glucose, the viable cell density and number increased 
progressively for 5 days, reaching a maximum density of 197,000 cells/cm
2
 or 1.97 
million cells per well.  Thereafter the viable cell density and number decreased 
progressively at days 6 and 7.  The decrease in cell number at days 6 and 7 was 
associated with an increased number of detached cells rather than a decrease in 
viability of cells recovered by trypsinisation.  When MIN6 cells were incubated with 
20 mM glucose there was similar growth kinetics as in cultures with 5.5 mM glucose 
- Figure 26.  In subsequent experiments MIN6 cells were incubated for a maximum 
of 5 days. 
 
 
Figure 26: Growth curve of MIN6 cells cultured in vitro with media containing 
5.5 mM and 20 mM glucose.  Data are mean ± SD; n = 3.  Key: - - , medium 
containing 5.5 mM glucose; ▲▬▲, medium containing 20 mM glucose. 
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5.2. Characterisation of the glyoxalase system of MIN6 cells in 
vitro 
5.2.1. Activity of glyoxalase 1 and glyoxalase 2 of MIN6 cells in 
vitro  
 The mean activity of Glo1 in MIN6 cells in vitro incubated in medium with 
5.5 mM glucose was 600 ± 87 mU per million cells.  The mean activity of Glo2 in 
MIN6 cells in vitro incubated in medium with 5.5 mM glucose was 549 ± 82 mU per 
million cells.  The activity of Glo1 and Glo2 was not changed significantly by 
incubation with 20 mM glucose – Figure 27.  The activity of MG reductase and 
dehydrogenase was measured in MIN6 cell lysates but was below the limit of 
detection (<0.5 mU per million cells).  Glo1 and the glyoxalase system is therefore 
the main enzymatic route for metabolism of MG in MIN6 cells in vitro. 
 
 
Figure 27: Enzymatic activities of the glyoxalase system in MIN6 cells. 
A. Activity of Glo1.  B. Activity of Glo2.  MIN6 cells were cultured in medium for 5 
days.  Data are mean ± SD; n = 5 - 6.   
 
 
 
5.2.2. Glyoxalase 1 gene expression of MIN6 cells in vitro  
The expression of Glo1 in MIN6 cells incubated in vitro in medium with 5.5 
mM glucose was studied by quantifying Glo1 mRNA by RT-PCR and normalising 
to 18S rRNA.  Normalised Glo1/ 18S RNA was 0.404 ± 0.014 and 0.407 ± 0.008 at 
passage 40 and 46 respectively (n = 3).  The mean expression of Glo1 in MIN6 cells 
incubated in vitro in medium with 20 mM glucose was 0.412 ± 0.006 and 0.403 ± 
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0.009 at passage 40 and 46 respectively (n = 3).  Hence, the expression was not 
significantly altered by either passage or incubation with 20 mM glucose.   
 
5.2.3. Dicarbonyls in MIN6 cells in vitro  
The MG content of MIN6 cells incubated in medium with 5.5 mM glucose 
was 5.95 ± 2.88 pmol per million cells.  The glyoxal content of MIN6 cells incubated 
in medium with 5.5 mM glucose was 0.31 ± 0.03 pmol per million cells.  The 3-DG 
content of MIN6 cells incubated in medium with 5.5 mM glucose was 2.09 ± 1.01 
pmol per million cells.  The cellular contents of MG, glyoxal and 3-DG were not 
changed significantly when MIN6 cells were incubated with 20 mM glucose - Figure 
28.  The concentration of MG, glyoxal and 3-DG in media of MIN6 cells incubated 
in 5.5 mM glucose was 76.1 ± 13.8 nM, 30.7 ± 1.8 nM and 1120 ± 145 nM 
respectively.  There was a 2.4-fold increase in the concentration of 3-DG measured 
in MIN6 culture media when MIN6 cells were cultured in 20 mM glucose - Figure 
28.  The concentration of MG and glyoxal in the medium was not significantly 
changed by incubation of MIN6 cells with 20 mM glucose.   
 
5.2.4. Glutathione and thiols in MIN6 cells in vitro  
The cellular amounts of reduced and oxidised glutathione and total thiols 
were measured in MIN6 cells following 5 day culture - Table 28.  There was no 
change in the amount of GSH, GSSG or total thiols in MIN6 cells following culture 
in media containing 20 mM glucose compared to in 5.5 mM glucose control.  The 
amount of S-D-lactoylglutathione in MIN6 cells was below the limit of detection 
(<1.1 pmol/10
6
 cells). 
 
Table 28: Cellular glutathione and thiols in MIN6 cultured for 5 days in vitro 
Analyte 5.5 mM glucose 20 mM glucose 
GSH (pmol/10
6 
cells) 858 ± 114 879 ± 60 
GSSG (pmol/10
6 
cells) 11.1 ± 3.5 13.7 ± 4.9 
Total thiols (nmol/10
6 
cells)
 
34.5 ± 1.8 35.0 ± 1.2 
Protein thiols (nmol/10
6 
cells) 33.7 ± 1.9 34.1 ± 1.2 
GSH, GSSG and total thiols data are mean ± SD; n = 4 - 6.  Protein thiols were 
deduced from the total thiols and GSH. 
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Figure 28: Dicarbonyls in MIN6 cells in vitro.  Panels A, C and E, cellular content 
of MG, glyoxal and 3-DG in MIN6 cells; panels B, D and F, concentration of MG, 
glyoxal and 3-DG in culture medium.  Data are mean ± SD; n = 5 - 6. Significance: 
***, P<0.001. 
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5.2.5. Flux of formation of D-lactate and concentration of L-
lactate in MIN6 cells in vitro  
The flux of formation of D-lactate is an approximate measure of the flux of 
production of MG where the metabolism of D-lactate is low or negligible.  The rate 
of formation of D-lactate in MIN6 cells over 5 days was 1.02 ± 0.34 nmol per 10
6
 
cells per day.  The concentration of D-lactate in the culture medium at baseline was 
6.25 ± 0.67 µM and increased to 12.0 ± 1.2 µM after 5 days.  When cell cultures 
were spiked with 10 µM exogenous D-lactate, the increment in flux of formation of 
D-lactate was not significantly different to in unspiked controls indicating that D-
lactate was not metabolised significantly in MIN6 cells.  Analysis of D-lactate in 
baseline medium and medium following incubation of MIN6 cells for 5 days in 5.5 
mM and 20 mM glucose showed a 41% increase in flux of formation of D-lactate 
when the cells were cultured in 20 mM glucose (P<0.01) – Figure 29.   
The concentration of L-lactate in the medium of MIN6 cell cultures was 
0.529 ± 0.011 mM (n = 5).  Following incubation of MIN6 cells with 5.5 mM and 20 
mM glucose for 5 days the concentration of L-lactate was 1.15 ± 0.07 mM and 1.19 
± 0.03 mM respectively (P<0.001 with respect to baseline; n = 5).  L-Lactate 
concentration in medium was not significantly altered by incubation with 20 mM 
glucose.     
 
 
Figure 29: Flux of formation of D-lactate by MIN6 cells in vitro.  MIN6 cells 
were cultured for 5 days.  Data are mean ± SD; n = 9. Significance: **, P<0.01.  
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5.2.6. Consumption of D-glucose by MIN6 cells in vitro  
The glucose consumption in MIN6 cells in vitro incubated in 5.5 mM glucose 
was 0.716 ± 0.068 µmol/10
6
 cells/day - Figure 30.  The consumption of glucose 
increased by 28% to 0.914 ± 0.098 µmol/10
6
 cells/day when culture medium 
contained 20 mM glucose - Figure 30.   
 
 
Figure 30: D-Glucose consumption in MIN6 cells in vitro.  MIN6 cells were 
cultured for 5 days.  Data are mean ± SD; n = 6.  Significance: **, P<0.01. 
 
The flux of formation of D-lactate from glucotriose was 0.0771 ± 0.0161 % 
when MIN6 cells were incubated in medium containing 5.5 mM glucose and was not 
changed significantly when MIN6 cells were cultured in 20 mM glucose. 
 
5.2.7. Glycation, oxidation and nitration adduct  residue content 
of cytosolic protein of MIN6 cells  
Analysis of glycation, oxidation and nitration adduct residues in hydrolysed 
protein from MIN6 cells cultured for 5 days in media containing 5.5 mM and 20 mM 
glucose showed no significant change in the adduct residues measured – Table 29. 
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Table 29: Protein glycation, oxidation and nitration adduct residues in MIN6 
cells in vitro 
Protein adduct residue 5.5 mM glucose 20 mM glucose 
FL (mmol/mol lys) 0.850 ± 0.143 0.898 ± 0.381 
CML (mmol/mol lys) 0.213 ± 0.026 0.175 ± 0.043 
CML/FL ratio 0.235 ± 0.045 0.224 ± 0.058 
CEL (mmol/mol lys) 0.0461 ± 0.0057 0.0415 ± 0.0126 
MG-H1 (mmol/mol arg) 0.351 ± 0.068 0.376 ± 0.117 
CMA (mmol/mol arg) 0.0182 ± 0.0029 0.0166 ± 0.0060 
3DG-H (mmol/mol arg) 0.153 ± 0.019 0.147 ± 0.015 
MetSO (mmol/mol met) 2.87 ± 0.80 3.63 ± 1.19 
NFK (mmol/mol trp) 1.09 ± 0.14 0.918 ± 0.14 
3-NT (mmol/mol tyr) 0.00227 ± 0.00024 0.00234 ± 0.00149 
Data are mean ± SD; n = 4 - 6. 
 
 
5.2.8. Protein glycation, oxidation and nitration free adducts in 
culture media 
Protein glycation, oxidation and nitration free adducts were quantified in 
MIN6 cell culture medium – Table 30.  Quantitatively, FL was the major glycation 
free adduct formed.  There were increases in the rate of formation of FL free adduct 
(4.1-fold) and 3DG-H free adduct (2-fold) when MIN6 cells were cultured in vitro in 
20 mM glucose.  There were no quantifiable increases in MOLD, NFK, MetSO, 
dityrosine or 3-NT in the medium during the culture. 
DMEM medium contains 798 µM lysine and 398 µM arginine and therefore 
part of the flux of glycation free adducts occurs by glycation of lysine and arginine 
in the extracellular medium.  To deduce the contribution of extracellular glycation to 
the flux of glycation free adducts, culture medium was incubated without cells to 
find the rate of glycation of lysine and arginine from glucose and dicarbonyls present 
– from serum and degradation of serum protein glycated by glucose and spontaneous 
fragmentation of glucose.  The rates were then corrected for a factor reflecting the 
effect of the presence of cells on the glycating agent.  The correction factor = (mean 
concentration of glycating agent in cell incubations/mean concentration of glycating 
agent in cell-free incubations).  For 5.5 mM and 20 mM glucose incubations 
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respectively: 0.68 and 0.89 for glucose; 0.20 and 0.32 for methylglyoxal; and 0.07 
and 0.06 for glyoxal.  The presence of cells did not change the extracellular 
concentration of 3-DG significantly.  Accordingly, rates of glycation free adduct 
production in cell cultures, the contribution of glycation in the extracellular medium 
to this and the proportion of  glycation free adduct production due to cells was 
deduced- Table 30.  This showed that most (>905) of FL free adduct was formed in 
the medium whereas for dicarbonyl derived AGEs, most AGE free adduct was 
formed in cells. 
 
5.3. Insulin expression in MIN6 cells in vitro 
 The expression of the mouse insulin genes were measured in MIN6 cells 
cultured in medium containing 5.5 mM and 20 mM glucose at both passage 40 and 
46 - Table 31.  Expression of Ins1 and Ins2 was equivalent and unaltered by culture 
in medium containing 20 mM glucose.  The expression of both Ins1 and Ins2 
decreased with passage; Ins1 declined by 11% and 9% and Ins2 by 3% and 5% in 5.5 
mM and 20 mM glucose respectively.  The ratio of Ins1:Ins2 expression also 
decreased with passage by 7% and 4% in 5.5 mM and 20 mM glucose respectively.  
A similar ratio change was observed in passage 40 MIN6 cells cultured in 20 mM 
glucose – the Ins1:Ins2 ratio decreased by 4% compared to cells cultured in 5.5 mM 
glucose. 
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Table 30: Protein glycation, oxidation and nitration free adduct flux of formation by MIN6 cells in vitro 
Free adduct  
Incubation with MIN6 cells Extracellular formation† 
% Adduct formed from cell 
proteolysis 
5.5 mM glucose 20 mM glucose 5.5 mM glucose 20 mM glucose 
5.5 mM 
glucose 
20 mM 
glucose 
FL 248 ± 18 1025 ± 32
***
 214 ± 18° 881 ± 109
***,
° 14 14 
CML 6.3 ± 2.4 6.9 ± 3.1 ND ND ND ND 
CEL 2.9 ± 1.1 2.5 ± 0.7 <LOD <LOD --- --- 
MG-H1 16.7 ± 3.1 14.6 ± 1.8 3.3 ± 0.2°°° 6.1 ± 0.9
***,
°°° 80 58 
CMA 22.0 ± 1.8 19.7 ± 2.3 1.9 ± 0.2°°° 1.6 ± 0.1°°° 91 92 
3DG-H 5.7 ± 1.4 11.5 ± 1.3
***
 3.6 ± 0.7° 7.2 ± 0.5 
***,
° 37 37 
Protein glycation, oxidation and nitration free adduct flux of formation (pmol/10
6
 cells/day).  Data are mean ± SD; n = 4 - 6.  Significance: ***, 
P<0.001 with respect to low glucose control; ° and °°°, P<0.05 and P<0.001 with respect to cell incubation production rate. 
† Extracellular formation rate was deduced in pmol/106 cells/day equivalents from incubation without cells. A correction factor to the rate in 
cell-free incubation is applied to allow for the decrease in glucose, methylglyoxal and glyoxal in the presence of cells.  This factor, mean 
concentration of glycating agent in cell incubations/ mean concentration of glycating agent in cell-free incubations, for 5.5 mM and 20 mM 
glucose incubations was respectively: 0.68 and 0.89 for glucose, 0.20 and 0.32 for methylglyoxal; and 0.07 and 0.06 for glyoxal. The presence of 
cells did not change the extracellular concentration of 3-DG significantly.  Abbreviation: ND, not determined. 
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Table 31: Insulin gene expression in MIN6 cells   
 5.5 mM glucose 20 mM glucose 
 Passage 40 Passage 46 Passage 40 Passage 46 
Ins1 0.644 ± 0.008 0.576 ± 0.013
**
 0.631 ± 0.005 0.577 ± 0.021
*
 
Ins2 0.603 ± 0.011 0.582 ± 0.006
*
 0.618 ± 0.005 0.585 ± 0.015
*
 
Ins1:Ins2 
ratio 
1.07 ± 0.01 0.990 ± 0.033
*
 1.02 ± 0.02°° 0.985 ± 0.012
*
 
MIN6 cells (30,000 cells per cm
2
) were incubated for 5 days.  Data are mean ± SD; n 
= 3 normalised to 18S RNA.  Significance: * and **, P< 0.05 and P<0.01 
respectively, compared to passage 40 cells in the same glucose concentration; °°, 
P<0.01 compared to 5.5 mM glucose condition of the same passage. 
 
5.4. The glyoxalase system and MIN6 cells under dicarbonyl 
stress 
5.4.1. Treatment of MIN6 with exogenous MG in vitro  
Treatment of MIN6 cells with 500 µM MG for 30 min produced a 2-fold 
increase in the cellular content of MG (5.69 ± 0.18 pmol per million cells in control 
samples to 12.6 ± 3.9 pmol per million cells in treated cells (P<0.05)).  The 
concentration of MG in the medium decreased from 500 µM at baseline to 356 ± 57 
µM at 30 min and was 0.546 ± 0.133 µM in control media (P<0.001). 
 
5.4.2. Effect of the cell permeable Glo1 inhibitor, BrBzGSHCp 2  
on MIN6 cell growth in vitro  
Endogenous dicarbonyls were increased by using a cell permeable inhibitor 
of Glo1 – BrBzGSHCp2.  A concentration-response of BrBzGSHCp2 for the effect 
on MIN6 cell growth was constructed - Figure 31.  There was no significant 
impairment in cell viability until MIN6 cells were treated with doses of 
BrBzGSHCp2 greater than 12 µM.  The median growth inhibitory concentration 
GC50 value of BrBzGSHCp2 was 27.3 ± 0.9 µM with a logistic regression coefficient 
n = 2.47 ± 0.22. 
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Figure 31: Dose response of MIN6 cells treated with BrBzGSHCp2 for 48 h.  
Data are mean ± SD; n = 6 for 7 concentrations.  Data were fitted to the equation: 
Viable cell number (% of control) = 100 x GC50
n
/(GC50
n
 = [BrBzGSHCp2]
n
), solving 
for GC50 and n. 
 
5.4.3. Effect of BrBzGSHCp2 on dicarbonyls 
MIN6 cells were treated with 10 µM BrBzGSHCp2 with 5.5 mM and 20 mM 
glucose for 48 h - Figure 32.  The cellular content of MG was not increased 
significantly by incubation with 10 µM BrBzGSHCp2, 20 mM glucose or both.  
Incubation with 10 µM BrBzGSHCp2 did however increase the cellular MG content 
when MIN6 cells were incubated with either 5.5 mM or 20 mM glucose (6.55 ± 1.84 
versus 13.4 ± 4.57 pmol per 10
6
 cells, P<0.05).     
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Figure 32: Effect of 10 µM BrBzGSHCp2 and 20 mM glucose on the dicarbonyl 
content of MIN6 cells and culture medium.  Panels A, C and E, cellular content of 
MG, glyoxal and 3-DG; panels B, D and F concentrations of MG, glyoxal and 3-DG 
in culture medium.  Data are mean ± SD; n = 3.  Significance: * and **, P<0.05 and 
P<0.01 respectively.  Key: , Control MIN6 cells;  MIN6 cells treated with 10 µM 
BrBzGSHCp2. 
 
The concentration of MG in the medium was increased ca. 2-fold by 
incubation with 10 µM BrBzGSHCp2.  The cellular content of glyoxal was increased 
58% by incubation with 20 mM glucose and the glyoxal concentration of culture 
medium was increased 14% by incubation with 10 µM BrBzGSHCp2.  The 3-DG 
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concentration of culture medium was increased 41% by incubation with 20 mM 
glucose. 
 
5.4.4. Effect of BrBzGSHCp2 on glutathione content of MIN6 
cells in vitro  
Incubation of MIN6 cells in vitro with 10 µM BrBzGSHCp2 for 48 h 
produced ca. 2-fold increase in the cellular content of GSH and ca. 3-fold increase in 
the cellular content of GSSG in both low and high glucose conditions - Figure 33.   
 
 
Figure 33: The effect of BrBzGSHCp2 on glutathione content in MIN6 cells.   
A. GSH and B. GSSG in MIN6 cells.  Data are mean ± SD; n = 3.  Significance: * 
and **, P<0.05 and P<0.01, respectively. 
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5.4.5. Effect of BrBzGSHCp2 on glyoxalase 1 and insulin 
expression of MIN6 cells in vitro  
The effect of BrBzGSHCp2 on Glo1 and insulin expression in MIN6 cells in 
vitro was analysed by measurement of Glo1 and insulin mRNA.  There was no 
significant change in Glo1 mRNA level when MIN6 cells were treated with 10 µM 
BrBzGSHCp2 for 48 h - Figure 34.  However, the combination of 20 mM glucose 
and BrBzGSHCp2 led to a 17% decrease in Glo1 mRNA, compared to control 
cultures in 5.5 mM glucose. 
 
 
Figure 34: Expression of Glyoxalase 1 in MIN6 cells treated with BrBzGSHCp2 
in vitro.  Glo1 expression in MIN6 cells treated with 10 µM BrBzGSHCp2 for 48 h, 
normalised to expression of 18S RNA.  Data are mean ± SD; n = 3.  Significance: *, 
P<0.05. 
 
There was a significant increase in Ins1 expression in MIN6 cells treated with 
10 µM BrBzGSHCp2 for 48 h - 7% and 3% in 5.5 mM and 20 mM glucose 
conditions respectively, compared to control - Figure 35.  Ins1 and Ins2 mRNA 
decreased by 3% and 4% respectively when MIN6 cells were cultured in 20 mM 
glucose compared to in 5.5 mM glucose.  The level of Ins2 mRNA did not 
significantly change when MIN6 cells were treated with BrBzGSHCp2 - Figure 35.  
There was consequently a shift in the ratio of Ins1:Ins2 mRNA, with an 8% (P<0.01) 
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and 11% (P<0.05) higher proportion of Ins1 in 5.5 mM and 20 mM glucose 
respectively when MIN6 cells were treated with 10 µM BrBzGSHCp2.   
 
 
Figure 35: Expression of Ins1 and Ins2 in MIN6 cells treated with BrBzGSHCp2 
A. Ins1 expression and B. Ins2 expression.  Data are mean ± SD; n = 3 of expression 
normalised to expression of 18S RNA.  Significance: *, ** and ***, P<0.05, P<0.01 
and P<0.001, respectively. 
** 
*** 
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6. Results: Effect of modification of collagen IV on MIN6 
cell adhesion and function 
6.1. Characterisation of collagen IV coated plates 
 Twenty-four well plates were coated with collagen IV overnight.  Coating of 
plates resulted in 6.29 ± 2.93 µg collagen/well adherence; 33.1% of the collagen 
added.  Total collagen was measured by CBQCA assay following extraction by 
washing wells twice with PBS and six times with 0.1% Triton X-100 in PBS.  In 
total, 96.6% of the collagen added to each well (19 µg) was recovered - Figure 36. 
 
 
Figure 36: Recovery of collagen from 24 well plate.  Data are mean ± SD; n = 3-4. 
 
6.2. Effect of collagen IV on MIN6 cell adhesion 
 Coating plates with human collagen IV increased the adhesion of MIN6 cells 
2-fold with respect to uncoated culture plates.  This increase was prevented by pre-
incubation of MIN6 cells with either anti-Itgb1 antibody or RGD peptide before 
plating onto coated plates; a 50% and 47% decrease relative to control cells was 
demonstrated for anti-Itgb1 antibody and RGD peptide respectively - Figure 37.  The 
initial adhesion showed more clustering of cells when plated onto collagen, 
compared to the equally dispersed cells plated onto control uncoated plates. 
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Figure 37: Collagen dependent adhesion of MIN6 cells in vitro.  Collagen 
dependent adhesion of MIN6 to human collagen was blocked by A. 5 µg/mL anti-
Itgb1 antibody and B. 2 µg/mL RGD.  Data are mean ± SD; n = 3.  Significance: * 
and **, P<0.05 and P<0.01, respectively. 
 
6.3. Effect of glycation of collagen IV with methylglyoxal on 
MIN6 cell adhesion 
6.3.1. Determination of adhesion by cell adhesion assay  
The use of 100 µM MG to modify the collagen resulted in a visual increase in 
the number of rounded and floating cells after 24 hours as well as a change in 
morphology.  There were less adherent, healthy cells and less cell-cell interactions 
with this MG-modified collagen coating of the wells.  In all other experiments with 
MG-glycated collagen, cells had a healthy morphology at the time points monitored.  
At both 24 and 72 h incubation on collagen, there was no clear difference in MIN6 
cell morphology when compared to collagen glycated with 4 µM or 10 µM MG.  
The effect of the modification of human collagen IV with MG on the adhesion of 
MIN6 cells is shown in Figure 38.  Adhesion compared to control collagen was 
increased by 66% and 98% when collagen was incubated for 24 h with 4 µM and 10 
µM MG respectively.  The same trends could be observed when experiments were 
repeated using mouse collagen IV - Figure 39.  Adhesion to mouse collagen coated 
plates was increased by 76% compared to uncoated plates, and adhesion increased a 
further 67% over control collagen when collagen had been glycated with 10 µM 
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MG.  Although cells on glycated collagen appeared loose when viewed under the 
microscope, there were large clusters of cells visible; this clustering may account for 
the increased number of cells adhered. 
 
 
Figure 38: MIN6 cell adhesion to human collagen IV modified with MG.  
Percentage cell adhesion after 2 h incubation.  Data are mean ± SD; n = 3.  
Significance: *, P<0.05. 
 
 
Figure 39: MIN6 cell adhesion to mouse collagen and MG-glycated collagen. 
Percentage cell adhesion after 2 h incubation on uncoated wells, mouse collagen IV 
and mouse collagen IV glycated with 10 µM MG for 24 hr.  Data are mean ± SD; n 
= 3 - 4.  Significance: * and **, P<0.05 and P<0.01, respectively. 
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6.3.2. Determination of force and energy of adhesion between 
MIN6 cells and collagen IV 
The maximum unbinding force and energy needed to detach MIN6 cells from 
collagen and MG-glycated collagen were measured using AFM-FS - Figure 40.  The 
median maximum unbinding force was 45% lower for collagen glycated with 10 µM 
compared to control collagen.  The total energy required to detach MIN6 cells from 
the collagen matrix also decreased – the median was 92% lower when collagen was 
glycated with MG.  The same effect was observed when MIN6 cells were pre-
incubated with RGD before plating onto control collagen – the median detachment 
energy had decreased by 91%.  Figure 41 shows the unbinding force and detachment 
energy for the three treatment groups.  
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Figure 40: Atomic Force Spectroscopy traces.  A. Force Spectroscopy trace for 
MIN6 cell on control collagen.  The cantilever was retracted (5 µm/s) and the force 
versus deflection measured until the cell and matrix were completely separated.  The 
same experiment was repeated using B. collagen glycated with 10 µM MG for 24 h 
and C. MIN6 cells pre-incubated with 2 µg/mL RGD.  D. A representative phase 
contrast image of a single MIN6 cell bound to the cantilever (cantilever width 50 
µm). 
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Figure 41: MG-glycation of collagen decreases MIN6-collagen adhesion.  
Quantification of (A) maximum unbinding force and (B) detachment energy.  Data 
of multiple cells from three separate experiments (42 - 59 data points) are expressed 
as box plots displaying minimum and maximum data points, median and 
interquartile range.  Significance: * and ***: P<0.05 and P<0.001, respectively. 
 
6.4. Effect of culture on collagen IV and MG-glycated collagen 
IV on gene expression in MIN6 cells 
 MIN6 cells were plated onto 24 well plates coated with collagen, collagen 
glycated with 10 µM MG and onto uncoated wells.  Cells were cultured for 3 days, 
the RNA extracted and the expression of genes of interest analysed - Table 32.  The 
expression of Glo1 in MIN6 cells was not altered by either culture on collagen IV or 
MG-glycation of the collagen matrix.  Expression of Ins2 was also unaltered by 
coating of plates with either collagen or MG-glycated collagen.  Ins1 expression 
tended to increase in MIN6 cells cultured on collagen, although this was regardless 
of whether or not the collagen was glycated.  Culture on MG-glycated mouse 
collagen resulted in a slight increase in the expression of Ins1 of 0.82% over culture 
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on uncoated plastic, whilst the same trend showed a 1.6% increase in expression in 
cells cultured on control human collagen compared to the uncoated control.  There 
was a 5% decrease in the expression of Itgb1 when MIN6 cells were cultured on 
MG-glycated collagen compared to culture on control collagen substrate.  E-cadherin 
expression decreased by 6% when MIN6 cells were cultured on MG-glycated 
collagen, compared to culture in uncoated wells.  Whilst there was no quantifiable 
change in Cx36 expression in MIN6 cells cultured on mouse collagen, this was 
potentially due to the variability in measurements, particularly of the expression in 
MIN6 cells cultured on MG-glycated mouse collagen.  In experiments performed 
using human collagen, there was a decrease (5%) in the expression of Cx36 in MIN6 
cells cultured on glycated collagen, compared to MIN6 cells cultured on control 
collagen – as shown in Figure 42.   
 
Table 32: Gene expression analysis of MIN6 cells cultured on mouse collagen 
Gene Uncoated Collagen coated 
Collagen coated 
+ 10 µM MG 
Ins1 0.725 ± 0.003 0.729 ± 0.004 0.731 ± 0.002
°
 
Ins2 0.654 ± 0.008 0.657 ± 0.009 0.653 ± 0.008 
Glo1 0.533 ± 0.010 0.541 ± 0.008 0.534 ± 0.012 
Itgb1 0.628 ± 0.002 0.633 ± 0.014 0.602 ± 0.011
*
 
E-cadherin 0.619 ± 0.005 0.610 ± 0.032 0.584 ± 0.016
°
 
Connexin36 0.436 ± 0.034 0.406 ± 0.009 0.402 ± 0.020 
 Data are mean ± SD; n = 3 - 4.  Significance: * and 
°
, P<0.05 compared to control 
collagen and uncoated wells respectively.  Gene expression normalised to 18S RNA.
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Figure 42: Expression of Cx36 in MIN6 cells cultured on human collagen IV.  
Cx36 mRNA normalised to 18S RNA in MIN6 cells following culture for 3 days in 
uncoated wells, on human collagen IV and human collagen IV glycated with 10 µM 
MG for 24 h.  Data are mean ± SD; n = 4.  Significance: ***, P<0.001. 
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7. Results: The glyoxalase system and dicarbonyl 
metabolism in an in vivo model of insulin resistance 
7.1. Impairments in glucose tolerance in high fat diet fed mice 
 The effects of the three different dietary regimes on body and organ weight, 
food intake and parameters relating to glucose tolerance and lipid content in C57BL6 
mice are detailed in Table 33.  The cumulative food consumption (kJ) was increased 
by 16% in the HFD group compared to the mice fed control chow.  When the HFD 
was supplemented with omega-3 fatty acids the food intake was not significantly 
different to that of the control mice.  Both the HFD and omega-3 fatty acid 
supplemented HFD led to increased weight gain compared to the control mice (3-
fold and 2.3-fold respectively).  Consequently, the total body weight at the end of the 
study was 40% and 29% higher in the HFD and supplemented groups respectively, 
when compared to those mice fed a diet of control chow.  The liver and brown 
adipose tissues were both significantly larger following HFD feeding – 17% and 2.5-
fold respectively.  When animals were fed a HFD supplemented with omega-3 fatty 
acids only the brown adipose tissue was significantly larger than the mass measured 
in control animals, however, the increase – 1.9-fold – was smaller than observed 
without the supplementation of the HFD.  The pancreas mass was not significantly 
different between the treatment groups.  Mice fed a HFD had increased plasma 
fasting glucose concentration (+73%), insulin (+5.2-fold), cholesterol (+2.1-fold), 
NEFA (+37%) and triglycerides (48%), compared to mice fed a normal chow diet.  
In addition, the hepatic steatosis – judged by measuring the lipid content of the liver 
- had increased 3.3-fold in HFD fed mice.  Mice fed a HFD also had impaired 
glucose tolerance – as judged by the 2.2-fold increase in the area under curve 
measurement in a glucose tolerance test.  Fasting plasma insulin was 2.2-fold higher 
in mice fed HFD supplemented with omega-3 fatty acids than in control mice and the 
increase in fasting plasma glucose was 48% over control animals - substantially less 
than the increases observed in mice fed a HFD without omega-3 fatty acid 
supplementation.  
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Table 33: Parameters relating to body weight, glucose tolerance and adiposity 
in mice fed three different feeding regimes 
Parameter Control HFD 
HFD + omega-3 
fatty acids 
Whole body parameters:    
Body weight (g) 32.2 ± 1.9 45.0 ± 2.8
***
 41.4 ± 5.2
***
 
Body weight gain (g) 6.0 ± 1.6 18.1 ± 2.8
***
 14.2 ± 3.3
***,
° 
Cumulative food intake (kJ) 2920 ± 258 3400 ± 170
***
 3040 ± 286 
Tissue weight (mg):    
Pancreas  137 ± 27 159 ± 24 145 ± 22 
Liver  1680 ± 175 1960 ± 300
*
 1650 ± 310 
Brown adipose tissue 117 ± 35 292 ± 92
***
 227 ± 85
**
 
Plasma parameters:    
Fasting glucose (mmol/L) 5.0 ± 0.9 8.6 ± 1.6
***
 7.3 ± 1.4
***
 
Fasting insulin (ng/mL) 0.281 ± 0.097 1.45 ± 0.46
***
 0.609 ± 0.265
**,
°°° 
Cholesterol (mmol/L) 2.01 ± 0.25 4.30 ± 0.47
***
 3.52 ± 0.48
***,
°° 
NEFA (mmol/L) 0.582 ± 0.195 0.797 ± 0.176
*
 0.495 ± 0.080°°° 
Triglycerides (mmol/L) 1.27 ± 0.35 1.88 ± 0.62
*
 1.28 ± 0.36° 
Other:    
Glucose tolerance  
(AUC, mmol/L x 180 min) 1520 ± 184 3300 ± 790
***
 2530 ± 331
***,
° 
Hepatic steatosis 
(mg/g tissue) 33.5 ± 4.9 111 ± 42
***
 62.6 ± 25.6
*,
° 
Data are mean ± SD; n = 8 - 9.  AUC: area under curve.  Significance: *, ** and ***, 
P<0.05, P<0.01 and P<0.001 compared to control group; and °, °° and °°°, P<0.05, 
P<0.01 and P<0.001 compared to HFD group. 
 
7.2. Analysis of gene expression in HFD fed mice 
 RNA was extracted from the pancreas of control fed, HFD fed and omega-3 
fatty acid supplemented HFD fed mice and the expression of Ins1, Ins2, Glo1 and 
ICAM-1 was analysed, using 18S RNA as a reference gene for normalisation.  The 
expression of Ins1 and ICAM-1 showed no significant difference between the three 
treatment groups - Figure 43.  Ins2 and Glo1 mRNA were below the limit of 
quantification.  
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Figure 43: Gene expression in the pancreas of HFD fed mice.  Expression of A. 
Ins1 and B. ICAM-1 in the pancreas.  Data are mean ± SD; n = 7. 
 
7.3. Activities of the glyoxalase system enzymes and pathway flux 
 The activity of Glo1 in the pancreas of control mice was 663 ± 120 mU per 
mg protein.  The activity of Glo2 in the pancreas of control mice was 130 ± 39 mU 
per mg protein.  The activity of Glo1 and Glo2 in the pancreas was not changed 
significantly by the three different dietary regimes - Figure 44.  D-Lactate was also 
measured in the pancreas – indicative of in situ flux through the glyoxalase system.  
The pancreas content of D-lactate of control mice was 0.583 ± 0.171 nmol per mg 
wet weight.  There was no significant change in the pancreas content of D-lactate 
with HFD and HFD with omega-3 fatty acid supplementation - Figure 45.  Total 
thiol content of the pancreas was also unchanged by the different diets.  Pancreas 
thiol contents were: 330 ± 62, 333 ± 116 and 327 ± 61 nmol per mg protein in 
control, HFD and HFD supplemented with omega-3 supplementation, respectively (n 
= 7 for each group).   
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Figure 44: Enzymatic activities of the glyoxalase system in the mouse pancreas.  
A. Activity of Glo1.  B. Activity of Glo2.  Mice were fed a control chow diet, HFD 
and HFD supplemented with omega-3 fatty acids.  Data are mean ± SD; n = 6 - 7. 
 
 
 
 
Figure 45: D-Lactate content of the mouse pancreas.  Mice were fed a control 
chow diet, HFD and HFD supplemented with omega-3 fatty acids.  Data are mean ± 
SD; n = 6 - 7. 
 
7.4. Effect of HFD feeding on dicarbonyls in pancreas and 
plasma 
 The concentration of dicarbonyls in the plasma of mice fed a control diet, 
HFD and HFD supplemented with omega 3 were measured - Figure 46.  There was 
no difference in the plasma concentration of MG, glyoxal or 3-DG in the three diet 
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groups.  The dicarbonyls were also measured in the pancreas – Figure 47.  There was 
a 24% and 35% increase in the MG in the pancreas in the HFD fed and the HFD 
supplemented with omega-3 fatty acid fed mice, respectively, compared to the 
amount in the pancreas of control chow fed mice.  The amount of glyoxal also 
increased in HFD fed mice supplemented with omega-3 fatty acids with respect to 
control (+55%) and with respect to HFD fed mice (+70%).  The glyoxal content of 
the pancreas of HFD fed mice was not significantly different to in the pancreas of 
control chow fed mice.  The 3-DG content of the pancreas was decreased 47% in 
HFD fed mice compared to control chow fed mice but not in HFD fed mice 
supplemented with omega-3 fatty acids.  The amount of MG in the pancreas was 
approximately 10-fold higher than both glyoxal and 3-DG. 
  
   
 
Figure 46: Concentration of dicarbonyls in mouse plasma.  Data are mean ± SD; 
n = 6 - 9.  Key: , MG;  glyoxal;  3-DG.  
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Figure 47: Dicarbonyls in mouse pancreas.  A. Amount of MG.  B. Amount of 
glyoxal.  C. Amount of 3-DG.  Pancreas of mice fed a control chow diet, HFD and 
HFD supplemented with omega-3 fatty acids.  Data are mean ± SD; n = 6 - 7.  
Significance: **, P<0.01. 
 
7.5. Formation of glycation, oxidation and nitration adduct 
residues on pancreatic and plasma protein 
7.5.1. Pancreatic and plasma protein  
Analysis of AGE residues of cytosolic protein of mouse pancreas indicated 
that MG-H1 was a major glycation adduct residue – 1.04 ± 0.21 mmol/mol arg of 
mice fed a control chow diet.  HFD feeding with and without omega-3 fatty acid 
supplementation did not change MG-H1 residue content - Table 34.  CMA adduct 
residue content of cytosolic protein of the mouse pancreas was decreased in both the 
HFD fed and HFD supplemented with omega-3 fatty acid fed mice by 30% and 37% 
respectively.   Similar decreases were observed in 3DG-H (20% and 17%) and 
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MetSO (20% and 19%) residue contents.  FL residue content of pancreatic protein 
was increased 24% in mice fed HFD supplemented with omega-3 fatty acids, 
compared to those fed HFD without omega-3 fatty acid supplementation.  
Protein glycation, oxidation and nitration adduct residues were also analysed 
in ECM pancreatic protein.  FL was decreased 54% in the pancreatic ECM protein of 
HFD and HFD supplemented with omega-3 fatty acid fed mice, compared to those 
fed control chow.  CML was also 27% higher in mice fed a HFD supplemented with 
omega-3 fatty acid, compared to mice fed control chow.  This resulted in a 3-fold 
increase in the CML/FL ratio.  Other oxidative adduct residues - MetSO, dityrosine 
and NFK residues - did not change between the treatment groups.  The glycation, 
oxidation and nitration adduct residue content on pancreatic ECM protein are given 
in Table 35.  
In the plasma protein there were 2.4-fold and 1.8-fold increases in MOLD in 
HFD and omega-3 fatty acid supplemented HFD respectively, when compared to 
mice fed control chow - Table 36.  FL also showed increased levels in HFD and 
omega-3 fatty acid supplemented HFD (33% and 24% respectively) when compared 
to control chow fed mice.  However, CEL was 43% lower in the plasma of HFD fed 
mice than control chow fed mice.  G-H1 residues on plasma proteins decreased by 
39% when the HFD was supplemented with omega-3 fatty acid compared to HFD 
without supplementation.  There were 37% and 28% increases in MetSO in the 
plasma of HFD fed and HFD supplemented with omega-3 fatty acid fed mice 
respectively, compared to the amount of this adduct in control chow fed mice, 
indicative of increased oxidative stress. 
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Table 34: Glycation, oxidation and nitration adduct residues in cytosolic protein 
of the mouse pancreas 
Protein adduct residue Control HFD HFD + omega-3 
fatty acids 
MG-H1  
(mmol/mol arg) 
1.04 ± 0.21 0.911 ± 0.124 1.02 ± 0.16 
CEL (mmol/mol lys) 0.0210 ± 0.0090 0.0229 ± 0.0048 0.0194 ± 0.0048 
MOLD  
(mmol/mol lys) 
0.308 ± 0.045 0.337 ± 0.110 0.385 ± 0.075 
G-H1 (mmol/mol arg) 0.0248 ± 0.0058 0.0236 ± 0.0071 0.0300 ± 0.0082 
CML (mmol/mol lys) 0.289 ± 0.038 0.281 ± 0.031 0.287 ± 0.036 
CMA (mmol/mol arg) 0.0371 ± 0.0059 0.0259 ± 0.0053
**
 0.0236 ± 0.0027
***
 
3DG-H  
(mmol/mol arg) 
0.257 ± 0.038 0.206 ± 0.017
*
 0.212 ± 0.029
*
 
Pentosidine 
(mmol/mol arg) 
0.00400 ± 
0.00063 
0.00361 ± 0.00045 0.00369 ± 0.00039 
FL (mmol/mol lys) 12.4 ± 3.8 9.23 ± 0.95 11.4 ± 2.3° 
Glucosepane 
(mmol/mol arg) 
0.150 ± 0.047 0.107 ± 0.026 0.102 ± 0.023 
MetSO  
(mmol/mol met) 
9.84 ± 1.13 7.89 ± 0.59
**
 8.02 ± 0.44
**
 
Dityrosine  
(mmol/mol tyr) 
0.602 ± 0.192 0.697 ± 0.156 0.679 ± 0.147 
NFK (mmol/mol trp) 0.615 ± 0.109 0.653 ± 0.077 0.712 ± 0.108 
CML/FL ratio 0.0254 ± 0.0085 0.0306 ± 0.0036 0.0258 ± 0.0050 
GEEK  
(mmol/mol lys) 
2.42 ± 0.36 2.52 ± 0.61 2.69 ± 0.59 
Data are mean ± SD; n = 6 - 7.  Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to control chow fed mice; °, P<0.05 compared to 
HFD fed mice. 
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Table 35: Glycation, oxidation and nitration adduct residues of extracellular 
matrix protein of mouse pancreas 
Protein adduct residue Control HFD HFD + omega-3 
fatty acids 
MG-H1  
(mmol/mol arg) 
0.373 ± 0.043 0.371 ± 0.049 0.417 ± 0.068 
CEL (mmol/mol lys) 0.0697 ± 0.0102 0.0743 ± 0.0240 0.0768 ± 0.0244 
G-H1 (mmol/mol arg) 0.0152 ± 0.0078 0.0179 ± 0.0074 0.0178 ± 0.0053 
CML (mmol/mol lys) 0.161 ± 0.015 0.190 ± 0.043 0.203 ± 0.033
*
 
CMA (mmol/mol arg) 0.0840 ± 0.0116 0.0768 ± 0.0119 0.0825 ± 0.0085 
3DG-H  
(mmol/mol arg) 
0.283 ± 0.060 0.265 ± 0.065 0.284 ± 0.049 
Pentosidine 
(mmol/mol arg) 
0.00266 ± 
0.00071 
0.00313 ± 0.00085 0.00297 ± 0.00073 
FL (mmol/mol lys) 16.4 ± 5.8 7.61 ± 3.87
**
 5.95 ± 1.65
**
 
Glucosepane 
(mmol/mol arg) 
0.0181 ± 0.0042 0.0287 ± 0.0127 0.0202 ± 0.0036 
MetSO  
(mmol/mol met) 
34.1 ± 2.4 32.8 ± 2.9 31.2 ± 2.3 
Dityrosine  
(mmol/mol tyr) 
1.35 ± 0.25 1.54 ± 0.37 1.51 ± 0.10 
NFK (mmol/mol trp) 0.735 ± 0.261 0.759 ± 0.254 0.580 ± 0.165 
CML/FL ratio 0.0109 ± 0.0038 0.0317 ± 0.0164
*
 0.0326 ± 0.0031
***
 
3-NT (mmol/mol tyr) 0.00710 ± 
0.00278 
0.00771 ± 0.00192 0.00838 ± 0.00247 
GEEK  
(mmol/mol lys) 
3.62 ± 1.60 3.30 ± 0.65 3.76 ± 1.84 
Data are mean ± SD; n = 6 - 7.  Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to control chow fed mice. 
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Table 36: Glycation, oxidation and nitration adduct residues of mouse plasma 
protein 
Protein adduct residue Control HFD HFD + omega-3 
fatty acids 
MG-H1 (mmol/mol arg) 0.310 ± 0.039 0.325 ± 0.043 0.274 ± 0.029 
CEL (mmol/mol lys) 0.287 ± 0.146 0.164 ± 0.031
*
 0.228 ± 0.071 
MOLD (mmol/mol lys) 0.0515 ± 0.0380 0.125 ± 0.033
**
 0.0914 ± 0.0176
*
 
G-H1 (mmol/mol arg) 0.0420 ± 0.0207 0.0584 ± 0.0143 0.0354 ± 0.0045°° 
CML (mmol/mol lys) 0.814 ± 0.161 0.841 ± 0.129 0.770 ± 0.093 
CMA (mmol/mol arg) 0.0306 ± 0.0085 0.0351 ± 0.0089 0.0289 ± 0.0041 
3DG-H (mmol/mol arg) 0.254 ± 0.066 0.302 ± 0.065 0.203 ± 0.029 
FL (mmol/mol lys) 1.89 ± 0.29 2.52 ± 0.44
**
 2.35 ± 0.38
*
 
Glucosepane  
(mmol/mol arg) 
0.134 ± 0.026 0.151 ± 0.026 0.126 ± 0.030 
MetSO (mmol/mol met) 3.26 ± 0.48 4.49 ± 0.35
***
 4.17 ± 0.86
*
 
Dityrosine  
(mmol/mol tyr) 
4.32 ± 0.92 4.39 ± 0.61 4.56 ± 0.72 
NFK (mmol/mol trp) 2.62 ± 0.35 2.46 ± 0.17 2.68 ± 0.19 
CML/FL ratio 0.440 ± 0.083 0.338 ± 0.065
*
 0.334 ± 0.064
*
 
Ornithine  
(mmol/mol arg) 
0.133 ± 0.064 0.167 ± 0.048 0.179 ± 0.049 
Data are mean ± SD; n = 7 - 9.  Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to control chow fed mice; °°, P<0.01 compared to 
HFD fed mice. 
 
 
7.5.2. Glycation, oxidation and nitration free adducts and 
related amino acids in the pancreas  
Glycation, oxidation and nitration free adducts and related amino acids in the 
pancreas cytosolic ultrafiltrates were analysed.  There were decreases in the 
concentration of glycation free adducts in the pancreas in HFD fed mice when 
compared to control chow fed mice - Table 37.  These decreases were also found in 
mice fed a HFD with omega-3 fatty acid supplementation.  Decreases in free adduct 
concentration in HFD fed mice were: MG-H1, 78%; G-H1, 40%; CMA, 67%; 3DG-
H, 58%; and FL, 57%.  CML was decreased by 18% in mice fed a HFD 
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supplemented with omega-3 fatty acid compared to in mice fed a HFD without 
supplementation.  Pentosidine increased by 11% in the pancreatic filtrate of HFD fed 
mice compared to control fed mice.  There were no significant changes in free 
adduct concentrations of MetSO or NFK in the pancreatic filtrates.  Dityrosine also 
decreased 28% in HFD when supplemented with omega-3 fatty acids, compared to 
control. 
Related amino acid concentrations were also measured in the pancreatic 
cytosol extracts - Table 37.  The concentration of tryptophan was lower in HFD and 
HFD supplemented with omega-3 fatty acid fed mice (43% and 65% respectively) 
compared to control chow fed mice, and the concentration of arginine was 22% 
lower in the pancreas of mice fed a HFD supplemented with omega-3 fatty acid than 
in control mice. 
 
168 
 
Table 37: Glycation, oxidation and nitration free adducts and related amino 
acids in pancreas cytosolic extracts 
Free adduct Control HFD 
HFD + omega-3 
fatty acid 
Glycation, oxidation and nitration free adducts (pmol/mg wet weight) 
MG-H1 1.61 ± 0.31 0.348 ± 0.036
***
 0.325 ± 0.035
***
 
CEL 0.342 ± 0.063 0.349 ± 0.124 0.428 ± 0.104 
MOLD 0.125 ± 0.040 0.155 ± 0.062 0.135 ± 0.052 
G-H1 0.375 ± 0.043 0.226 ± 0.060
***
 0.163 ± 0.047
***
 
CML 18.1 ± 2.8 20.1 ± 1.8 16.5 ± 2.0°° 
CMA 0.154 ± 0.017 0.0502 ± 0.0046
***
 0.0468 ± 0.0099
***
 
3DG-H 0.734 ± 0.113 0.312 ± 0.085
***
 0.255 ± 0.044
***
 
Pentosidine 0.109 ± 0.009 0.122 ± 0.007
*
 0.111 ± 0.009 
FL 11.8 ± 2.2 5.04 ± 0.68
***
 4.69 ± 0.91
***
 
MetSO 0.616 ± 0.232 0.498 ± 0.049 0.619 ± 0.098 
Dityrosine 0.835 ± 0.220 0.654 ± 0.141 0.604 ± 0.136
*
 
NFK 0.134 ± 0.042 0.113 ± 0.037 0.108 ± 0.026 
Amino acids (nmol/mg wet weight) 
Arg 0.357 ± 0.070 0.299 ± 0.067 0.277 ± 0.045
*
 
Lys 1.05 ± 0.10 0.974 ± 0.074 0.970 ± 0.117 
Met 0.408 ± 0.101 0.385 ± 0.051 0.387 ± 0.048 
Tyr 0.402 ± 0.098 0.418 ± 0.092 0.447 ± 0.075 
Trp 0.0379 ± 0.0106 0.0217 ± 0.0115
*
 0.0134 ± 0.0070
***
 
Data are mean ± SD; n = 6 - 7.  Significance: * and ***, P<0.05 and P<0.001, 
respectively, compared to control chow fed mice; °°, P<0.01 compared to HFD fed 
mice. 
 
 
7.5.3. Glycation, oxidation and nitration free adducts and 
related amino acids in plasma 
Glycation, oxidation and nitration free adducts and related amino acid 
concentrations of plasma were also determined.  There were significant decreases in 
the adduct concentration of a number of glycation markers in both HFD fed and 
HFD supplemented with omega-3 fatty acid fed mice, compared to control chow fed 
mice - Table 38.  These decreases were: MG-H1, 70%; CMA, 60%; 3DG-H, 89%; 
169 
 
and FL, 90%.  CML free adduct was decreased 23% in plasma from HFD fed mice 
compared to control mice.  The plasma filtrate concentration of the oxidative marker 
MetSO was unchanged in the different feeding regimes.  Free adduct concentrations 
of NFK in the plasma were higher in the mice fed a HFD, compared with both 
control chow fed and omega-3 fatty acid supplemented HFD fed mice.   
Analysis of amino acids in the plasma filtrates indicated a 24% decreased 
concentration of arginine in the HFD fed mice, compared with control chow fed 
mice.  There were no significant changes in arginine in mice fed a HFD 
supplemented with omega-3 fatty acid.  The concentration of tyrosine was increased 
47% in plasma of mice fed a HFD supplemented with omega -3 fatty acids compared 
with control chow fed mice.   
 
Table 38: Glycation, oxidation and nitration free adducts and related amino 
acids in plasma 
Free adduct Control HFD 
HFD + omega-3 
fatty acid 
Glycation, oxidation and nitration free adducts (nM) 
MG-H1 525 ± 139 160 ± 41
***
 146 ± 40
***
 
CEL 6440 ± 410 5940 ± 3170 9130 ± 1620 
CML 4600 ± 1100 3560 ± 657
*
 4120 ± 1220 
CMA 14.0 ± 3.1 5.54 ± 1.13
***
 5.52 ± 2.75
***
 
3DG-H 862 ± 260 91.4 ± 56.5
***
 183 ± 41
***
 
FL 1870 ± 1298 188 ± 99
**
 - 
MetSO  435 ± 112 384 ± 115 450 ± 49 
NFK 67.4 ± 14.9 93.1 ± 21.9
*
 52.5 ± 20.1°° 
Amino acids (µM) 
Arg  80.4 ± 12.0 60.9 ± 11.1
**
 70.7 ± 15.8 
Lys 252 ± 52 276 ± 39 287 ± 54 
Met 94.1 ± 21.4 86.2 ± 9.6 98.2 ± 8.7 
Tyr 58.7 ± 12.3 69.4 ± 15.3 86.4 ± 19.6
**
 
Data are mean ± SD; n = 7 - 9.  Significance: *, ** and ***, P<0.05, P<0.01 and 
P<0.001, respectively, compared to control chow fed mice; °°, P<0.01 compared to 
HFD fed mice. 
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7.6. Localisation of insulin, collagen IV and MG-H1 residues in 
the mouse pancreas 
 Immunostaining was used to observe localisation of insulin, collagen IV and 
MG-H1 residues in sections of the mouse pancreas as well as any changes in 
localisation or co-localisation of these proteins and protein adducts following the 
different dietary regimes.  Sections of pancreas from control, HFD and HFD 
supplemented with omega-3 fatty acid fed mice were analysed for these markers.  
Additional controls were analysed from each pancreas for auto-fluorescence and 
non-specific binding of secondary antibodies – an example is show in Figure 48.  
This showed no significant non-specific binding of secondary antibodies.  Co-
staining for collagen IV and insulin in pancreas sections is shown in Figure 49.  
Small amounts of collagen IV were present around the immunostaining of insulin, 
but this was different in appearance to the extensive collagen IV network observed in 
other regions of the pancreas.  Co-staining of MG-H1 residues and insulin showed 
no clear co-localisation - Figure 50.  Background fluorescence was also higher in 
these sections.  Immunostaining for collagen and MG-H1 residues showed some co-
localisation, particularly in the sections from the pancreas of a HFD fed mouse – 
Figure 51.  There is a defined network of collagen IV within the pancreas sections; 
this is particularly evident in the pancreas sections from a control chow fed mouse.  
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Figure 48: Examples of Immunostaining control sections.  Representative 
sections showing (A) background fluorescence in HFD pancreas section and (B) 
staining using secondary antibodies alone in omega-3 fatty acid supplemented HFD 
pancreas section (goat anti-mouse 488 and goat anti-chicken 555).  Scale bar: 20 µm. 
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Figure 49: Immunostaining of collagen IV and insulin in the mouse pancreas.  
Co-staining of collagen IV and insulin in sections of the pancreas from (A) control 
chow fed mouse, (B) HFD fed mouse and (C) HFD supplemented with omega-3 
fatty acid fed mouse.  Scale bar: 20 µm. 
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Figure 50: Immunostaining of MG-H1 residues and insulin in the mouse 
pancreas.  Co-staining of MG-H1 residues and insulin in sections of the pancreas 
from (A) control chow fed mouse and (B) HFD fed mouse.  Scale bar: 20 µm. 
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Figure 51: Immunostaining of collagen IV and MG-H1 residues in the mouse 
pancreas.  Co-staining of collagen IV and MG-H1 residues in sections of the 
pancreas from (A) control chow fed mouse, (B) HFD fed mouse and (C) HFD 
supplemented with omega-3 fatty acid fed mouse.  Scale bar: 20 µm. 
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8. Discussion 
8.1. Effect of increased glucose concentration on pancreatic beta 
cell function – a possible role of dicarbonyl stress 
 In 1948 Dohan and Lukens showed that hyperglycaemia per se could play a 
pathogenic role in damage to the pancreas and development of diabetes (Dohan and 
Lukens, 1948).  Others showed that infusion of glucose in Sprague-Dawley rats for 
48 to 96 h caused a loss of GSIS (Leahy, et al., 1987).  However, modest increases 
in basal plasma glucose concentration from 4.7 to 6.0 mM for 53 h in adult humans 
increased beta cell function and insulin secretion (Flax, et al., 1991).  Loss of beta 
cell responsiveness to elevated glucose concentrations was termed “glucose toxicity” 
or “glucotoxicity” (Yki-Järvinen, 1992).  Mechanisms involved are thought to 
include oxidative stress – where dicarbonyl stress by methylglyoxal is also 
implicated, dysregulation of beta cell glucose metabolism and other mechanisms that 
disrupt normal nutrient sensing (Liu, et al., 1998; Nolan and Prentki, 2008; 
Robertson and Harmon, 2006). 
 Protein glycation may have a role in early stage beta cell dysfunction.  If so, 
it is unlikely to be via glucose-mediated glycation as this is relatively slow and 
unresponsive to IGT.  In addition, genetic knockout of fructosamine-3-kinase, 
responsible for FL repair, did not impair beta cell function (Pascal, et al., 2010).  
Rather, increased methylglyoxal formation and dicarbonyl stress are more likely 
involved as increased methylglyoxal formation occurs even in short term increases in 
glucose concentration (Beisswenger, et al., 2001).  The methylglyoxal scavenger, 
aminoguanidine, partly prevented glucotoxicity both in vitro and in vivo (Piercy, et 
al., 1998; Tanaka, et al., 1999; Thornalley, et al., 2000).  If methylglyoxal and 
related dicarbonyls have an important role in glucotoxicity, it is likely that inducers 
of endogenous enzymatic protection of dicarbonyl stress – particularly Glo1 inducers 
– will be more effective and potentially less toxic than dicarbonyl scavengers (Kim, 
et al., 2013; Xue, et al., 2012). 
 The glyoxalase system and dicarbonyl metabolism have not been 
characterised in insulinoma cell lines in vitro or in the pancreas in an in vivo study 
relating to diabetes or beta cell dysfunction.  Current research related to glycation 
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damage and diabetes is largely in the area of diabetic complications and how these 
can be limited and treated most effectively.  In this study methylglyoxal metabolism 
by the glyoxalase system is investigated in the MIN6 insulinoma cell line and in an 
in vivo model of insulin resistance – HFD fed C57BL6 mice, to advance 
understanding of dicarbonyl metabolism in beta cell dysfunction and glucotoxicity. 
 
8.2. The glyoxalase system and dicarbonyl metabolism in an in 
vitro beta cell line model – insulinoma MIN6 cells 
 MIN6 cells are widely used as a cell line model of pancreatic beta cells.  
Methylglyoxal, formed mainly from triosephosphate intermediates of glycolysis, 
reacts reversibly with GSH and protein thiols to form hemithioacetal adducts - 
Figure 52.  There are also initial reversible adducts of methylglyoxal with arg and lys 
residues of protein.  To characterise methylglyoxal metabolism by glyoxalase in 
MIN6 cells activities of Glo1 and Glo2, concentrations of methylglyoxal, GSH and 
protein thiols and flux of D-lactate formation were measured.  When exogenous D-
lactate was added to MIN6 cell cultures there was no significant metabolism of it, 
suggesting that formation of D-lactate by the glyoxalase system in this case 
represents flux of formation of methylglyoxal.  D-lactate is metabolised in 
mammalian cells by mitochondrial 2-hydroxyacid dehydrogenase (Thornalley, 
1993). 
 
 
Figure 52: Methylglyoxal in MIN6 cells – formation, protein glycation and 
metabolism by glyoxalase.  Key: DHimid, Dihydroxyimidazolidine; Gly, Glycosyl 
adduct; SLG, S-D-lactoylglutathione; HTA, hemithioacetal. 
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8.2.1. The effect of high glucose and dicarbonyl stress on 
dicarbonyl metabolism in MIN6 cells in vitro  
Incubation of MIN6 cells in high glucose concentration (20 mM) showed no 
decrease in cell growth or viability.  Glucose concentrations of up to 25 mM are 
routinely used in the culture medium for the growth of MIN6 cells by others (Cheng, 
et al., 2012b; Kelly, et al., 2010).  MIN6 cells could be cultured for up to 5 days 
without cell detachment.  Beyond this the viable cell number was decreased at six 
and seven days where cell detachment was evident.  
Activities of the glyoxalase enzymes were present in MIN6 cells whereas 
activities of methylglyoxal dehydrogenase and methylglyoxal reductase were not 
detected.  Measurement of enzymatic activities of Glo1 and Glo2 showed that the 
glyoxalase system was dominant – activities of methylglyoxal dehydrogenase and 
methylglyoxal reductase were below the limit of detection in MIN6 cells (<0.5 mU 
per million cells) and do not have a significant role in dicarbonyl metabolism in 
MIN6 cells.  This suggests that the glyoxalase system is the major defence against 
dicarbonyl stress in MIN6 cells.  Our research team has previously reported the 
metabolism of methylglyoxal to D-lactate in isolated rat pancreatic beta cells, 
indicating metabolism of methylglyoxal via the glyoxalase pathway in mature beta 
cells (Cook, et al., 1998).  Glo1 and aldoketo reductases metabolising methylglyoxal 
may be induced and the in situ activity of Glo1 is impaired by GSH depletion.  
Aldoketo reductases may therefore be important in supporting the detoxification of 
methylglyoxal in some circumstances (Rabbani and Thornalley, 2012c).  
The expression of Glo1 in MIN6 cells was not altered by either culture from 
passage 40 to passage 46 or by the glucose concentration in the medium.  The 
protective capacity of the glyoxalase system does not therefore deteriorate with 
passage over this range in this cell line, nor is its expression influenced by the 
glucose concentration within this physiological range.  The activity of Glo1 and 
Glo2 were not significantly altered when MIN6 cells were cultured in 20 mM 
glucose.  This demonstrates that in 20 mM glucose the protective capacity of the 
glyoxalase system in MIN6 cells is not increased, indicating that MIN6 cells are 
more at risk of glycation damage due to higher amounts of glucose and associated 
metabolites. 
The dicarbonyl content of MIN6 cells and culture medium were measured to 
indicate the cellular exposure of MIN6 cells to dicarbonyls and whether this was 
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altered by a higher concentration of glucose in the culture medium.  The content of 
MG, glyoxal and 3-DG in MIN6 cells in vitro was not altered by culture in media 
containing 20 mM glucose.  The media concentrations of MG and glyoxal were not 
affected by the glucose concentration.  The concentration of 3-DG in the medium 
increased 2.4-fold when cells were cultured in 20 mM glucose, compared to control 
cultures.  Methylglyoxal is formed mainly in the cytosol of cells and a minor fraction 
leaks from cells by passive diffusion of the unhydrated form across membranes.  
There is also a slow formation from spontaneous degradation of glycated protein and 
glucose in the medium (Thornalley, et al., 1999).  The methylglyoxal measured is 
the sum of free methylglyoxal and methylglyoxal bound reversibly to protein.  As 
Glo1 activity was not changed in high glucose cultures – nor was GSH (see later), 
the lack of increase in methylglyoxal concentration in cells and medium suggests 
that MIN6 cells are resistant to increases of triosephosphates when incubated in high 
glucose concentration.  This is consistent with previous studies showing that 
decrease of glyceraldehyde-3-phosphate dehydrogenase by ca. 36% in high glucose 
cultures or in hydrogen peroxide treatment did not increase triosephosphates in 
MIN6 cells (Sakai, et al., 2003).  Lack of increase in glyoxal is consistent with no 
marked increase in lipid peroxidation.  Increased 3-DG concentration in the culture 
medium may relate to increased degradation of glucose in culture medium to 3-DG 
non-enzymatically.  
Cellular glutathione content was analysed to indicate whether this could 
affect the in situ activity of the glyoxalase system.  Total glutathione in MIN6 cells, 
GSH + 2 x GSSG, was ca. 880 pmol per 10
6
 cells.  This is intermediate between ca. 
200 and 3000 pmol per 10
6
 cells of previous reports – determined by redox cycling 
assays (Kaneko, et al., 2009; Kondo, et al., 2000).  The proportion of total 
glutathione present as GSSG (2.5%) is also much lower than the 36% previously 
reported (Kitiphongspattana, et al., 2007).  Kitiphongspattana et al. (2007) likely 
oxidised the cell extracts during sample processing.  The assay for GSH and GSSG 
developed herein using stable isotopic dilution analysis LC-MS/MS has higher 
specificity, sensitivity and analytical recovery than previous techniques and is likely 
an improved estimate.  There were no differences in the GSH or GSSG content of 
MIN6 cells cultured in 5.5 mM or 20 mM glucose, indicating that the in situ activity 
of Glo1 is not impaired or enhanced by change in the cellular content of GSH.  In 
addition, this also showed that the absolute cell content of GSSG and GSSG/total 
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glutathione were not affected by the glucose concentration.  An increase in absolute 
cell content of GSSG and GSSG/total glutathione would be indicative of an increase 
in oxidative stress.  Lack of change suggests that there is no evidence of increased 
cytoplasmic oxidative stress in high glucose cultures.  MIN6 cells incubated in high 
glucose concentration do not appear to suffer marked oxidative stress – as previous 
reports have suggested (Sakai, et al., 2003).  This was further supported by no 
differences in the total thiol or the protein thiol content in MIN6 cells cultured in 
vitro in the two different glucose conditions.  Previous estimates of increased 
formation of ROS in MIN6 cells in high glucose appear to have been rates of ROS 
formation within the ability of the cells to metabolise them and prevent oxidative 
damage (Sakai, et al., 2003). 
The rate of formation of D-lactate by MIN6 cells in control cultures was 1.02 
± 0.34 nmol per 10
6
 cells per day or 0.0771 ± 0.0161% of glucotriose flux.  This was 
a slightly higher rate of formation, than found in the transformed endothelial cell 
line, HMEC-1, where the rate of formation of D-lactate in cultures with 5 mM 
glucose was ca. 0.4 nmol per 10
6
 cells per day and ca. 0.04% of glucotriose flux (Z 
Irshad, unpublished observations).  The rate of formation of D-lactate by MIN6 cells 
increased 41% cultured in high glucose in vitro, compared to 5.5 mM glucose.  This 
indicates a higher flux of formation of D-lactate, and hence a higher flux of 
methylglyoxal through the glyoxalase system.  With unchanged activity of Glo1, 
GSH or protein thiols this is expected to have produced a similar increase in cellular 
methylglyoxal concentration but this was not found.  The concentration of L-lactate 
was not altered by culture in medium containing 5.5 or 20 mM glucose.   
The rate of glucose consumption increased 28% when MIN6 cells were 
incubated in 20 mM glucose, and consequently the proportion of glucotriose leading 
to formation of D-lactate was unaltered.  Therefore, the increased metabolism of 
glucose by MIN6 cells in 20 mM glucose only increased the flux of formation of 
methylglyoxal proportionate to the increase in glucose metabolism.  There was no 
evidence for increased ‘leak’ of methylglyoxal from glycolysis in high glucose.  This 
was different to the increased proportion of glucotriose flux converted to 
methylglyoxal in high glucose concentration, as found for red blood cells  
(Thornalley, 1988).  The increased rate of glucotriose metabolism and D-lactate 
formation in hyperglycaemia, therefore, appears to be ca. 28 – 41%.  With no change 
in Glo1 activity, GSH and protein thiols a similar increase in cellular concentration 
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of methylglyoxal was expected. Relatively high data dispersion in methylglyoxal 
measurement may have obscured detection of this. 
Protein glycation, oxidation and nitration adduct residues were measured in 
cytosolic protein of MIN6 cells herein for the first time.  Quantification of glycation, 
oxidation and nitration adduct residues on cellular protein of MIN6 cells indicated 
that glycation, oxidation and nitration adducts were present on the protein.  The 
major AGE residue was MG-H1 at 0.351 mmol/mol arg.  This is similar to the level 
previously reported in the mouse brain cortex (Kurz, et al., 2011).  CEL residue 
content was ca. 8-fold lower, as expected for the arginine-directed glycation of 
methylglyoxal (Thornalley, 2005).  FL residue content was relatively low at 0.85 
mmol/mol lys.  There were no significant changes in the amount of protein glycated, 
oxidised or nitrated in MIN6 cells incubated in 5.5 mM and 20 mM glucose in vitro.  
There was also no change in the CML/FL residue ratio – a marker of oxidative stress 
(Knecht, et al., 1991).  This suggests there is no detectable increase in proteome 
damage by glycation, oxidation and nitration in the cytosol of MIN6 cells incubated 
in high glucose concentration. 
Glycated, oxidised and nitrated cellular proteins undergo cellular proteolysis 
and related glycation, oxidation and nitration free adducts are released into the 
culture medium.  The flux of formation of these was measured in MIN6 cell cultures.  
Some free adducts are further metabolised - NFK and MetSO – and fluxes could not 
therefore be deduced.  The production of MG-H1, CEL, CML and CMA was not 
affected by the culture of MIN6 cells in 5.5 mM or 20 mM glucose, although these 
markers were produced indicating clearance of protein glycated by both MG and 
glyoxal from MIN6 cells.  The flux of formation of FL and 3DG-H free adducts in 
MIN6 cells in vitro was increased ca. 4.1-fold and 2-fold, respectively, when MIN6 
cells were cultured in 20 mM glucose.  There are contributions to the formation of 
FL and 3DG-H free adducts by the direct reaction of glucose with lysine (798 µM) 
and 3-DG with arginine (398 µM) in the DMEM culture medium.  Glucose (5.5 mM 
and 20 mM) is present in the culture medium and methylglyoxal, glyoxal and 3-DG 
are present from that in serum and that formed by degradation of glucose and serum 
protein glycated by glucose (Thornalley, et al., 1999).  The rate of formation of 
glycation free adducts in the culture medium and contributions from the medium 
were deduced.  Greater than 90% of FL free adduct formation occurred in the 
medium.  This is because the glucose concentration is low inside MIN6 cells and the 
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cell volume is low - ca. 0.1% of the volume of the culture.  In addition, FL may be 
deglycated in cells by fructosamine-3-phosphokinase (Pascal, et al., 2010).  In 
contrast, the flux of formation of the dicarbonyl derived AGEs originate mainly from 
the cells.  This is because the concentration of the dicarbonyls is 10 – 100 fold higher 
inside cells, and arg and lys residues inside cells are ca. 100 fold higher than the lys 
and arg concentration in the medium.  Therefore, although the volume of the 
medium is ca. 1000-fold greater than the volume of the MIN6 cells in the medium, 
the markedly higher rate of dicarbonyl glycation inside cells contributes mostly to 
the flux of dicarbonyl-derived AGE formation.   
Analysis of the basal expression of Ins1 and Ins2 in MIN6 cells confirmed 
that these genes are expressed.  Whilst MIN6 cells are known to secrete insulin in 
response to glucose and this expression was therefore expected, it was important to 
confirm this in our cell line model, since glucose responsiveness, insulin expression 
and secretion have all been reported to be diminished with continued passage of 
MIN6 cells (Cheng, et al., 2012b; Roderigo-Milne, et al., 2002).  Consistent with 
this, a decrease in the expression of Ins1 and Ins2 mRNA was observed from 
passage 40 to passage 46.  The observed decline in Ins1 expression was greater than 
the decline in Ins2 which led to a decrease in the ratio of Ins1:Ins2 in the MIN6 cells.  
Roderigo-Milne et al. (2002) suggested that there may be differential regulation of 
these genes which leads to a shift in this ratio in some circumstances.  It was also 
suggested that Ins1 mRNA expression was both diminished more than Ins2 mRNA 
expression by repeated passage, - consistent with the results in section 5.3, and also 
more responsive to glucose stimulation and cell-cell contacts than Ins2.  Incubation 
of MIN6 cells in 20 mM glucose led to a decrease in the ratio of Ins1:Ins2 at passage 
40 compared to the mRNA expression ratio observed in control MIN6 cells of the 
same passage cultured alongside in 5.5 mM glucose.  Whilst the connection between 
this insulin expression ratio and insulin secretion and glucose responsiveness is not 
conclusive, a similar shift to that observed in the current study was reported by 
Roderigo-Milne et al. (2002) with continued passage when insulin secretion and 
glucose responsiveness are known to decline.  Therefore a similar mechanism could 
underlie this shift in ratio – a loss of glucose responsiveness and insulin secretion 
with prolonged exposure to high glucose.  This shift in insulin mRNA expression 
ratio was no longer apparent at passage 46, when the insulin expression had declined 
for both Ins1 and Ins2.  Based on the expression of these genes and the physiological 
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impairments reported in high passage MIN6 cells, all experiments were performed 
over the passage range 40 - 45 to limit the decline in insulin expression. 
The efficient metabolism of dicarbonyls in MIN6 cells is emphasised further 
in experiments with exogenous methylglyoxal.  Approximately one third of a bolus 
dose of 500 µM MG had been metabolised by MIN6 cells in vitro within 30 min.  
The cellular methylglyoxal increased 2-fold.  This also highlights the limitation of 
studies which use high exogenous doses of MG to treat cells.  It is rapidly 
metabolised and consequently the physiological effects are difficult to judge, 
especially of concentrations to which cells would not be exposed endogenously.  
Incubation of MIN6 cells in vitro with the cell permeable inhibitor of glyoxalase 1, 
BrBzGSHCp2 indicated that the potency and cytotoxicity of this cell permeable Glo1 
inhibitor was less than previously reported in other cell types, potentially due to 
differences in esterase activity, necessary to cleave the BrBzGSHCp2 rendering the 
active form.  It has previously been shown that 1 µM is sufficient to increase 
dicarbonyl levels in the endothelial cell line HMEC-1 and that 10 µM is cytotoxic to 
HL60 cells, decreasing viability to below 10% (Dobler, et al., 2006; Thornalley, et 
al., 1996).  In MIN6 cells 10 µM BrBzGSHCp2 was necessary to elicit increases in 
dicarbonyl levels and the GC50 was 27.3 ± 0.9 µM.   
Incubation of MIN6 cells in vitro with 10 µM BrBzGSHCp2 for 48 h resulted 
in an increase in the cellular content of methylglyoxal only when incubations of low 
and high glucose were combined.  Incubation of MIN6 cells in vitro with 10 µM 
BrBzGSHCp2 for 48 h also resulted in ca. a 2-fold increase in cellular GSH and 
GSSG content, when compared to the content in control MIN6 cells incubated 
alongside.  The increase in cellular GSSG may be due to inhibition of glutathione 
reductase by BrBzGSHCp2.  However, the concurrent increase in GSH means that it 
is more likely that this treatment is increasing GSH synthesis or impairing 
glutathione export from MIN6 cells.  Increased GSH content of cells will increase 
the in situ activity of Glo1 and thereby provide resistance to decreases in the in situ 
activity of Glo1 and increases in methylglyoxal concentration. 
The expression of Glo1 and the insulin genes were also altered following 
treatment with BrBzGSHCp2.  Ins1 expression increased when cells were treated 
with BrBzGSHCp2, indicative of a potential increase in insulin production and 
secretion capacity, whilst the combination of high glucose and BrBzGSHCp2 led to a 
decrease in Glo1 expression compared to the expression in control untreated MIN6 
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cells in low glucose.  However, it could not be determined whether these changes 
were actually due to the increases in dicarbonyls observed with this treatment, or 
whether they were due to other disturbances in cell metabolism related to the 
changes in glutathione and potential inhibition of glutathione reductase. 
 
8.2.2. The effect of glycation of ECM collagen IV on MIN6 cells 
in vitro  
Glycation of ECM proteins by methylglyoxal and effect on cell function has 
been investigated previously by this group and others: detachment of human HMEC-
1 and aortal endothelial cells from collagen IV modified minimally by 
methylglyoxal; peripheral neurone detachment from laminin and fibronectin 
modified minimally by methylglyoxal; fibrosarcoma HT1080 and osteosarcoma 
MG63 cell detachment from collagen I with mild methylglyoxal modification; and 
detachment of mesangial cells from collagen IV modified by methylglyoxal   
(Dobler, et al., 2006; Duran-Jimenez, et al., 2009; Paul and Bailey, 1999; Pozzi, et 
al., 2009).  ECM proteins typically have a long half-life, and this, combined with 
their important physiological function has long made them an interesting target of 
glycation research.  Other research has focussed on the interactions between 
pancreatic beta cells and components of the basement membrane (Iino, et al., 2004; 
Nikolova, et al., 2006; Weber, et al., 2008).  Basement membrane proteins are 
known to be essential to pancreatic beta cell function – isolated primary islets can 
only survive in culture with the addition of ECM proteins in their culture 
environment.  The beneficial effects on beta cell physiology have been demonstrated 
in beta cell lines.  However, whilst these studies have indicated the importance of 
ECM and basement membrane proteins to pancreatic beta cells, the effect of 
glycation of collagen IV or other basement membrane proteins on the adhesion and 
function of beta cells has not been investigated. 
Incubation of type IV collagen in culture plates overnight led to the adhesion 
of 33% of this collagen – washing the wells with Triton X-100 was necessary to 
remove adhered collagen IV.  Collagen coated plates were incubated with 
methylglyoxal for 24 h at 37 °C which was sufficient to modify the collagen.  The 
concentrations of methylglyoxal herein are comparable to the concentrations 
observed in physiological systems and the increases typically observed in diabetes.  
Since plates were washed following incubation of collagen with methylglyoxal, any 
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remaining methylglyoxal is adhered to collagen and therefore not free in solution to 
directly enter and affect MIN6 cells.  Previous studies have characterised this 
glycation of collagen IV and shown that incubation of collagen IV with MG results 
in an increase in MG-H1 adduct residue formation on collagen with specific 
modifications occurring on the arginine motifs of the integrin binding sites (Dobler, 
et al., 2006). 
Coating of culture plates with collagen IV increased cell adhesion.  This is in 
agreement with previous studies investigating the effect of ECM proteins on 
adhesion in the beta cell line MIN6 in vitro (Iino, et al., 2004; Weber, et al., 2008).  
In addition, culture of primary islets necessitates the presence of ECM proteins to 
prevent anoikis.  The benefits of collagen IV to cultured MIN6 cells, both in this 
study and reported in the literature, is consistent with the effects seen in primary 
tissue, although adherence and survival of MIN6 is possible without collagen.  These 
effects were due to the specific interactions between MIN6 cells and collagen IV via 
integrin binding sites since adhesion was blocked by pre-incubation of cells with 
both the peptide RGD and an anti-Itgb1 antibody. 
Plated collagen IV was glycated by incubation with methylglyoxal and the 
interactions of MIN6 cells with MG-glycated collagen IV were investigated.  It was 
hypothesised that the increase in MG-H1 adduct residue formation on the integrin 
binding sites of collagen IV would block the binding sites and be detrimental to cell 
adhesion – as has been previously reported in both endothelial cells and in 
fibrosarcoma HT1080 and osteosarcoma MG63 cell lines (Dobler, et al., 2006; Paul 
and Bailey, 1999).  However, herein the addition of increasing concentrations of 
methylglyoxal increased the proportion of adhered MIN6 cells in vitro.  This 
appeared to be due not to an increase in the number of cells directly attached to the 
glycated collagen IV substrate, but rather, due to an increase in clustering of MIN6 
cells that were not attached.  Therefore, although there was an increase in adhesion 
measured by cell counting, this is likely due to an increase in cell-cell contacts, in 
spite of an actual decrease in the number of cells directly attached to the plate.  This 
is consistent with experimental observations that cells cultured on MG-modified 
collagen IV appeared looser and in clusters when viewed under a microscope and 
less appeared to be directly attached to the culture plate.  This potentially indicates 
an experimental limitation of this adhesive beta cell line which is known to form 
clusters and pseudo-islets in culture.  The same effect of MG-glycated collagen IV 
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on MIN6 cells was observed with both human and mouse collagen IV.  The increase 
in adhesion when collagen IV was modified by methylglyoxal was unexpected.  
Additionally, it is unlikely that this was actually due to an increase in the interactions 
between cells and the basement membrane protein collagen IV.  Therefore, these 
cell-extracellular matrix interactions were investigated at the single cell level by use 
of AFM-FS to determine the energy required to separate individual MIN6 cells from 
collagen and MG-glycated collagen.  These experiments showed a substantial 
decrease in the total energy required to separate a single MIN6 cell from collagen IV 
both when the collagen was glycated with MG and when cells were pre-incubated 
with the integrin blocking peptide RGD.  The maximum unbinding force also 
decreased when collagen was modified by methylglyoxal.  These results indicate that 
MG-glycation of collagen IV is detrimental to adhesion of the cell line MIN6 in 
vitro.  The specific integrin interaction of MIN6 cells with collagen IV is blocked by 
formation of MG-H1 adduct residues, and consequently the energy required to 
detach cells from the basement membrane protein is vastly decreased.  This is 
suggestive of an increase in cell detachment and anoikis if similar effects are 
observed with beta cells in vivo.  In addition, if cells remain adhered, albeit loosely, 
perhaps through a decline in the number of functional attachment sites, this may 
impair communication between beta cells and the basement membrane and 
consequently ablate beta cell function. 
Expression of genes associated with communication between beta cells, 
communication between beta cells and the basement membrane, the glyoxalase 
system and insulin were analysed to assess whether the plated collagen substrate 
affected these aspects of beta cell function.  Glo1 mRNA expression was unaltered 
by plating on uncoated, collagen IV or MG-glycated collagen IV coated plates. 
The mRNA expression of Ins2 in MIN6 cells was not significantly different 
between the three culture conditions, whereas the expression of Ins1 increased in 
MIN6 cells cultured on collagen, compared to those in uncoated wells.  However, 
this increase was small.  Previous studies have shown beneficial effects of collagen 
IV on insulin gene expression and secretion.  Nikolova et al. (2006) demonstrated 
that both Ins1 and Ins2 mRNA expression increased when MIN6 cells were cultured 
on collagen IV, compared to expression in control cells on uncoated plates.  
However, the control uncoated plates used were non-tissue culture-treated and the 
authors do not state the effect of using non-tissue culture plates for culture on 
186 
 
adhesion or other cellular effects of MIN6 cells in vitro.  In addition, their 
experiments were performed with incubations of 3 - 4 days and the exact culture 
period is not stated.  It is not therefore known whether the experimental protocol is 
comparable to expect similar changes in insulin gene expression.  The beneficial 
effect of collagen IV and another basement membrane protein, laminin, was also 
demonstrated by Weber et al. (2008).  They established that when MIN6 cells were 
cultured in a three-dimensional poly(ethylene glycol) hydrogel the presence of 
basement membrane proteins markedly increased the measured GSIS.  However, 
insulin gene expression was not reported in this study.  Earlier work by Kaido et al. 
(2004) demonstrated in human adult beta cells that the beneficial effect of collagen 
IV on insulin secretion was specific and occurred through the integrin heterodimer 
α1β1.  Whilst these studies have demonstrated the favourable effects of collagen IV 
on insulin gene expression and more noticeably on insulin secretion, the effects of 
glycation of collagen IV on insulin gene expression or secretion has not been 
reported.  This project has demonstrated that there is no significant effect of MG-
glycation of collagen IV on insulin gene expression in cultured MIN6 cells.  
Culture of MIN6 cells for three days on collagen IV glycated by 
methylglyoxal resulted in a decrease in the mRNA expression of Itgb1 compared to 
expression in cells cultured on control collagen IV alone.  Methylglyoxal has been 
shown to modify arginine motifs of the integrin binding sites on type IV collagen, 
and thereby block the interaction with the cellular integrin receptors.  The 
subsequent down-regulation of Itgb1 suggests negative feedback, down-regulating 
Itgb1 when receptors have no substrate with which to bind.  However, the existence 
of such a mechanism would need to be investigated further at the protein level to 
determine whether this decrease in mRNA expression actually translates into a 
decrease in the active protein within the cells. 
 E-cadherin is involved in communication between beta cells within the islets 
of Langerhans.  It is a developmental gene and its expression declines within beta 
cells when the organ is fully developed and there is sufficient cell-cell adhesion.  It 
has been described as an adhesive molecule involved in the maintenance of viability 
and an increase in apoptosis has been reported in E-cadherin negative beta cells 
(Parnaud, et al., 2011).  Additionally, down-regulation of E-cadherin using RNAi 
has previously been shown to decrease GSIS in confluent MIN6 cells (Jaques, et al., 
2008).  Therefore the decrease in E-cadherin mRNA expression in MIN6 cells 
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cultured in vitro on MG-glycated collagen IV could be implicated in impaired GSIS, 
potentially via a loss of beta cell to beta cell communication.  Impairment in GSIS is 
often observed in beta cell dysfunction in the pathogenesis of diabetes.  
Alternatively, the decrease in E-cadherin may result in an increase in cell apoptosis, 
and consequently a decrease in beta cell mass if these effects are also observed in 
vivo and the decline in mRNA expression is severe enough.  However, since E-
cadherin expression is also known to decrease when the islets are fully formed and 
sufficient cell-cell contacts have been made, this decrease in E-cadherin could be a 
consequence of the cell clustering observed when MIN6 cells were cultured on MG-
glycated collagen IV.   
 Cx36 is involved in communication between pancreatic beta cells.  It is 
necessary for the control of insulin biosynthesis and secretion from beta cells as well 
as for survival under cell stress (Cigliola, et al., 2013).  Alterations in Cx36 
expression or in downstream signalling may be implicated in altered beta cell 
function and the pathogenesis of diabetes.  The decrease in Cx36 expression 
observed in MIN6 cells cultured on MG-glycated human collagen may suggest 
impaired insulin secretion or even beta cell survival.  It also suggests interplay 
between cell-cell and cell-extracellular matrix interactions, with impaired cell-
extracellular matrix interactions resulting in attenuation of cell-cell communication 
through a decrease in both E-cadherin and Cx36 expression.  However, this decrease 
in Cx36 expression could not be reliably reproduced in MIN6 cells cultured on MG-
glycated mouse collagen IV, potentially due to the higher variability observed 
between replicates.  
 Studies with similar insulinoma cell lines, INS-1 and HIT-T15, treated with 
both exogenous methylglyoxal and AGEs to investigate dicarbonyl stress have been 
reported (Fiory, et al., 2011; Puddu, et al., 2012).  The supraphysiological levels of 
methylglyoxal and AGE-modified protein used, however, suggest findings and 
related conclusions may have limited physiological relevance.  
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8.3. Studies with the HFD fed mouse model of insulin resistance 
and beta cell dysfunction: the effects of HFD and omega-3 
fatty acid supplementation on the glyoxalase system and 
dicarbonyl metabolism 
 The HFD fed C57BL6 mouse is a well-studied model of insulin resistance 
and the development of diabetes.  The induction of T2DM in mice by HFD was first 
reported in 1988 where it was shown to exhibit a genetic predisposition to develop 
the disease (Surwit, et al., 1988).  These mice had elevated fasting blood glucose and 
insulin levels and at the time it was suggested that this model would be relevant in 
advancing understanding of the pathophysiology of T2DM in humans.  Since then, 
other studies have confirmed insulin resistance and impaired glucose tolerance in 
this animal model (Hancock, et al., 2008; Kuda, et al., 2009; Souza-Mello, et al., 
2010; Winzell and Ahrén, 2004).  Data from the current study is consistent with 
these previous reports.  Fasting plasma glucose and insulin concentrations increased 
markedly and glucose tolerance was impaired in mice fed a HFD.  This was related 
to increased weight gain compared to control animals, as a result of an increase in 
food intake.  Consequently, cholesterol, fatty acids and lipids measured in the plasma 
and liver also increased.  In addition, it was shown that supplementing the HFD with 
LC-PUFA - omega-3 fatty acids - improved glucose homeostasis.  Measurements of 
fasting insulin and glucose tolerance, hepatic steatosis and cholesterol were still 
significantly higher than in control chow fed mice but showed large improvements 
when compared to HFD fed mice, indicative of improved glucose tolerance and less 
insulin resistance when the HFD was supplemented with LC-PUFA.  Plasma NEFA 
and triglyceride concentrations were also comparable with those observed in control 
chow fed mice.  These findings are consistent with recent reports indicating that 
HFD supplementation with omega-3 fatty acids prevents some of the metabolic 
changes observed in insulin resistance (Jilkova, et al., 2013; Kuda, et al., 2009; 
Rossmeisl, et al., 2009). 
Analysis of gene expression from the pancreatic samples proved problematic.  
This was due to the heterogeneity of the pancreas and so whilst there was a high 
amount of measurable mRNA in the pancreas, the mRNA of genes of interest was 
difficult to detect and quantify, most likely due to the high amount of digestive 
enzymes and other proteins within the exocrine pancreas.  Consequently, Ins2 and 
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Glo1 were below the limit of quantification in the pancreas.  Analysis of Ins1 
indicated no difference in expression in the pancreas of mice fed the three dietary 
regimes.  This is despite an increase in the fasting insulin concentration in the plasma 
of HFD fed and HFD supplemented with omega-3 fatty acid fed mice.  The changes 
in plasma concentration may also be explained at the protein level, without changes 
in the mRNA expression occurring – rather, changes in insulin secretion and in the 
regulation of protein translation.   
It has been suggested that the concentration of inflammatory cytokines 
increases in the pancreas of HFD fed rats (Yan, et al., 2012).  However, herein data 
failed to show a change in ICAM-1 mRNA expression in the pancreas of HFD fed 
mice.  This discrepancy may be due to the sample heterogeneity or to differences in 
the study protocol or species investigated – the study by Yan et al. (2012) was 
performed over 20 weeks in Wistar rats.  In addition, Mathur et al. (2007) associated 
the inflammatory markers TNF-α and interleukin-1β (IL-1β) in the mouse pancreas 
with an increase in pancreas mass in obesity; a similar increase in pancreas mass was 
not observed in the current study.  However, the study by Mathur et al. (2007) has 
limitations: - samples were pooled from all mice for analysis and control C57BL6J 
mice were compared to leptin deficient obese mice.  Differences observed may 
therefore be due to strain differences or differences in leptin metabolism and not 
necessarily due to obesity or insulin resistance.  Inflammation and ICAM-1 
expression were not followed up further and remaining analysis instead focussed on 
the glyoxalase system and examining the effects of these dietary regimes on 
dicarbonyl stress. 
Activities of the glyoxalase system enzymes and the D-lactate and total thiol 
content of the pancreas gave an indication as to the effect of diet-induced insulin 
resistance and diabetes on dicarbonyl metabolism by the glyoxalase system in the 
pancreas.  Studies quantifying these analytes in the pancreas following these dietary 
treatments is lacking, indeed dicarbonyl stress in the pancreas has not been examined 
in either an in vivo or in vitro model.  The current study showed that there were no 
alterations in the glyoxalase enzymatic activities or in the amount of D-lactate in the 
pancreas following these different diets.  Therefore there are no alterations in 
methylglyoxal flux through the dicarbonyl system or in the activity of the enzymes 
responsible for this metabolism.  Since there was no change in the metabolism of 
dicarbonyls in the pancreas, the steady state amount of dicarbonyls was measured in 
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the pancreas to indicate whether there were any changes in the cellular exposure to 
these reactive damaging metabolites.  This indicated that there was an increase in 
methylglyoxal in the pancreas in both the HFD fed mice and the omega-3 fatty acid 
supplemented HFD fed mice.  Glyoxal increased when the HFD was supplemented 
with omega-3 fatty acids, consistent with an increase in lipid peroxidation, but there 
was no increase in glyoxal in the HFD group compared to the levels observed in the 
control group.  The decrease in 3-DG observed in the pancreas following HFD 
feeding is consistent with a decrease in glucose and fructose metabolism in the 
presence of high amounts of lipids.  There were no changes in the amount of 
dicarbonyls in the plasma which implies that the changes observed in the pancreas 
are a result of altered pancreatic metabolism and not due to an increased flux coming 
from the plasma.  This is consistent with the concentration of these analytes being 
higher in the pancreas than observed in the plasma. 
The higher amount of methylglyoxal in the pancreas of HFD fed mice 
indicates that there would be an increase in glycation of protein by methylglyoxal.  
Consequently, glycation, oxidation and nitration adduct residues on cytosolic and 
extracellular matrix proteins within the pancreas and plasma proteins were measured 
to assess damage by methylglyoxal or other metabolites.  These experiments 
indicated that there was a higher degree of glycation by methylglyoxal in the 
pancreas than in the plasma, as shown by the higher levels of MG-H1, MOLD and 
ornithine adducts, - consistent with the higher exposure of the pancreas to 
methylglyoxal.  However, despite an increase in the methylglyoxal content of the 
pancreas in the HFD fed mice, there were no differences in the levels of these MG-
glycation adducts within the pancreas, in either cytosolic or ECM protein, following 
the different dietary regimes.  MOLD did however increase in the plasma, suggesting 
an increase in exposure to methylglyoxal resulted in this glycation.  Other changes in 
the pancreas suggest a decrease in glycation by both glyoxal (CMA adduct residues) 
and 3-DG (3DG-H adduct residues) as well as oxidative stress (MetSO) following 
HFD feeding.  This is contrary to expectations of an increase in glycation damage, 
especially given the higher methylglyoxal content, and also contrary to published 
reports of increased oxidative stress following HFD and in insulin resistance 
(Kondo, et al., 2013; Matsuzawa-Nagata, et al., 2008; Yan, et al., 2012).  Similarly, 
changes in glycation and oxidation adduct residues on ECM protein within the 
pancreas were small – an increase in CML was observed when HFD was 
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supplemented with omega-3 fatty acids, consistent with the increase in glyoxal in 
this group.  This was in combination with both decreased FL and an increase in the 
CML/FL ratio, indicative of increased oxidative stress.  However, there were no 
corresponding changes in MetSO, dityrosine or NFK and consequently no further 
indications of oxidative stress in the pancreatic ECM protein.  Given the long half-
life associated with ECM proteins, such as collagen IV, it was anticipated that 
increased glycation and oxidation would be observed.  It is therefore hypothesised 
that these findings are due to an increase in protein turnover and clearance in the 
HFD stressed mice, with associated metabolic disturbances.  
In the plasma there were both increases in MOLD formation and decreases in 
CEL formation following a HFD.  These are both methylglyoxal derived adduct 
residues, and with MG-H1 adduct formation unaltered there is no significant overall 
change in methylglyoxal derived glycation adducts.  The glyoxal derived 
hydroimidazolone, G-H1 was also lower in the plasma of mice fed a HFD 
supplemented with omega-3 fatty acid than in plasma of mice fed a HFD without 
supplementation.  This is consistent with the lower plasma NEFA and triglyceride 
levels in this treatment group, and may occur as a result of less lipid peroxidation 
decreasing the glyoxal exposure of plasma proteins.  The increase in FL adduct 
residues on plasma protein is indicative of an increase in early stage glycation by 
glucose when plasma glucose levels are increased in the diabetic state following a 
HFD.  The ratio of CML to FL decreased as a result of the increased FL formation, 
indicating no alteration in the oxidative formation of CML from FL when higher 
amounts of FL were present.  The increase in MetSO formation was however 
suggestive of an increase in oxidative stress in the plasma of mice fed a HFD. 
Analysis of the free adducts of these markers in the pancreas indicated 
substantial decreases in a number of glycation markers following a HFD feeding 
regime including: the hydroimidazolones and other dicarbonyl glycation adducts – 
MG-H1, G-H1, 3DG-H and CMA; and the early stage glucose glycation adduct, FL.  
This was contrary to expectations of increased free adducts if an increase in protein 
turnover in the HFD fed mice accounts for the lack of increases in glycation adducts 
on pancreatic protein.  Consequently, it is hypothesised that this increased protein 
turnover is in combination with increased clearance of damaged adducts from the 
pancreas during metabolic stress.  In addition, the free amino acid concentration of 
both arginine and tryptophan were decreased indicative of a lower amino acid 
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bioavailability, perhaps due to the increased protein turnover suggested herein.  
Other measured amino acids were not significantly altered by these different diets.   
In the plasma the free adduct concentrations of MG-H1, CMA, CML, 3DG-H 
and FL were lower following a HFD than following a diet consisting of control 
chow.  This was in combination with a decrease in the free arginine concentration, 
but no significant alterations in other measured amino acids.  In addition, the free 
adduct concentration of NFK increased in HFD, but not when the diet was 
supplemented with omega-3 fatty acids; this change is indicative of an increase in 
oxidative damage in the plasma of mice following a HFD.  Supplementation of the 
HFD with omega-3 fatty acid goes some way to prevent this oxidative damage.  
Together these changes are consistent with the changes observed in the pancreas and 
are suggestive of a combination of increased protein turnover and increased renal 
clearance of damaged protein and damaged protein adducts following a HFD.  It has 
previously been reported that despite autophagy being down-regulated in a number 
of insulin-sensitive tissues in the insulin resistant state, the activity in the pancreas, 
and in particular beta cells, is in fact increased and consequently an increase in 
protein turnover would therefore be expected (Chen and White, 2011; Ebato, et al., 
2008; Jung, et al., 2008; Yoshizaki, 2012).  However, measurement of these damage 
marker adducts in urine with indications of increases in glycation markers are 
necessary for this hypothesis to be conclusive. 
Analysis of free citrulline in both the pancreas and plasma indicated no 
change in the free adducts.  Free adducts in the pancreas were 69.5 ± 7.2, 70.5 ± 8.6 
and 65.3 ± 11.1 pmol per mg wet weight in control, HFD fed and HFD supplemented 
with omega-3 fatty acid fed mice, respectively (n = 6 - 7).  Free adducts in the 
plasma were 34.0 ± 4.2, 30.2 ± 6.6 and 31.5 ± 5.8 µM in control, HFD fed and HFD 
supplemented with omega-3 fatty acid fed mice, respectively (n = 8 - 9).  This is 
contrary to recent reports of elevated systemic citrulline combined with a decrease in 
the arginine bioavailability in diet-induced obese mice (Sailer, et al., 2013).  These 
effects were tissue specific, with arginine and citrulline bioavailability unchanged in 
the intestine and kidney.  The data herein showed decreased plasma and pancreas 
arginine following HFD and HFD supplemented with omega-3 fatty acids, 
respectively, indicative of disturbances in arginine metabolism following a HFD. 
 Immunostaining of collagen IV and insulin in the pancreas indicated that 
collagen IV is present within the islets of Langerhans and that this provides 
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structural integrity.  No differences were observed in the localisation of these 
proteins in pancreatic sections from mice fed the different diets.  Sections were also 
immunostained for both MG-H1 and insulin and MG-H1 and collagen IV in 
combination.  This indicated that MG-H1 and insulin do not co-localise; whilst 
sections showed both MG-H1 and insulin staining, the MG-H1 appears to surround 
the islet and not occur within it.  In addition, this immunostaining potentially shows 
a higher degree of MG-H1 staining in the pancreas sections from a HFD fed mouse 
than from a control chow fed mouse.  This was again noted in the sections co-stained 
for MG-H1 and collagen IV; pancreas sections from HFD fed mice demonstrated 
more staining for MG-H1 than observed in sections from control chow fed mice.  
Furthermore, this staining is ECM localised – it displays similar localisation to 
observed for collagen IV.  In HFD fed mice pancreas sections co-localisation of 
collagen IV and MG-H1 was observed, indicating that the MG-H1 adduct residues 
were likely adducts on collagen IV.  These images show methylglyoxal-modification 
of ECM proteins within the pancreas and also indicate an increase in the MG-H1 
residues, although this could not be confirmed by LC-MS/MS quantification.  
Staining of collagen IV displays an extensive and well-defined network in the 
pancreas; this is clearest in the sections from the control pancreas.  This may be due 
to disruption of the collagen IV network by glycation following HFD, hence the 
corresponding increase in MG-H1 adduct immunostaining, or alternatively the 
increased lipid content following HFD may have interfered with this structure.  
 
8.4. Other advances: quantification of GSH and related 
metabolites by LC-MS/MS 
 Application of LC-MS/MS for detection of metabolites gives high selectivity 
and sensitivity and has been used routinely for quantification analysis in a variety of 
matrices.  Published estimates of GSH and GSSG vary due to differences in both 
sample preparation and assay methodology – values obtained by different 
investigators span two orders of magnitude (Rossi, et al., 2002).  Chromatographic 
methods have advantages over the spectrophotometric methods – they are more 
selective and measure and distinguish related compounds simultaneously, whereas 
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spectrophotometric assays, such as that used by Kaneko et al. (2009) measure total 
glutathione content.   
As discussed by Rossi et al. (2002) and Roberts and Francetic (1993) 
consideration should be taken to sample preparation in order to reliably quantify the 
concentration of GSH and associated metabolites.  Protein precipitation by 
acidification is usually the first step in preparation of samples for quantification of 
glutathione.  This gives robust estimates of glutathione; the acid also inactivates γ-
glutamyl transpeptidase, the enzyme responsible for the first step in the degradation 
of GSH (Roberts and Francetic, 1993).  This enzyme is reported to be of a high level 
in the pancreas, kidney and liver and can lead to vast underestimates of glutathione 
in tissue samples.  TCA was shown to be the most effective acid for the precipitation 
of protein, compared to perchloric and sulfosalicylic acids, since the loss of GSH 
from de-proteinised solutions was minimal (Rossi, et al., 2002).  In addition, the 
oxidation of thiol groups in acidified samples was shown to be minimal, although 
this did increase substantially if the de-proteinised samples were neutralised. 
 An LC-MS/MS method for the detection and quantification of GSH, GSSG 
and S-D-lactoylglutathione was developed.  Spike recovery was assessed for all three 
analytes and indicated that this method is a reliable method of measuring these 
metabolites, with almost complete recovery.  The concentrations of GSH and GSSG 
are within the physiological range and consistent with suggestions of a low 
concentration of GSSG when oxidation of GSH during sample preparation is 
avoided (Roberts and Francetic, 1993; Rossi, et al., 2002).  The assessment of intra-
batch variability indicated that the method is robust and reproducible.  In addition, 
calibration curves were reproducible, with slopes consistent when re-prepared for 
fresh analysis.  The limitation of this method is that despite the LoD for S-D-
lactoylglutathione being assessed as 1.1 pmol/10
6
 cells, this analyte has been below 
the LoD in all samples tested and not detectable.  
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9. Conclusions and further work 
9.1. Conclusions 
 This PhD project is composed of 3 parts: 
(i) Characterisation of the glyoxalase system and dicarbonyl metabolism in a 
beta cell line model and investigation of the effects of high glucose and 
dicarbonyl stress on this system.   
(ii) Investigation of the effect of MG-glycation of the ECM protein collagen 
IV on the functionality and adhesion of MIN6 cells in vitro. 
(iii) Characterisation of dicarbonyl metabolism in the pancreas of diet induced 
insulin resistant C57BL6 male mice.  The extent of damage to the 
proteome by glycation, oxidation and nitration is also assessed. 
 
 An LC-MS/MS assay was validated for the detection and quantification of 
GSH and related metabolites and had a LoD of 0.92, 1.46 and 0.54 pmol for GSH, 
GSSG and S-D-lactoylglutathione respectively.  This method is shown to be robust 
and takes into account important aspects of sample preparation to ensure that 
quantification of analytes is reliable. 
Results from the beta cell line model, MIN6, indicate that MIN6 cells 
cultured in high glucose have an increased nutrient consumption and that this in turn 
increases the glycolytic flux.  There is a consequential increase in the flux of 
formation of D-lactate, indicative of higher MG production and higher flux through 
the glyoxalase system but the proportion of flux from glycolysis was not affected by 
culture in high glucose.  The cellular content of MG, glyoxal and 3-DG did not 
increase when MIN6 cells were incubated in high glucose.  This indicates that 
although there is more MG production, as indicated by the D-lactate flux, this is 
largely within the capacity of the cells to metabolise it and therefore changes in MG 
were not detected in the MIN6 cells.  This is despite the measured activity of the 
glyoxalase system not increasing when the cellular demands upon it have increased.  
Glycation, oxidation and nitration of MIN6 cellular proteins occurred in vitro but the 
amounts of these adduct residues on cellular proteins were not affected by the 
increase in glucose.  Impaired adhesion to collagen IV was demonstrated following 
methylglyoxal-glycation of collagen.  This was suggestive of altered beta cell 
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function through changes in the expression of genes involved in both cell-cell and 
cell-extracellular matrix interactions. 
Observations from experimental diabetes suggest that whilst methylglyoxal 
does increase in the pancreas of HFD fed mice this is not associated with 
quantifiable changes in glycation adduct residues on protein.  It is concluded that 
whilst an increase in MG-H1 formation does occur as a result of the higher 
methylglyoxal content of the pancreas, a combination of increased protein turnover 
in the pancreas and renal clearance of damaged proteins and free adducts results in 
no measurable increase in glycated or oxidised protein.  The pancreas is therefore 
highly effective in removing damaged and dysfunctional proteins which would 
otherwise impose cell stress.  Supplementation of the HFD with omega-3 fatty acids 
has not been observed to have any significant effect on the glycation status of the 
pancreas in this model, despite going some way to prevent insulin resistance and 
associated metabolic disturbances.  Immunostaining images have also indicated that 
glycation damage observed within the pancreas is predominantly ECM directed. 
In summary, the data generated from this in vitro model of beta cells and in 
vivo model of diabetes suggests there are indications of dicarbonyl stress within beta 
cells and the pancreas - increased flux of methylglyoxal formation in MIN6 cells in 
vitro and increase concentration of methylglyoxal in the pancreas in HFD fed mice 
in vivo.  Increased pancreatic methylglyoxal in HFD-fed mice without increased 
methylglyoxal modified protein does not mean that the pancreas is resistant to 
protein glycation.  Since glycation by methylglyoxal is non-enzymatic pancreatic 
proteins are likely being increasingly damaged and degraded.  Consequential 
decreases in protein concentration or compensatory gene expression may 
increasingly drive the pancreas into a state of increased protein turnover which 
eventually takes its toll as pancreatic dysfunction sets in.  Clearance of damaged 
protein and an increased protein turnover are vital to maintenance of beta cell health.  
In times of continued stress, it is likely that this increased protein turnover will 
impact detrimentally on other aspects of beta cell function and contribute to the 
decline in beta cell function observed in T2DM.  This study has also indicated that 
ECM proteins of the pancreas are particularly susceptible to glycation and that this 
could contribute to the demise of beta cell mass through cell-detachment stimulated 
cell apoptosis – anoikis. 
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 A limitation of this study has been that the pancreas is a heterogeneous cell 
population and that the cells of interest, pancreatic beta cells, are only a small subset 
of this organ.  However, this thesis has shown that glycation occurs within both 
cultured beta cells and in the pancreas, and that methylglyoxal does accumulate.  The 
effect of protein glycation on beta cell function is limited by the high rate of protein 
turnover and clearance of damaged proteins from the system.  Perhaps under more 
prolonged glycation stress, further impairments in beta cell function would be 
observed, especially with regards to their interactions with ECM proteins such as 
collagen IV. 
 
9.2. Further work 
 In this thesis a method to quantify S-D-lactoylglutathione was developed.  
This analyte was, however, below the LoD in all samples tested.  Further 
development of this assay on the more sensitive Xevo triple quadrupole mass 
spectrometer may enable detection and quantification of this analyte which would 
give a more complete picture as to dicarbonyl metabolism and the activity of the 
glyoxalase system in these cell systems. 
 The studies with MIN6 cells require follow-up with mature mammalian beta 
cells and pancreatic islets since transformed insulinoma cells can give misleading 
metabolic effects as models of beta cells. 
Co-localisation of collagen IV and the methylglyoxal glycation adduct MG-
H1 have been observed within the pancreas and the effects of this glycation indicated 
within an in vitro model of beta cells.  It would be interesting to follow up these 
findings in a primary cell model and additionally investigate whether this glycation 
has a direct effect on insulin secretion or on E-cadherin or Cx36 protein level.  The 
in vivo study suggested the pancreatic proteome may suffer increased glycation with 
related changes in protein turnover (and possible increased compensatory gene 
expression).  Characterisation of the HFD fed mouse pancreatic dicarbonyl 
proteome, proteome dynamics and changes in gene transcription are now required.  
Finally, studies with Glo1 transgenic and Glo1deficient mice would reveal the link 
between dicarbonyl stress and the development of insulin resistance and 
glucotoxicity. 
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Appendix A: Primer sequences 
Primer Sequence (Sense, Antisense) 
Glo1 5’- CCCAGCTGCTGCTCCGATCCAGACCCT -3’ 
5’- CCGCGATATCGTTCTTATCCTCA -3’ 
Ins1 5’- CAACCGTGTAAATGCCACTG -3’ 
5’- CCTGCTACGGATGGACTGTT -3’ 
Ins2 5’- CCATCAGCAAGCAGGAAGCCTATC -3’ 
5’- CCCCACACACCAGGTAGAGAGCG -3’ 
(Nikolova, et al., 2006) 
Itgb1 5’- TTCAGACTTCCGCATTGGCTTTGG -3’ 
5’- TGGGCTGGTGCAGTTTTGTTCAC -3’ 
(Ramirez, et al., 2011) 
E-cadherin 5’- AGCCATTGCCAAGTACATCC -3’ 
5’- AAAGACCGGCTGGGTAAACT -3’ 
Cx36 5’- GGAATGGACCATCTTGGAGA -3’ 
5’- TCGTACACCGTCTCCCCTAC -3’ 
ICAM-1 5’- TTCACACTGAATGCCAGCTC -3’ 
5’- GTCTGCTGAGAGCCCCTCTTG -3’ 
18S Qiagen commercial stock.  Sequence not known 
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